1. Guidelines Sub-Committee. 1993 Guidelines for the management
of mild hypertension: memorandum from a World
Health Organization/International Society of Hypertension
meeting. J. Hypertens. 1993; 11: 905–918. GL
2. Guidelines Sub-Committee. 1999 World Health Organization/
International Society of Hypertension Guidelines for the management
of hypertension. J. Hypertens. 1999; 17: 151–183. GL
3. Guidelines Committee. 2003 European Society of Hypertension-
European Society of Cardiology guidelines for the
management of arterial hypertension. J. Hypertens. 2003; 21:
1011–1053. GL
4. Top 10 papers published. The Scientist 2005; 19: 26. OS
5. ESH/ESC Hypertension Practice Guidelines Committee.
Practice guidelines for primary care physicians: 2003 ESH/
/ESC hypertension guidelines. J. Hypertens. 2003; 21: 1779–
–1786. GL
6. Simoons M.L., van der Putten N., Wood D., Boersma E.,
Bassand J.P. The Cardiology Information System: the need
for data standards for integration of systems for patient care,
registries and guidelines for clinical practice. Eur. Heart J. 2002;
23: 1148–1152. GL
7. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton
J., Abbott R., Godwin J., Dyer A, Stamler J. Blood pressure,
stroke, and coronary heart disease. Part 1, prolonged differences
in blood pressure: prospective observational studies
corrected for the regression dilution bias. Lancet 1990; 335:
765–774. MA
8. Report of the Joint National Committee on Detection, Evaluation
and Treatment of High Blood Pressure: a cooperative
study. JAMA 1977; 237: 255–261. GL
9. The 1980 report of the Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure. Arch.
Intern. Med. 1980; 140: 1280–1285. GL
10. Collins R., Peto R., MacMahon S., Herbert P., Fieback
N.H., Eberlein K.A., Godwin J., Qizilbash N., Taylor J.O.,
Hennekens C.H. Blood pressure, stroke, and coronary heart
disease. Part 2, short-term reductions in blood pressure: overview
of randomised drug trials in their epidemiological context.
Lancet 1990; 335: 827–839. MA
11. Prospective Studies Collaboration. Age-specific relevance
of usual blood pressure to vascular mortality: a meta-analysis
of individual data for one million adults in 61 prospective studies.
Lancet 2002; 360: 1903–1913. MA
12. European cardiovascular disease statistics, British Heart
Foundation 2000; www.dphpc.ox.ac/UKbhfhprg. RV
13. Kannel W.B. Blood pressure as a cardiovascular risk factor:
prevention and treatment. JAMA 1996; 275: 1571–1576. OS
14. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K.
The progression from hypertension to congestive heart failure.
JAMA 1996; 275: 1557–1562. OS
15. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S.,
Klauber M.R., McCann T.J., Browner D. Mortality over a period
of 10 years in patients with peripheral arterial disease.
N. Engl. J. Med. 1992; 326: 381–386. OS
16. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati
F.L., Ford C.E., Shulman N.B., Stamler J. Blood pressure
and end-stage renal disease in men. N. Engl. J. Med. 1996;
334: 13–18. OS
17. Kearney P.M., Whelton M., Reynolds K., Muntner P.,
Whelton P.K., He J. Global burden of hypertension: analysis
of worldwide data. Lancet 2005; 365: 217–223. OS
18. Martiniuk A.L., Lee C.M., Lawes C.M., Ueshima H., Suh I.,
Lam T.H., Gu D., Feigin V., Jamrozik K., Ohkubo T., Woodward
M., for the Asia-Pacific Cohort Studies Collaboration.
Hypertension: its prevalence and population-attributable fraction
for mortality from cardiovascular disease in the Asia-Pacific
region. J. Hypertens. 2007; 25: 73–79. OS
19. Wolf-Maier K., Cooper R.S., Banegas J.R., Giampaoli S.,
Hense H.W., Joffres M., Kastarinen M., Poulter N., Primatesta
P., Rodriguez-Artalejo F., Stegmayr B., Thamm M., Tuomilehto
J., Vanuzzo D., Vescio F. Hypertension prevalence
and blood pressure levels in 6 European countries, Canada,
and the United States. JAMA 2003; 289: 2363–2369. OS
20. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S.,
Murray C.J., Comparative Risk Assessment Collaborating
Group. Selected major risk factors and global and regional
burden of disease. Lancet 2002; 360: 1347–1360. RV
21. Franklin S.S. Ageing and hypertension: the assessment of
blood pressure indices in predicting coronary heart disease.
J. Hypertens. 1999; 17 (supl. 5): S29–S36. RV
22. Benetos A., Zureik M., Morcet J., Thomas F., Bean K.,
Safar M., Ducimetiere P., Guize L. A decrease in diastolic blood
pressure combined with an increase in systolic blood pressure
is associated with a higher cardiovascular mortality in men.
J. Am. Coll. Cardiol. 2000; 35: 673–680. OS
23. Staessen J.A., Gasowski J., Wang J.G., Thijs L., Den Hond E.,
Boissel J.P., Coope J., Ekbom T., Gueyffier F., Liu L., Kerlikowske
K., Pocock S., Fagard R.H. Risks of untreated and treated
isolated systolic hypertension in the elderly: meta-analysis
of outcome trials. Lancet 2000; 355: 865–872. MA
24. Darne B., Girerd X., Safar M., Cambien F., Guize L. Pulsatile
versus steady component of blood pressure: a cross-sectional
analysis and a prospective analysis on cardiovascular
mortality. Hypertension 1989; 13: 392–400. OS
25. Benetos A., Safar M., Rudnichi A., Smulyan H., Richard
J.L., Ducimetieere P., Guize L. Pulse pressure: a predictor of
long-term cardiovascular mortality in a French male population.
Hypertension 1997; 30: 1410–1415. OS
26. Gasowski J., Fagard R.H., Staessen J.A., Grodzicki T.,
Pocock S., Boutitie F., Gueyffier F., Boissel J.P., INDANA
Project Collaborators. Pulsatile blood pressure component as
predictor of mortality in hypertension: a meta-analysis of clinical
trial control groups. J. Hypertens. 2002; 20: 145–151. MA
27. Blacher J., Staessen J.A., Girerd X., Gasowski J., Thijs L.,
Liu L., Wang J.G., Fagard R.H., Safar M.E. Pulse pressure not
mean pressure determines cardiovascular risk in older hypertensive
patients. Arch. Intern. Med. 2000; 160: 1085–1089. MA
28. Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P.,
Giannattasio C., Hayoz D., Pannier B., Vlachopoulos C.,
Wilkinson I., Struijker-Boudier H., on behalf of the European
Network for non invasive investigation of large arteries.
Expert consensus document on arterial stiffness: methodological
issues and clinical applications. Eur. Heart J. 2006; 27:
2588–2605. GL
29. Pickering G. The nature of essential hypertension. J & A.
Churchill Ltd, London 1961; 1–151. RV
30. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C.,
Green L.A., Izzo J.L. Jr, Jones D.W., Materson B.J., Oparil S.,
Wright J.T. Jr, Roccella E.J., National Heart, Lung, and Blood
Institute; National High Blood Pressure Education Program
Coordinating Committee. Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. Hypertension 2003;
42: 1206–1252. GL
31. Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B.,
D’Agostino R.B., Levy D. Residual lifetime risk for developing
hypertension in middle-aged women and men: The Framingham
Heart Study. JAMA 2002; 287: 1003–1010. OS
32. Vasan R.S., Larson M.G., Leip E.P., Kannel W.B., Levy
D. Assessment of frequency of progression to hypertension in
non-hypertensive participants in the Framingham Heart Study:
a cohort study. Lancet 2001; 358: 1682–1686. OS
33. Vasan R.S., Larson M.G., Leip E.P., Evans J.C., O’Donnell
C.J., Kannel W.B., Levy D. Impact of high-normal blood
pressure on the risk of cardiovascular disease. N. Engl. J. Med.
2001; 345: 1291–1297. OS
34. Mancia G., Grassi G. European, American and British
Guidelines: similarities and differences. W: Black H.R.,
Elliott W.J. (red.). Hypertension. A companion to Braunwald’s
Heart diseases. Saunders-Elsevier, Amsterdam 2007:
571–575. RV
35. Kannel W.B. Risk stratification in hypertension: new insights
from the Framingham Study. Am. J. Hypertens. 2000; 13
(supl. 1): S3–S10. OS
36. Thomas F., Rudnichi A., Bacri A.M., Bean K., Guize L.,
Benetos A. Cardiovascular mortality in hypertensive men according
to presence of associated risk factors. Hypertension
2001; 37: 1256–1261. OS
37. Wei M., Mitchell B.D., Haffner S.M., Stern M.P. Effects
of cigarette smoking, diabetes, high cholesterol, and hypertension
on all-cause mortality and cardiovascular disease mortality
in Mexican Americans. The San Antonio Heart Study.
Am. J. Epidemiol. 1996; 144: 1058–1065. OS
38. Assmann G., Schulte H. The Prospective Cardiovascular
Munster (PROCAM) study: prevalence of hyperlipidemia in
persons with hypertension and/or diabetes mellitus and the
relationship to coronary heart disease. Am. Heart J. 1988; 116:
1713–1724. OS
39. Mancia G., Parati G., Borghi C., Ghironzi G., Andriani E.,
Marinelli L., Valentini M., Tessari F., Ambrosioni E. Hypertension
prevalence, awareness, control and association with
metabolic abnormalities in the San Marino population: the
SMOOTH study. J. Hypertens. 2006; 24: 837–843. OS
40. Mancia G., Facchetti R., Bombelli M., Friz H.P., Grassi G.,
Giannattasio C., Sega R. Relationship of office, home, and
ambulatory blood pressure to blood glucose and lipid variables
in the PAMELA population. Hypertension 2005; 45:
1072–1077. OS
41. Asia Pacific Cohort Studies Collaboration. Joint effects of
systolic blood pressure and serum cholesterol on cardiovascular
disease in the Asia Pacific region. Circulation 2005; 112:
3384–3390. OS
42. Multiple Risk Factor Intervention Trial Research Group
Relationship between baseline risk factors and coronary heart
disease and total mortality in the Multiple Risk Factor Intervention
Trial. Multiple Risk Factor Intervention Trial Research
Group. Prev. Med. 1986; 15: 254–273. OS
43. Wood D., De Backer G., Faergeman O., Graham I., Mancia
G., Pyorala K. Prevention of coronary heart disease in clinical
practice. Summary of recommendations of the Second Joint
Task Force of European and other Societies on Coronary
Prevention. J. Hypertens. 1998; 16: 1407–1414. GL
44. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C.,
Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham
I., Mancia G., Manger Cats V., Orth-Gomer K., Perk J.,
Pyorala K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber
S., Thomsen T., Wood D. European guidelines on cardiovascular
disease prevention in clinical practice. Third Joint
Task Force of European and Other Societies on Cardiovascular
Disease Prevention in Clinical Practice. Eur. Heart J. 2003;
24: 1601–1610. GL
45. D’Agostino R.B.S., Grundy S., Sullivan L.M., Wilson P.
Validation of the Framingham coronary heart disease prediction
scores: results of a multiple ethnic groups investigation.
JAMA 2001; 286: 180–187. OS
46. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti
A., De Backer G., De Bacquer D., Ducimetiere P., Jousilahti
P., Keil U., Njolstad I., Oganov R.G., Thomsen T., Tunstall-
Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen
L., Graham I.M. Estimation of ten-year risk of fatal
cardiovascular disease in Europe: the SCORE project. Eur.
Heart J. 2003; 24: 987–1003. OS
47. World Health Organization/International Society of
Hypertension. 2003 World Health Organization (WHO)/
/International Society of Hypertension (ISH) statement on
management of hypertension. J. Hypertens. 2003; 21: 1983–
–1992. GL
48. Evans J.G., Rose G. Hypertension. Br. Med. Bull. 1971;
27: 37–42. RV
49. Executive Summary of the Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults. JAMA 2001; 285: 2486–2497. GL
50. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson
J.E., Plutzky J., Popma J.J., Stevenson W. The cardiovascular
disease continuum validated: clinical evidence of improved
patient outcomes: part I: Pathophysiology and clinical
trial evidence (risk factors through stable coronary artery disease).
Circulation 2006; 114: 2850–2870. RV
51. Cockroft D.W., Gault M.H. Prediction of creatinine clearance
from serum creatinine. Nephron 1976; 16: 31–41.
52. Hallan S., Asberg A., Lindberg M., Johnsen H. Validation
of the Modification of Diet in Renal Disease formula for estimating
GFR with special emphasis on calibration of the serum
creatinine assay. Am. J. Kidney Dis. 2004; 44: 84–93.
53. Olsen M.H., Wachtell K., Bella J.N., Palmieri V., Gerdts E.,
Smith G., Nieminen M.S., Dahlof B., Ibsen H., Devereux R.B.
Albuminuria predicts cardiovascular events independently of
left ventricular mass in hypertension: a LIFE substudy. J. Hum.
Hypertens. 2004; 18: 453–459. OS
54. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., Rasmussen
S., Thijs L., Ibsen H., Jeppesen J. Prognostic value of
aortic pulse wave velocity as index of arterial stiffness in the
general population. Circulation 2006; 113: 664–670. OS
55. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B.,
Guize L., Ducimetiere P., Benetos A. Aortic stiffness is an independent
predictor of all-cause and cardiovascular mortality in
hypertensive patients. Hypertension 2001; 37: 1236–1241. OS
56. Feringa H.H., Bax J.J., van Waning V.H., Boersma E.,
Elhendy A., Schouten O., Tangelder M.J., van Sambeek M.H.,
van den Meiracker A.H., Poldermans D. The long-term prognostic
value of the resting and postexercise ankle-brachial
index. Arch. Intern. Med. 2006; 166: 529–535. OS
57. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen
M.S., Papademetriou V., Rokkedal J., Harris K., Aurup P.,
Dahlof B. Prognostic significance of left ventricular mass change
during treatment of hypertension. JAMA 2004; 292: 2350–
–2356. OS
58. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K.,
Lindholm L.H., Mogensen C.E., Dahlof B., Devereux R.B.,
de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Lederballe-
-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wan Y.
Reduction in albuminuria translates to reduction in cardiovascular
events in hypertensive patients: Losartan Intervention
For Endpoint reduction in hypertension study. Hypertension
2005; 45: 198–202. OS
59. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F.,
Zhang Z., Shahinfar S., Snapinn S., Cooper M.E., Mitch W.E.,
Brenner B.M. Albuminuria, a Therapeutic Target for Cardiovascular
Protection in Type 2 Diabetic Patients With Nephropathy.
Circulation 2004; 110: 921–927. OS
60. Olsen M.H., Wachtell K., Ibsen H., Lindholm L.H., Dahlof
B., Devereux R.B., Kjeldsen S.E., Oikarinen L., Okin P.M.,
LIFE Study Investigators. Reductions in albuminuria and in
electrocardiographic left ventricular hypertrophy independently
improve prognosis in hypertension: the LIFE study.
J. Hypertens. 2006; 24: 775–781. OS
61. Verdecchia P., Angeli F., Borgioni C., Gattobigio R., de
Simone G., Devereux R.B., Porcellati C. Changes in cardiovascular
risk by reduction of left ventricular mass in hypertension:
a meta-analysis. Am. J. Hypertens. 2003; 16: 895–899. MA
62. Benetos A., Rudnichi A., Thomas F., Safar M., Guize L.
Influence of heart rate on mortality in a French population:
role of age, gender, and blood pressure. Hypertension 1999;
33: 44–52. OS
63. Palatini P., Thijs L., Staessen J.A., Fagard R.H., Bulpitt C.J.,
Clement D.L., de Leeuw P.W., Jaaskivi M., Leonetti G., Nachev
C., O’Brien E.T., Parati G., Rodicio J.L., Roman E., Sarti
C., Tuomilehto J., Systolic Hypertension in Europe (Syst-
-Eur) Trial Investigators. Predictive value of clinic and ambulatory
heart rate for mortality in elderly subjects with systolic
hypertension. Arch. Intern. Med. 2002; 162: 2313–2321. OS
64. Kannel W.B., Kannel C., Paffenbarger R.S. Jr, Cupples L.A.
Heart rate and cardiovascular mortality: the Framingham study.
Am. Heart J. 1987; 113: 1489–1494. OS
65. Palatini P., Benetos A., Grassi G., Julius S., Kjeldsen S.E.,
Mancia G., Narkiewicz K., Parati G., Pessina A.C., Ruilope
L.M., Zanchetti A. European Society of Hypertension Identification
and management of the hypertensive patient with elevated
heart rate: statement of a European Society of Hypertension
Consensus Meeting. J. Hypertens. 2006; 24: 603–610. GL
66. Levy R.L., White P.D., Stroud W.D., Hillman C.C. Transient
tachycardia: prognostic significance alone and in association
with transient hypertension. JAMA 1945; 129: 585–588. OS
67. King D.E., Everett C.J., Mainous A.G. 3rd, Liszka H.A.
Long-term prognostic value of resting heart rate in subjects with
prehypertension. Am. J. Hypertens. 2006; 19: 796–800. OS
68. Palatini P., Casiglia E., Pauletto P., Staessen J., Kaciroti N.,
Julius S. Relationship of tachycardia with high blood pressure
and metabolic abnormalities: a study with mixture analysis in
three populations. Hypertension 1997; 30: 1267–1273. OS
69. Mancia G., Bombelli M., Corrao G., Facchetti R., Madotto F.,
Giannattasio C., Trevano F.Q., Grassi G., Zanchetti A., Sega R.
Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro
Associazioni (PAMELA) study: daily life blood pressure, cardiac
damage, and prognosis. Hypertension 2007; 49: 40–47. OS
70. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A.,
Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L.
Effect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEART
study): case-control study. Lancet 2004; 364: 937–952. OS
71. Fourth Joint Task Force of European and other Societies
on Cardiovascular Disease Prevention in Clinical Practice.
European Guidelines on cardiovascular disease prevention in
clinical practice. Eur. Heart J. 2007: w przygotowaniu. GL
72. Mancia G., Ferrari A., Gregorini L., Parati G., Pomidossi G.,
Bertinieri G., Grassi G., di Rienzo M., Pedotti A., Zanchetti A.
Blood pressure and heart rate variabilities in normotensive and
hypertensive human beings. Circ. Res. 1983; 53: 96–104. OS
73. Sega R., Cesana G., Bombelli M., Grassi G., Stella M.L.,
Zanchetti A., Mancia G. Seasonal variations in home and
ambulatory blood pressure in the PAMELA population. Pressione
Arteriose Monitorate E Loro Associazioni. J. Hypertens.
1998; 16: 1585–1592. OS
74. Modesti P.A., Morabito M., Bertolozzi I., Massetti L., Panci G.,
Lumachi C., Giglio A., Bilo G., Caldara G., Lonati L., Orlandini
S., Maracchi G., Mancia G., Gensini G.F., Parati G.
Weather-related changes in 24-hour blood pressure profile:
effects of age and implications for hypertension management.
Hypertension 2006; 47: 155–161. OS
75. O’Brien E., Asmar R., Beilin L., Imai Y., Mallion J.M.,
Mancia G., Mengden T., Myers M., Padfield P., Palatini P.,
Parati G., Pickering T., Redon J., Staessen J., Stergiou G.,
Verdecchia P. European Society of Hypertension Recommendations
for Conventional, Ambulatory and Home Blood Pressure
Measurement. J. Hypertens. 2003; 21: 821–848. GL
76. O’Brien E., Waeber B., Parati G., Staessen J., Myers M.G.
Blood pressure measuring devices: recommendations of the
European Society of Hypertension. Br. Med. J. 2001; 322: 531–
–536. GL
77. Mancia G., Omboni S., Parati G., Clement D.L., Haley
W.E., Rahman S.N., Hoogma R.P. Twenty-four hour ambulatory
blood pressure in the Hypertension Optimal Treatment
(HOT) study. J. Hypertens. 2001; 19: 1755–1763. OS
78. Mancia G., Omboni S., Ravogli A., Parati G., Zanchetti A.
Ambulatory blood pressure monitoring in the evaluation of
antihypertensive treatment: additional information from a large
data base. Blood Press 1995; 4: 148–156. OS
79. Mancia G., Parati G., Bilo G., Maronati A., Omboni S.,
Hennig M., Zanchetti A. Assessment of long-term antihypertensive
treatment by clinic an ambulatory blood pressure. Data
from the ELSA Study. J. Hypertens. 2007; 25: 1087–1094. OS
80. Fagard R.H., Staessen J.A., Thijs L. Relationships between
changes in left ventricular mass and in clinic and ambulatory
blood pressure in response to antihypertensive therapy.
J. Hypertens. 1997; 15: 1493–1502. OS
81. Mancia G., Zanchetti A., Agabiti-Rosei E., Benemio G.,
De Cesaris R., Fogari R., Pessina A., Porcellati C., Rappelli A.,
Salvetti A., Trimarco B. Ambulatory blood pressure is superior
to clinic blood pressure in predicting treatment induced
regression of left ventricular hypertrophy. Circulation 1997;
95: 1464–1470. OS
82. Fagard R.H., Staessen J.A., Thijs L. Prediction of cardiac
structure and function by repeated clinic and ambulatory blood
pressure. Hypertension 1997; 29: 22–29. OS
83. Verdecchia P., Schillaci G., Guerrieri M., Gatteschi C.,
Benemio G., Boldrini F., Porcellati C. Circadian blood pressure
changes and left ventricular hypertrophy in essential hypertension.
Circulation 1990; 81: 528–536. OS
84. Mancia G., Parati G., Hennig M., Flatau B., Omboni S.,
Glavina F., Costa B., Scherz R., Bond G., Zanchetti A. Relation
between blood pressure variability and carotid artery damage
in hypertension: baseline data from European Lacidipine
Study on Atherosclerosis (ELSA). J. Hypertens. 2001; 19:
1981–1989. OS
85. Redon J., Baldo E., Lurbe E., Bertolin V., Lozano J.V.,
Miralles A., Pascual J.M. Microalbuminuria, left ventricular
mass and ambulatory blood pressure in essential hypertension.
Kidney Int. Supl. 1996; 55: S81–S84. OS
86. Imai Y., Ohkubo T., Sakuma M., Tsuji I.I., Satoh H., Nagai K.,
Hisamichi S., Abe K. Predictive power of screening blood pressure,
ambulatory blood pressure and blood pressure measured
at home for overall and cardiovascular mortality: a prospective
observation in a cohort from Ohasama, Northern Japan.
Blood Press Monit. 1996; 1: 251–254. OS
87. Staessen J.A., Thijs L., Fagard R., O’Brien E.T., Clement D.,
de Leeuw P.W., Mancia G., Nachev C., Palatini P., Parati G.,
Tuomilehto J., Webster J. Predicting cardiovascular risk using
conventional vs ambulatory blood pressure in older patients with
systolic hypertension. JAMA 1999; 282: 539–546. OS
88. Clement D.L., De Buyzere M.L., De Bacquer D.A., de
Leeuw P.W., Duprez D.A., Fagard R.H., Gheeraert P.J., Missault
L.H., Braun J.J., Six R.O., Van Der Niepen P., O’Brien E.
Prognostic value of ambulatory blood pressure recordings in
patients with treated hypertension. New Engl. J. Med. 2003;
348: 2407–2415. OS
89. Sega R., Facchetti R., Bombelli M., Cesana G., Corrao G.,
Grassi G., Mancia G. Prognostic value of ambulatory and home
blood pressure compared with office blood pressure in the general
population: follow-up results from the PAMELA study.
Circulation 2005; 111: 1777–1783. OS
90. Fagard R.H., Celis H. Prognostic significance of various
characteristics of out-of-the-office blood pressure. J. Hypertens.
2004; 22: 1663–1666. OS
91. Dolan E., Stanton A., Thijs L., Hinedi K., Atkins N., McClory
S., Den Hond E., McCormack P., Staessen J.A., O’Brien E.
Superiority of ambulatory over clinic blood pressure measurement
in predicting mortality. Hypertension 2005; 46: 156–161. OS
92. Fagard R.H., Van Den Broeke C., De Cort P. Prognostic
significance of blood pressure measured in the office, at home
and during ambulatory monitoring in older patients in general
practice. J. Hum. Hypertens. 2005; 19: 801–807. OS
93. Hansen T.W., Jeppesen J., Rasmussen S., Ibsen H., Torp-
-Pedersen C. Ambulatory blood pressure and mortality. A population-
based study. Hypertension 2005; 45: 499–504. OS
94. Kikuya M., Ohkubo T., Asayama K., Metoki H., Obara T.,
Saito S., Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y.
Ambulatory blood pressure and 10-year risk of cardiovascular
and noncardiovascular mortality. The Ohasama Study. Hypertension
2005; 45: 240–245. OS
95. Pickering T.G., Shimbo D., Haas D. Ambulatory blood pressure
monitoring. New Engl. J. Med. 2006; 354: 2368–2374. RV
96. Redon J., Campos C., Narciso M.L., Rodicio J.L., Pascual J.M.,
Ruilope L.M. Prognostic value of ambulatory blood pressure
monitoring in refractory hypertension: a prospective study.
Hypertension 1998; 31: 712–718. OS
97. Coats A.J.S., Radaelli A., Clark S.J., Conway J., Sleight P.
The influence of ambulatory blood pressure monitoring on
the design and interpretation of trials in hypertension. J. Hypertension
1992; 10: 385–391. OS
98. Mancia G., Ulian L., Parati G., Trazzi S. Increase in blood
pressure reproducibility by repeated semi-automatic blood pressure
measurements in the clinic environment. J. Hypertens.
1994; 12: 469–473. OS
99. Parati G., Pomidossi G., Casadei V., Mancia G. Lack of
alerting reactions and pressor responses to intermittent cuff
inflations during non-invasive blood pressure monitoring.
Hypertension 1985; 7: 597–601. OS
100. Mancia G., Omboni S., Parati G., Ravogli A., Villani A.,
Zanchetti A. Lack of placebo effect on ambulatory blood pressure.
Am. J. Hypertens. 1995; 8: 311–315. OS
101. Staessen J.A., Thijs L., Clement D., Davidson C., Fagard R.,
Lehtonen A., Mancia G., Palatini P., O’Brien E.T., Parati G.,
Webster J., Amery A. Ambulatory blood pressure decreases on
long-term placebo treatment in older patients with isolated systolic
hypertension. J. Hypertens. 1994; 12: 1035–1039. OS
102. O’Brien E., Sheridan J., O’Malley K. Dippers and non-
-dippers. Lancet 1988; 2: 397. RV
103. Ohkubo T., Hozawa A., Yamaguchi J., Kikuya M., Ohmori
K., Michimata M., Matsubara M., Hashimoto J., Hoshi H.,
Araki T., Tsuji I., Satoh H., Hisamichi S., Imai Y. Prognostic
significance of the nocturnal decline in blood pressure in individuals
with and without high 24-h blood pressure: the Ohasama
study. J. Hypertens. 2002; 20: 2183–2189. OS
104. Verdecchia P., Porcellati C., Schillaci G., Borgioni C.,
Ciucci A., Battistelli M., Guerrieri M., Gatteschi C., Zampi I.,
Santucci A. Ambulatory blood pressure. An independent predictor
of prognosis in essential hypertension. Hypertension
1994; 24: 793–801. OS
105. Metoki H., Ohkubo T., Kikuya M., Asayama K., Obara T.,
Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y. Prognostic
significance for stroke of a morning pressor surge and
a nocturnal blood pressure decline, The Ohasama Study.
Hypertension 2006; 47: 149–154. OS
106. Hansen T.W., Jeppesen J., Rasmussen S., Ibsen H., Torp-
-Pedersen C. Ambulatory blood pressure monitoring and risk
of cardiovascular disease: a population based study. Am.
J. Hypertens. 2006; 19: 243–250. OS
107. Willich S.N., Goldberg R.J., Maclure M., Perriello L.,
Muller J.E. Increased onset of sudden cardiac death in the first
three hours after awakening. Am. J. Cardiol. 1992; 70: 65–68. OS
108. Rocco M.B., Barry J., Campbell S., Nabel E., Cook E.F.,
Goldman L., Selwyn A.P. Circadian variation of transient
myocardial ischemia in patients with coronary artery disease.
Circulation 1987; 75: 395–400. OS
109. Muller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler
C.A., Parker C., Poole W.K., Passamani E., Roberts R.,
Robertson T. Circadian variation in the frequency of onset of
acute myocardial infarction. N. Engl. J. Med. 1985; 313: 1315–
–1322. OS
110. Elliott W.J. Circadian variation in the timing of stroke
onset: a meta-analysis. Stroke 1998; 29: 992–996. MA
111. Millar-Craig M.W., Bishop C.N., Raftery E.B. Circadian
variation of blood-pressure. Lancet 1978; 1: 795–797. OS
112. Kario K., Pickering T.G., Umeda Y., Hoshide S.,
Hoshide Y., Morinari M., Murata M., Kuroda T., Schwartz J.E.,
Shimada K. Morning surge in blood pressure as a predictor
of silent and clinical cerebrovascular disease in elderly hypertensives:
a prospective study. Circulation 2003; 107:
1401–1406. OS
113. Mancia G., Zanchetti A. Cardiovascular regulation during
sleep. W: Orem J. (red.). Handbook of Physiology during
Sleep. Academic Press, New York 1980: 1–55. RV
114. El-Tamimi H., Mansour M., Pepine C.J., Wargovich T.J.,
Chen H. Circadian variation in coronary tone in patients with
stable angina. Protective role of the endothelium. Circulation
1995; 92: 3201–3205. OS
115. Otto M.E., Svatikova A., Barretto R.B., Santos S., Hoffmann
M., Khandheria B., Somers V. Early morning attenuation
of endothelial function in healthy humans. Circulation
2004; 109: 2507–2510. OS
116. Brown N.J., Agirbasli M.A., Williams G.H., Litchfield W.R.,
Vaughan D.E. Effect of activation and inhibition of the reninangiotensin
system on plasma PAI-1. Hypertension 1998; 32:
965–971. OS
117. Weber M.A. The 24-hour blood pressure pattern: does it
have implications for morbidity and mortality? Am. J. Cardiol.
2002; 89: 27A–33A. RV
118. Undar L., Turkay C., Korkmaz L. Circadian variation in
circulating platelet aggregates. Ann. Med. 1989; 21: 429–433. OS
119. Frattola A., Parati G., Cuspidi C., Albini F., Mancia G.
Prognostic value of 24-hour blood pressure variability. J. Hypertens.
1993; 11: 1133–1137. OS
120. Sander D., Kukla C., Klingelhofer J., Winbeck K., Conrad
B. Relationship between circadian blood pressure patterns
and progression of early carotid atherosclerosis: A 3-year follow-
up study. Circulation 2000; 102: 1536–1541. OS
121. Verdecchia P., Borgioni C., Ciucci A., Gattobigio R., Schillaci
G., Sacchi N., Santucci A., Santucci C., Reboldi G., Porcellati
C. Prognostic significance of blood pressure variability in
essential hypertension. Blood Press Monit. 1996; 1: 3–11. OS
122. Mancia G., Bombelli M., Facchetti R., Madotto F., Corrao
G., Quarti-Trevano F., Grassi G., Sega R. Long term prognostic
value of blood pressure variability in the general population:
result of the PAMELA study. Hypertension 2007;
49 (6): 1265–1270. OS
123. Staessen J., Fagard R.H., Lijnen P.J., Van Hoof R., Amery
A.K. Mean and range of the ambulatory pressure in normotensive
subjects from a meta-analysis of 23 studies. Am. J. Cardiol.
1991; 67: 723–727. MA
124. Mancia G., Sega R., Bravi C., De Vito G., Valagussa F.,
Cesana G., Zanchetti A. Ambulatory blood pressure normality:
results from the PAMELA Study. J. Hypertens. 1995; 13:
1377–1390. OS
125. Ohkubo T., Imai Y., Tsuji I., Nagai K., Ito S., Satoh H.,
Hisamichi S. Reference values for 24-hour ambulatory blood
pressure monitoring based on a prognostic criterion: the Ohasama
Study. Hypertension 1998; 32: 255–259. OS
126. Sakuma M., Imai Y., Nagai K., Watanabe N., Sakuma H.,
Minami N., Satoh H., Abe K. Reproducibility of home blood
pressure measurements over a 1-year period. Am. J. Hypertens.
1997; 10: 798–803. OS
127. Ohkubo T., Imai Y., Tsuji I., Nagai K., Kato J., Kikuchi
N., Nishiyama A., Aihara A., Sekino M., Kikuya M., Ito S.,
Satoh H., Hisamichi S. Home blood pressure measurement
has a stronger predictive power for mortality than does screening
blood pressure measurement: a population-based observation
in Ohasama, Japan. J. Hypertens. 1998; 16: 971–
–975. OS
128. Zarnke K.B., Feagan B.G., Mahon J.L., Feldman R.D.
A randomized study comparing a patient-directed hypertension
management strategy with usual office-based care. Am.
J. Hypertens. 1997; 10: 58–67. OS
129. Pickering T., James G.D., Boddie C., Hrashfield G.A.,
Blank S., Laragh J.H. How common is white coat hypertension?
JAMA 1988; 259: 225–228. OS
130. Parati G., Ulian L., Santucci C., Omboni S., Mancia G.
Difference between clinic and daytime blood pressure is not
a measure of the white coat effect. Hypertension 1998; 31: 1185–
–1189. OS
131. Mancia G., Bertinieri G., Grassi G., Parati G., Pomidossi G.,
Ferrari A., Gregorini L., Zanchetti A. Effects of blood-pressure
measurement by the doctor on patient’s blood pressure and
heart rate. Lancet 1983; 2: 695–698. OS
132. Mancia G., Parati G., Pomidossi G., Grassi G., Casadei R.,
Zanchetti A. Alerting reaction and rise in blood pressure during
measurement by physician and nurse. Hypertension 1987;
9: 209–215. OS
133. Mancia G., Facchetti R., Bombelli M., Grassi G., Sega R.
Long-term risk of mortality associated with selective and combined
elevation in office, home, and ambulatory blood pressure.
Hypertension 2006; 47: 846–853. OS
134. Ohkubo T., Kikuya M., Metoki H., Asayama K., Obara T.,
Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y. Prognosis
of masked hypertension and white-coat hypertension
detected by 24-h ambulatory blood pressure monitoring. J. Am.
Coll. Cardiol. 2005; 46: 508–515. OS
135. Khattar R.S., Senior R., Lahiri A. Cardiovascular outcome
in white-coat versus sustained mild hypertension. A 10-
year follow-up study. Circulation 1998; 98: 1892–1897. OS
136. Fagard R.H., Staessen J.A., Thijs L., Gasowski J., Bulpitt C.J.,
Clement D., de Leeuw P.W., Dobovisek J., Jaaskivi M., Leonetti
G., O’Brien E., Palatini P., Parati G., Rodicio J.L., Vanhanen
H., Webster J. Response to antihypertensive treatment
in older patients with sustained or nonsustained systolic hypertension.
Circulation 2000; 102: 1139–1144. OS
137. Bobrie G., Chatellier G., Genes N., Clerson P., Vaur L.,
Vaisse B., Menard J., Mallion J.M. Cardiovascular prognosis
of ‘‘masked hypertension’’ detected by blood pressure self-
-measurement in elderly treated hypertensive patients. JAMA
2004; 291: 1342–1349. OS
138. Verdecchia P., Reboldi G.P., Angeli F., Schillaci G.,
Schwartz J.E., Pickering T.G., Imai Y., Ohkubo T., Kario K.
Short- and long-term incidence of stroke in white-coat hypertension.
Hypertension 2005; 45: 203–208. OS
139. Sega R., Trocino G., Lanzarotti A., Carugo S., Cesana G.,
Schiavina R., Valagussa F., Bombelli M., Giannattasio C.,
Zanchetti A., Mancia G. Alterations of cardiac structure in
patients with isolated office, ambulatory or home hypertension.
Data from the general PAMELA population. Circulation
2001; 104: 1385–1392. OS
140. Wing L.M.H., Brown M.A., Beilin L.J., Ryan P., Reid C.
Reverse white-coat hypertension in older hypertensives.
J. Hypertens. 2002; 20: 639–644. OS
141. Björklund K., Lind L., Zethelius B., Andren B., Lithell H.
Isolated ambulatory hypertension predicts cardiovascular morbidity
in elderly men. Circulation 2003; 107: 1297–1302. OS
142. Lurbe E., Torro I., Alvarez V., Nawrot T., Paya R., Redon
J., Staessen J.A. Prevalence, persistence, and clinical significance
of masked hypertension in youth. Hypertension
2005; 45: 493–498. OS
143. Mancia G., Parati G. Reactivity to physical and behavioral stress
and blood pressure variability in hypertension. W: Julius S.,
Bassett D.R. (red.). Handbook of Hypertension. Vol. 9. Behavioral
Factors in Hypertension. Elsevier Sci. Publ. 1987: 104–122. RV
144. Pescatello L.S., Franklin B.A., Fagard R., Farquhar W.B.,
Kelley G.A., Ray C.A. American College of Sports Medicine
Position Stand: Exercise and Hypertension. Med. Sci. Sports
Exerc. 2004; 36: 533–553. GL
145. Singh J.P., Larson M.G., Manolio T.A., O’Donnell C.J.,
Lauer M., Evans J.C., Levy D. Blood pressure response during
treadmill testing as a risk factor for new-onset hypertension: the
Framingham Heart Study. Circulation 1999; 99: 1831–1836. OS
146. Carroll D., Smith G.D., Shipley M.J., Steptoe A., Brunner
E.J., Marmot M.G. Blood pressure reactions to acute psychological
stress and future blood pressure status: a 10-year
follow-up of men in the Whitehall II study. Psychosom. Med.
2001; 63: 737–743. OS
147. Manolio T.A., Burke G.L., Savage P.J., Sidney S., Gardin J.M.,
Oberman A. Exercise blood pressure response and 5-year risk
of elevated blood pressure in a cohort of young adults: the
CARDIA study. Am. J. Hypertens. 1994; 7: 234–241. CT
148. Fagard R., Staessen J., Amery A. Exercise blood pressure
and target organ damage in essential hypertension. J. Hum.
Hypertension 1991; 5: 69–75. OS
149. Filipovsky J., Ducimetiere P., Safar M. Prognostic significance
of exercise blood pressure and heart rate in middle-
-aged men. Hypertension 1992; 20: 337–339. OS
150. Lauer M.S., Levy D., Anderson K.M., Plehn J.F. Is there
a relationship between exercise systolic blood pressure response and
left ventricular mass? Ann. Intern. Med. 1992; 116: 203–210. OS
151. Smith D.H.G., Neutel J.M., Graettinger W.F., Myers J.,
Froelicher V.F., Weber M.A. Impact of left ventricular hypertrophy
on blood pressure responses to exercise. Am. J. Cardiol.
1992; 69: 225–228. OS
152. Fagard R., Staessen J., Thijs L., Amery A. Relation of left
ventricular mass and filling to exercise blood pressure and rest
blood pressure. Am. J. Cardiol. 1995; 75: 53–57. OS
153. Markovitz J.H., Raczynski J.M., Lewis C.E., Flack J.,
Chesney M., Chettur V., Hardin J.M., Johnson E. Lack of independent
relationships between left ventricular mass and cardiovascular
reactivity to physical and psychological stress in the
CARDIA study. Am. J. Hypertens. 1996; 9: 915–923. OS
154. Fagard R.H., Pardaens K., Staessen J.A., Thijs L. Should
exercise blood pressure be measured in clinical practice?
J. Hypertens. 1998; 16: 1215–1217. RV
155. Kokkinos P., Pittaras A., Narayan P., Faselis C., Singh S.,
Manolis A. Exercise capacity and blood pressure associations
with left ventricular mass in prehypertensive individuals. Hypertension
2007; 49: 55–61. OS
156. Al’Absi M., Devereux R.B., Lewis C.E., Kitzman D.W.,
Rao D.C., Hopkins P., Markovitz J., Arnett D.K. Blood pressure
responses to acute stress and left ventricular mass. Am.
J. Cardiol. 2002; 89: 536–540. OS
157. Rostrup M., Smith G., Björnstad H., Westheim A., Stokland O.,
Eide I. Left ventricular mass and cardiovascular reactivity in young
men. Hypertension 1994; 23 (supl. I): I168–I171. OS
158. Al’Absi M., Devereux R.B., Rao D.C., Kitzman D., Oberman
A., Hopkins P., Arnett D.K. Blood pressure stress reactivity
and left ventricular mass in a random community sample
of African-American and Caucasian men and women. Am.
J. Cardiol. 2006; 97: 240–244. OS
159. Fagard R.H., Pardaens K., Staessen J.A., Thijs L. Prognostic
value of invasive hemodynamic measurements at rest and during
exercise in hypertensive men. Hypertension 1996; 28: 31–36. OS
160. Kjeldsen S.E., Mundal R., Sandvik L., Erikssen G., Thaulow
E., Erikssen J. Supine and exercise systolic blood pressure
predict cardiovascular death in middle-aged men. J. Hypertens.
2001; 19: 1343–1348. OS
161. Palatini P. Exaggerated blood pressure response to exercise:
pathophysiologic mechanisms and clinical relevance.
J. Sports. Med. Phys. Fitness 1998; 38: 1–9. OS
162. O’ Rourke M.F. Principles and definitions of arterial stiffness,
wave reflections and pulse pressure amplification. W: Safar
M.E., O’Rourke M.F. (red.). Arterial stiffness in hypertension.
Handbook of Hypertension. Elsevier 2006; 23: 3–19. RV
163. Morgan T., Lauri J., Bertram D., Anderson A. Effect of
different antihypertensive drug classes on central aortic pressure.
Am. J. Hypertens. 2004; 17: 118–123.
164. Chen C.H., Nevo E., Fetics B., Pak P.H., Yin F.C., Maughan
W.L., Kass D.A. Estimation of central aortic pressure
waveform by mathematical transformation of radial tonometry
pressure. Validation of generalized transfer function. Circulation
1997; 95: 1827–1836.
165. Hope S.A., Tay D.B., Meredith I.T., Cameron J.D. Use
of arterial transfer functions for the derivation of aortic waveform
characteristics. J. Hypertens. 2003; 21: 1299–1305.
166. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton
A., Collier D., Hughes A.D., Thurston H., O’Rourke M.,
CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes
Trial Investigators; CAFE Steering Committee and Writing
Committee. Differential impact of blood pressure-lowering
drugs on central aortic pressure and clinical outcomes: principal
results of the Conduit Artery Function Evaluation (CAFE)
study. Circulation 2006; 113: 1213–1225. RT
167. Dhakam Z., McEniery C.M., Yasmin, Cockcroft J.R.,
Brown M.J., Wilkinson I.B. Atenolol and eprosartan: differential
effects on central blood pressure and aortic pulse wave
velocity. Am. J. Hypertens. 2006; 19: 214–219. RT
168. Ryden L., Standl E., Bartnik M., Van den Berghe G.,
Betteridge J., de Boer M.J., Cosentino F., Jonsson B., Laakso M.,
Malmberg K., Priori S., Ostergren J., Tuomilehto J., Thrainsdottir
I. Task Force on Diabetes and Cardiovascular Diseases
of the European Society of Cardiology (ESC); European Association
for the Study of Diabetes (EASD). Guidelines on
diabetes, pre-diabetes, and cardiovascular diseases: executive
summary: The Task Force on Diabetes and Cardiovascular
Diseases of the European Society of Cardiology (ESC) and of
the European Association for the Study of Diabetes (EASD).
Eur. Heart J. 2007; 28: 88–136. GL
169. Ridker P.M. High-sensitivity C-reactive protein: potential
adjunct for global risk assessment in the primary prevention of
cardiovascular disease. Circulation 2001; 103: 1813–1818. OS
170. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D.,
Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J.,
Benjamin E.J., D’Agostino R.B., Vasan R.S. Multiple biomarkers
for the prediction of first major cardiovascular events and
death. N. Engl. J. Med. 2006; 355: 2631–2639. OS
171. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive
protein, the metabolic syndrome, and risk of incident cardiovascular
events: an 8-year follow-up of 14 719 initially healthy
American women. Circulation 2003; 107: 391–397. OS
172. Sattar N., Gaw A., Scherbakova O., Ford I., O’Reilly D.S.,
Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M.,
Shepherd J. Metabolic syndrome with and without C-reactive
protein as a predictor of coronary heart disease and diabetes in
the West Of Scotland Coronary Prevention Study. Circulation
2003; 108: 414–419. OS
173. Olsen M.H., Wachtell K., Tuxen C., Fossum E., Bang L.E.,
Hall C., Ibsen H., Rokkedal J., Devereux R.B., Hildebrandt P.
N-terminal pro-brain natriuretic peptide predicts cardiovascular
events in patients with hypertension and left ventricular hypertrophy:
a LIFE study. J. Hypertens. 2004; 22: 1597–1604. OS
174. Luft F.C. Molecular genetics of human hypertension.
J. Hypertens. 1998; 16: 1871–1878. RV
175. Melander O. Genetic factors in hypertension –– what is known
and what does it mean? Blood Press 2001; 10: 254–270. RV
176. Cadman P.E., O’Connor D.T. Pharmacogenomics of
hypertension. Current Opin. Nephrol. Hypertens. 2003; 12:
61–70. RV
177. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms
of human hypertension. Cell 2001; 104: 545–556. RV
178. Jensen J.S., Feldt-Rasmussen B., Strandgaard S., Schroll M.,
Borch-Johnsen K. Arterial hypertension, microalbuminuria,
and risk of ischemic heart disease. Hypertension 2000; 35: 898–
–903. OS
179. De Leeuw P.W., Ruilope L.M., Palmer C.R., Brown M.J.,
Castaigne A., Mancia G., Rosenthal T., Wagener G. Clinical
significance of renal function in hypertensive patients at high
risk: results from the INSIGHT trial. Arch. Intern. Med. 2004;
164: 2459–2464. RT
180. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J.,
Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L.,
Kelepouris E., Klag M.J., Parfrey P., Pfeffer M., Raij L., Spinosa
D.J., Wilson P.W. American Heart Association Councils
on Kidney in Cardiovascular Disease, High Blood Pressure
Research, Clinical Cardiology, and Epidemiology and Prevention.
Kidney disease as a risk factor for development of cardiovascular
disease: a statement from the American Heart Association
Councils on Kidney in Cardiovascular Disease, High
Blood Pressure Research, Clinical Cardiology, and Epidemiology
and Prevention. Circulation 2003; 108: 2154–2169. GL
181. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F.,
Hoogwerf B., Halle J.P., Young J., Rashkow A., Joyce C., Nawaz
S., Yusuf S., HOPE Study Investigators. Albuminuria and
risk of cardiovascular events, death, and heart failure in diabetic
and nondiabetic individuals. JAMA 2001; 286: 421–426. OS
182. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K.,
Lindholm L.H., Mogensen C.E., Dahlof B., Devereux R.B.,
Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E.,
Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Okin P.M.,
Omvik P., Oparil S., Wedel H., Snapinn S.M., Aurup P. Albuminuria
and cardiovascular risk in hypertensive patients with
left ventricular hypertrophy: the LIFE study. Ann. Intern. Med.
2003; 139: 901–906. OS
183. Jager A., Kostense P.J., Ruhe H.G., Heine R.J., Nijpels G.,
Dekker J.M., Bouter L.M., Stehouwer C.D. Microalbuminuria
and peripheral arterial disease are independent predictors
of cardiovascular and all-cause mortality, especially among
hypertensive subjects: five-year follow-up of the Hoorn Study.
Arterioscler. Thromb. Vasc. Biol. 1999; 19: 617–624. OS
184. Bigazzi R., Bianchi S., Baldari D., Campese V.M. Microalbuminuria
predicts cardiovascular events and renal insufficiency
in patients with essential hypertension. J. Hypertens.
1998; 16: 1325–1333. OS
185. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H.,
de Zeeuw D., van Veldhuisen D.J., Gans R.O., Janssen W.M.,
Grobbee D.E., de Jong P.E., Prevention of Renal and Vascular
End Stage Disease (PREVEND) Study Group. Urinary
albumin excretion predicts cardiovascular and noncardiovascular
mortality in general population. Circulation 2002; 106: 1777–
–1782. OS
186. National Kidney Foundation. Executive summary. Am.
J. Kid. Dis. 2004; 43 (supl. 1): S16–S33. RV
187. Levy D., Salomon M., D’Agostino R.B., Belanger A.J.,
Kannel W.B. Prognostic implications of baseline electrocardiographic
features and their serial changes in subjects with left
ventricular hypertrophy. Circulation 1994; 90: 1786–1793. OS
188. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli
W.P. Prognostic implications of echocardiographically
determined left ventricular mass in the Framingham Heart
Study. N. Engl. J. Med. 1990; 322: 1561–1566. OS
189. Koren M.J., Devereux R.B., Casale P.N., Savage D.D.,
Laragh J.H. Relation of left ventricular mass and geometry to
morbidity and mortality in uncomplicated essential hypertension.
Ann. Intern. Med. 1991; 114: 345–352. OS
190. Salonen J.T., Salonen R. Ultrasound B-mode imaging in
observational studies of atherosclerotic progression. Circulation
1993; 87 (supl. II): II56–II65. OS
191. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., Grobbee
D.E. Common carotid intima-media thickness and risk of
stroke and myocardial infarction: The Rotterdam Study. Circulation
1997; 96: 1432–1437. OS
192. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C.R.,
Liu C.H., Azen S.P. The role of carotid arterial intima-media
thickness in predicting clinical coronary events. Ann. Intern.
Med. 1998; 128: 262–269. OS
193. O’Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A.,
Burke G.L., Wolfson S.K. Jr. Carotid-artery intima and media
thickness as a risk factor for myocardial infarction and stroke
in older adults. Cardiovascular Health Study Collaborative
Research Group. N. Engl. J. Med. 1999; 340: 14–22. OS
194. Cuspidi C., Ambrosioni E., Mancia G., Pessina A.C.,
Trimarco B., Zanchetti A. Role of echocardiography and carotid
ultrasonography in stratifying risk in patients with essential
hypertension: the Assessment of Prognostic Risk Observational
Survey. J. Hypertens. 2002; 20: 1307–1314. OS
195. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S.,
Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman
J.M., Wedel H., Lindholm L.H., Dahlof B., LIFE Study Investigators.
Regression of electrocardiographic left ventricular
hypertrophy during antihypertensive treatment and the prediction
of major cardiovascular events. JAMA 2004; 292: 2343–2349. OS
196. Fagard R.H., Staessen J.A., Thijs L., Celis H., Birkenhager W.H.,
Bulpitt C.J., de Leeuw P.W., Leonetti G., Sarti C., Tuomilehto J.,
Webster J., Yodfat Y., Systolic Hypertension in Europe (Syst-Eur)
Trial Investigators. Prognostic significance of electrocardiographic
voltages and their serial changes in elderly with systolic hypertension.
Hypertension 2004; 44: 459–464. OS
197. La Rovere M.T., Pinna G.D., Maestri R., Mortara A.,
Capomolla S., Febo O., Ferrari R., Franchini M., Gnemmi M.,
Opasich C., Riccardi P.G., Traversi E., Cobelli F. Short-term
heart rate variability strongly predicts sudden cardiac death in
chronic heart failure patients. Circulation 2003; 107: 565–570. OS
198. Bigger J.T. Jr, Fleiss J.L., Steinman R.C., Rolnitzky L.M.,
Kleiger R.E., Rottman J.N. Frequency domain measures of
heart period variability and mortality after myocardial infarction.
Circulation 1992; 85: 164–171. OS
199. Kleiger R.E., Miller J.P., Bigger J.T. Jr, Moss A.J., for the
Multicentre Post-Infarction Research Group. Decreased heart rate
variability and its association with increased mortality after acute
myocardial infarction. Am. J. Cardiol. 1987; 59: 256–262. OS
200. Reichek N., Devereux R.B. Left ventricular hypertrophy:
relationship of anatomic, echocardiographic and electrocardiographic
findings. Circulation 1981; 63: 1391–1398. OS
201. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J.,
Campo E., Sachs I., Reichek N. Echocardiographic assessment
of left ventricular hypertrophy: comparison to necropsy findings.
Am. J. Cardiol. 1986; 57: 450–458. OS
202. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A.,
Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J.,Shanewise J., Solomon S., Spencer K.T., St John Sutton M.,
Stewart W. American Society of Echocardiography’s Nomenclature
and Standards Committee; Task Force on Chamber Quantification;
American College of Cardiology Echocardiography
Committee; American Heart Association; European Association
of Echocardiography. European Society of Cardiology.
Recommendations for chamber quantification. Eur. J. Echocardiogr.
2006; 7: 79–108. GL
203. Jennings G., Wong J. Reversibility of left ventricular hypertrophy
and malfunction by antihypertensy treatment.
W: Hansson L., Birkenhager W.H. (red.). Handbook of Hypertension.
Elsevier Science, Amsterdam 1997; 18: 184–223. RV
204. Muiesan M.L., Salvetti M., Monteduro C., Bonzi B., Paini
A., Viola S., Poisa P., Rizzoni D., Castellano M., Agabiti-
-Rosei E. Left ventricular concentric geometry during treatment
adversely affects cardiovascular prognosis in hypertensive
patients. Hypertension 2004; 43: 731–738. OS
205. De Simone G., Devereux R.B., Koren M.J., Mensah G.A.,
Casale P.N., Laragh J.H. Midwall left ventricular mechanics.
An independent predictor of cardiovascular risk in arterial
hypertension. Circulation 1996; 93: 259–265. OS
206. Aurigemma G.P., Gottdiener J.S., Shemanski L., Gardin J.,
Kitzman D. Predictive value of systolic and diastolic function
for incident congestive heart failure in the elderly: The Cardiovascular
Health Study. J. Am. Coll. Cardiol. 2001; 37:
1042–1048. OS
207. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F.,
Komajda M., Tavazzi L., Smiseth O.A., Gavazzi A., Haverich
A., Hoes A., Jaarsma T., Korewicki J., Levy S., Linde C.,
Lopez-Sendon J.L., Nieminen M.S., Pierard L., Remme W.J.,
Task Force for the Diagnosis and Treatment of Chronic Heart
Failure of the European Society of Cardiology. Guidelines
for the diagnosis and treatment of chronic heart failure: executive
summary (update 2005): The Task Force for the Diagnosis
and Treatment of Chronic Heart Failure of the European
Society of Cardiology. Eur. Heart J. 2005; 26: 1115–1140. GL
208. Ogunyankin K.O., Burggraf G.W., Abiose A.K., Malik P.G.
Validity of revised Doppler echocardiographic algorithms and
composite clinical and angiographic data in diagnosis of diastolic
dysfunction. Echocardiography 2006; 23: 817–828. OS
209. Bursi F., Weston S.A., Redfield M.M., Jacobsen S.J., Pakhomov
S., Nkomo V.T., Meverden R.A., Roger V.L. Systolic
and diastolic heart failure in the community. JAMA 2006; 296:
2209–2216. OS
210. Zanchetti A., Agabiti-Rosei E., Ambrosioni E., Chiariello N.,
Leonetti G., Mancia G., Pessina A.C., Rizzon P., Salvetti A.,
Trimarco B., Volpe M. Left ventricular diastolic dysfunction
in a cohort of hypertensive patients attending hospital outpatient
clinics in Italy, the APROS-DIADYS project. J. Hypertension
2006; 24 (supl. 6): 41 (abstract). OS
211. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., Seward J.B.
Risks for atrial fibrillation and congestive heart failure in patients
>/= 65 years of age with abnormal left ventricular diastolic
relaxation. Am. J. Cardiol. 2004; 93: 54–58. OS
212. Redfield M.M., Jacobsen S.J., Burnett J.C. Jr, Mahoney D.W.,
Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic
ventricular dysfunction in the community: appreciating the
scope of the heart failure epidemic. JAMA 2003; 289: 194–202. OS
213. Bella J.N., Palmieri V., Roman M.J., Liu J.E., Welty T.K.,
Lee E.T., Fabsitz R.R., Howard B.V., Devereux R.B. Mitral
ratio of peak early to late diastolic filling velocity as a predictor
of mortality in middle-aged and elderly adults. The Strong
Heart Study. Circulation 2002; 105: 1928–1933. OS
214. Laukkanen J.A., Kurl S., Eranen J., Huttunen M., Salonen
J.T. Left atrium size and the risk of cardiovascular death
in middle-aged men. Arch. Intern. Med. 2005; 165: 1788–
–1793. OS
215. Verdecchia P., Reboldi G., Gattobigio R., Bentivoglio M.,
Borgioni C., Angeli F., Carluccio E., Sardone M.G., Porcellati
C. Atrial fibrillation in hypertension: predictors and outcome.
Hypertension 2003; 41: 218–223. OS
216. Kizer J.R., Bella J.N., Palmieri V., Liu J.E., Best L.G.,
Lee E.T., Roman M.J., Devereux R.B. Left atrial diameter as
an independent predictor of first clinical cardiovascular events
in middle-aged and elderly adults: the Strong Heart Study
(SHS). Am. Heart J. 2006; 151: 412–418. OS
217. Ciulla M., Paliotti R., Hess D.B., Tjahja E., Campbell S.E.,
Magrini F., Weber K.T. Echocardiographic patterns of myocardial
fibrosis in hypertensive patients: endomyocardial biopsy
versus ultrasonic tissue characterization. J. Am. Soc. Echocardiogr.
1997; 10: 657–664. OS
218. Hoyt R.M., Skorton D.J., Collins S.M., Melton H.E. Ultrasonic
backscatter and collagen in normal ventricular myocardium.
Circulation 1984; 69: 775–782. OS
219. Ciulla M.M., Paliotti R., Esposito A., Diez J., Lopez B.,
Dahlof B., Nicholls M.G., Smith R.D., Gilles L., Magrini F.,
Zanchetti A. Different effects of antihypertensive therapies
based on losartan or atenolol on ultrasound and biochemical
markers of myocardial fibrosis: results of a randomized trial.
Circulation 2004; 110: 552–557. RT
220. Zanchetti A., Bond M.G., Hennig M., Neiss A.,
Mancia G., Dal Palu C., Hansson L., Magnani B., Rahn K.H.,
Reid J.L., Rodicio J., Safar M., Eckes L., Rizzini P., European
Lacidipine Study on Atherosclerosis investigators.
Calcium antagonist lacidipine slows down progression of
asymptomatic carotid atherosclerosis: principal results of
the European Lacidipine Study on Atherosclerosis (ELSA),
a randomized, double-blind, long-term trial. Circulation
2002; 106: 2422–2427. RT
221. Zanchetti A., Bond M.G., Hennig M., Tang R., Hollweck
R., Mancia G., Eckes L., Micheli D., ELSA Investigators.
Absolute and relative changes in carotid intima-media
thickness and atherosclerotic plaques during long-term antihypertensive
treatment: further results of the European Lacidipine
Study on Atherosclerosis (ELSA). J. Hypertens. 2004;
22: 1201–1212. RT
222. Zanchetti A., Agabiti Rosei E., Dal Palu C., Leonetti G.,
Magnani B., Pessina A. The Verapamil in Hypertension and
Atherosclerosis Study (VHAS): results of long-term randomized
treatment with either verapamil or chlorthalidone on carotid
intima-media thickness. J. Hypertens. 1998; 16: 1667–
–1676. RT
223. Hiatt W.R. Medical treatment of peripheral arterial disease
and claudication. N. Engl. J. Med. 2001; 344: 1608–1621. RV
224. Vogt M.T., Cauley J.A., Newman A.B., Kuller L.H.,
Hulley S.B. Decreased ankle/arm blood pressure index and
mortality in elderly women. JAMA 1993; 270: 465–469. OS
225. McKenna M., Wolfson S., Kuller L. The ratio of ankle
and arm arterial pressure as an independent predictor of mortality.
Atherosclerosis 1991; 87: 119–128. OS
226. Vogt M.T., McKenna M., Anderson S.J., Wolfson S.K.,
Kuller L.H. The relationship between ankle-arm index and
mortality in older men and women. J. Am. Geriatr. Soc. 1993;
41: 523–530. OS
227. Burek K.A., Sutton-Tyrrell K., Brooks M.M., Naydeck B.,
Keller N., Sellers M.A., Roubin G., Jandova R., Rihal C.S.
Prognostic importance of lower extremity arterial disease in patients
undergoing coronary revascularization in the Bypass
Angioplasty Revascularization Investigation (BARI). J. Am.
Coll. Cardiol. 1999; 34: 716–721. OS
228. Safar M.E., Levy B.I., Struijker-Boudier H. Current perspectives
on arterial stiffness and pulse pressure in hypertension
and cardiovascular diseases. Circulation 2003; 107: 2864–
–2869. RV
229. Laurent S., Katsahian S., Fassot C., Tropeano A.I., Laloux
B., Boutouyrie P. Aortic stiffness is an independent predictor
of fatal stroke in essential hypertension. Stroke 2003; 34:
1203–1206. OS
230. Boutouyrie P., Tropeano A.I., Asmar R., Gautier I., Benetos
A., Lacolley P., Laurent S. Aortic stiffness is an independent
predictor of primary coronary events in hypertensive
patients: a longitudinal study. Hypertension 2002; 39: 10–15. OS
231. Park J.B., Schiffrin E.L. Small artery remodeling is the
most prevalent (earliest?) form of target organ damage in mild
essential hypertension. J. Hypertension 2001; 19: 921–930. OS
232. Korsgaard N., Aalkjaer C., Heagerty A.M., Izzard A.S.,
Mulvany M.J. Histology of subcutaneous small arteries from
patients with essential hypertension. Hypertension 1993; 22:
523–526.
233. Rizzoni D., Porteri E., Guelfi D., Muiesan M.L., Valentini
U., Cimino A., Girelli A., Rodella L., Bianchi R., Sleiman I.,
Agabiti-Rosei E. Structural alterations in subcutaneous small
arteries of normotensive and hypertensive patients with non-
-insulin-dependent diabetes mellitus. Circulation 2001; 103:
1238–1244.
234. Schofield I., Malik R., Izzard A., Austin C., Heagerty A.
Vascular structural and functional changes in type 2 diabetes
mellitus: evidence for the roles of abnormal myogenic responsiveness
and dyslipidemia. Circulation 2002; 106: 3037–3043. OS
235. Rizzoni D., Porteri E., Boari G.E., De Ciuceis C., Sleiman
I., Muiesan M.L., Castellano M., Miclini M., Agabiti-
Rosei E. Prognostic significance of small-artery structure in
hypertension. Circulation 2003; 108: 2230–2235.
236. Greenland P., Gaziano J.M. Clinical practice. Selecting
asymptomatic patients for coronary computed tomography or
electrocardiographic exercise testing. N. Engl. J. Med. 2003;
349: 465–473. RV
237. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T.
Endothelial dysfunction, oxidative stress, and risk of cardiovascular
events in patients with coronary artery disease. Circulation
2001; 104: 2673–2678. OS
238. Halcox J.P., Schenke W.H., Zalos G., Mincemoyer R.,
Prasad A., Waclawiw M.A., Nour K.R, Quyyumi A.A. Prognostic
value of coronary vascular endothelial dysfunction.
Circulation 2002; 106: 653–665. OS
239. Taddei S., Salvetti A. Endothelial dysfunction in essential
hypertension: clinical implications. J. Hypertens. 2002; 20:
1671–1674. RV
240. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K.,
Link A., Bohm M., Nickenig G. Circulating endothelial progenitor
cells and cardiovascular outcomes. N. Engl. J. Med.
2005; 353: 999–1007. OS
241. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing
kidney function –– measured and estimated glomerular filtration
rate. N. Engl. J. Med. 2006; 354: 2473–2483.
242. Moe S., Drueke T., CunninghamJ., Goodman W., Martin
K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan
G., Kidney Disease: Improving Global Outcomes (KDIGO).
Definition and classification of chronic kidney disease: a position
statement from Kidney Disease: Improving Global Outcomes
(KDIGO). Kidney Int. 2005; 67: 2089–2100. GL
243. Shlipak M.G., Katz R., Sarnak M.J., Fried L.F., Newman
A.B., Stehman-Breen C., Seliger S.L., Kestenbaum B.,
Psaty B., Tracy R.P., Siscovick D.S. Cystatin C and prognosis for
cardiovascular and kidney outcomes in elderly persons without
chronic kidney disease. Ann. Intern. Med. 2006; 145: 237–246. OS
244. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C.,
Parfrey P.S., Levy D. Cardiovascular disease and mortality in
a community-based cohort with mild renal insufficiency. Kidney
Int. 1999; 56: 2214–2219. OS
245. Parving H.H. Initiation and progression of diabetic nephropathy.
N. Engl. J. Med. 1996; 335: 1682–1683. RV
246. Ruilope L.M., Rodicio J.L. Clinical relevance of proteinuria
and microalbuminuria. Curr. Opin. Nephrol. Hypertens.
1993; 2: 962–967. RV
247. Redon J., Williams B. Microalbuminuria in essential hypertension:
redefining the threshold. J. Hypertens. 2002; 20:
353–355. RV
248. Arnlov J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D.,
Benjamin E.J., D’Agostino R.B., Vasan R.S. Low-grade albuminuria
and incidence of cardiovascular disease events in nonhypertensive
and nondiabetic individuals: the Framingham Heart Study.
Circulation 2005; 112: 969–975. OS
249. Zanchetti A., Hansson L., Dahlof B., Elmfeldt D., Kjeldsen
S., Kolloch R., Larochelle P., McInnes G.T., Mallion J.M.,
Ruilope L., Wedel H. Effects of individual risk factors on the
incidence of cardiovascular events in the treated hypertensive
patients of the Hypertension Optimal Treatment Study. HOT
Study Group. J. Hypertens. 2001; 19: 1149–1159. OS
250. Ruilope L.M., Salvetti A., Jamerson K., Hansson L., Warnold
I., Wedel H., Zanchetti A. Renal function and intensive
lowering of blood pressure in hypertensive participants of the
Hypertension Optimal Treatment (HOT) study. J. Am. Soc.
Nephrol. 2001; 12: 218–225. RT
251. De Leeuw P.W., Thijs L., Birkenhager W.H., Voyaki S.M.,
Efstratopoulos A.D., Fagard R.H., Leonetti G., Nachev C.,
Petrie J.C., Rodicio J.L., Rosenfeld J.J., Sarti C., Staessen J.A.,
Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Prognostic significance of renal function in elderly patients
with isolated systolic hypertension: results from the Syst-
Eur trial. J. Am. Soc. Nephrol. 2002; 13: 2213–2222. OS
252. Segura J., Ruilope L.M., Zanchetti A. On the importance
of estimating renal function for cardiovascular risk assessment.
J. Hypertens. 2004; 22: 1635–1639. RV
253. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright
J.T. Jr, Whelton P.K., Barzilay J., Batuman V., Eckfeldt J.H.,
Farber M.A., Franklin S., Henriquez M., Kopyt N., Louis G.T.,
Saklayen M., Stanford C., Walworth C., Ward H., Wiegmann T.,
ALLHAT Collaborative Research Group. Cardiovascular outcomes
in high-risk hypertensive patients stratified by baseline glomerular
filtration rate. Ann. Intern. Med. 2006; 144: 172–180. OS
254. Keith N.H., Wagener H.P., Barker M.W. Some different
types of essential hypertension: their course and prognosis. Am.
J. Med. Sci. 1939; 197: 332–343. OS
255. Cuspidi C., Macca G., Salerno M., Michev L., Fusi V.,
Severgnini B., Corti C., Meani S., Magrini F., Zanchetti A.
Evaluation of target organ damage in arterial hypertension:
which role for qualitative funduscopic examination? Ital. Heart
J. 2001; 2: 702–706. OS
256. Dimmitt S.B., West J.N., Eames S.M., Gibson J.M., Gosling
P., Littler W.A. Usefulness of ophthalmoscopy in mild
to moderate hypertension. Lancet 1989; 1: 1103–1106. OS
257. Fuchs F.D., Maestri M.K., Bredemeier M., Cardozo S.E.,
Moreira F.C., Wainstein M.V., Moreira W.D., Moreira L.B.
Study of the usefulness of optic fundi examination of patients
with hypertension in a clinical setting. J. Hum. Hypertens.
1995; 9: 547–551. OS
258. Wong T.Y., Klein R., Sharrett A.R., Duncan B.B., Couper
D.J., Tielsch J.M., Klein B.E., Hubbard L.D. Retinal arteriolar
narrowing and risk of coronary heart disease in men
and women. The Atherosclerosis Risk in Communities Study.
JAMA 2002; 287: 1153–1159. OS
259. Wong T.Y., Klein R., Sharrett A.R., Couper D.J., Klein B.E.,
Liao D.P., Hubbard L.D., Mosley T.H., ARIC Investigators.
Atheroslerosis Risk in Communities Study. Retinal microvascular
abnormalities and incident stroke: the Atherosclerosis
Risk in Communities Study. Lancet 2001; 358: 1134–1140. OS
260. Martinez-Perez M.E., Hughes A.D., Stanton A.V., Thom S.A.,
Chapman N., Bharath A.A., Parker K.H. Retinal vascular tree
morphology: a semi-automatic quantification. IEEE Trans.
Biomed. Eng. 2002; 49: 912–917.
261. Hughes A.D., Martinez-Perez E., Jabbar A.S., Hassan
A., Witt N.W., Mistry P.D., Chapman N., Stanton A.V., Beevers
G., Pedrinelli R., Parker K.H., Thom S.A. Quantification
of topological changes in retinal vascular architecture in
essential and malignant hypertension. J. Hypertens. 2006;
24: 889–894.
262. Antonios T.F., Singer D.R., Markandu N.D., Mortimer P.S.,
MacGregor G.A. Rarefaction of skin capillaries in borderline
essential hypertension suggests an early structural abnormality.
Hypertension 1999; 34: 655–658. OS
263. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W.,
Edwards H.V., Watt G.C. Impaired microvascular dilatation
and capillary rarefaction in young adults with a predisposition
to high blood pressure. J. Clin. Invest. 1997; 99: 1873–1879. OS
264. Price T.R., Manolio T.A., Kronmal R.A., Kittner S.J., Yue N.C.,
Robbins J., Anton-Culver H., O’Leary D.H. Silent brain infarction
on magnetic resonance imaging and neurological abnormalities
in community-dwelling older adults: the Cardiovascular
Health Study. Stroke 1997; 28: 1158–1164. OS
265. Liao D., Cooper L., Cai J., Toole J.F., Bryan N.R., Hutchinson
R.G., Tyroler H.A. Presence and severity of cerebral
white matter lesions and hypertension, its treatment, and its
control: The ARIC Study. Stroke 1996; 27: 2262–2270. OS
266. Vermeer S.E., Koudstaal P.J., Oudkerk M., Hofman A., Breteler
M.M. Prevalence and risk factors of silent brain infarcts in the
population-based Rotterdam Scan Study. Stroke 2002; 33: 21–25. OS
267. Longstreth W.T. Jr, Manolio T.A., Arnold A., Burke G.L.,
Bryan N., Jungreis C.A., Enright P.L., O’Leary D., Fried L.
Clinical correlates of white matter findings on cranial magnetic
resonance imaging of 3301 elderly people. The Cardiovascular
Health Study. Stroke 1996; 27: 1274–1282. OS
268. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E.,
Koudstaal P.J., Oudkerk M., Hofman A., Breteler M.M. Cerebral
white matter lesions and the risk of dementia. Arch.
Neurol. 2004; 61: 1531–1534. OS
269. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A.,
Koudstaal P.J., Breteler M.M., Rotterdam Scan Study. Silent
brain infarcts and white matter lesions increase stroke risk in
the general population: the Rotterdam Scan Study. Stroke 2000;
34: 1126–1129. OS
270. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson
L.A., Nilsson L., Persson G., Oden A., Svanborg A.
15-year longitudinal study of blood pressure and dementia.
Lancet 1996; 347: 1141–1145. OS
271. Kilander L., Nyman H., Boberg M., Hansson L., Lithell H.
Hypertension is related to cognitive impairment: A 20-year
follow-up of 999 men. Hypertension 1998; 31: 780–786. OS
272. Launer L.J., Masaki K., Petrovitch H., Foley D., Havlik
R.J. The association between midlife blood pressure levels and
late-life cognitive function. The Honolulu-Asia Aging Study.
JAMA 1995; 274: 1846–1851. OS
273. Mancia G. Role of outcome trials in providing information
on antihypertensive treatment: importance and limitations.
Am. J. Hypertens. 2006; 19: 1–7. RV
274. Zanchetti A. Evidence-based medicine in hypertension:
what type of evidence? J. Hypertens. 2005; 23: 1113–1120. RV
275. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene
M.R., Babeanu S., Bossini A., Fagard R., Gil-Extremera B.,
Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H.,
Webster J., Yodfat Y., Birkenhager W.H., Systolic Hypertension
in Europe Investigators. The prevention of dementia with
antihypertensive treatment: new evidence from the Systolic
Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med.
2002; 162: 2046–2052. CT
276. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene
M.R., Babeanu S., Bossini A., Fagard R., Gil-Extremera B.,
Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H.,
Webster J., Yodfat Y., Birkenhager W.H., Systolic Hypertension
in Europe Investigators. Systolic Hypertension in Europe (Syst-
-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive
therapy on outcome in the Systolic Hypertension
in Europe Trial. J. Hypertens. 2004; 22: 847–857. CT
277. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S.
Renal insufficiency as a predictor of cardiovascular outcomes
and the impact of ramipril: the HOPE randomized trial. Ann.
Intern. Med. 2001; 134: 629–636. CT
278. Veterans Administration Cooperative Study Group on
Antihypertensive Agents. Effects of treatment on morbidity in
hypertension. II. Results in patients with diastolic blood pressure
averaging 115 through 129 mmHg. JAMA 1967; 202:
1026–1034. RT
279. Medical Research Council Working Party. MRC trial of
treatment of mild hypertension: principal results. Medical
Research Council BMJ 1985; 291: 97–104. RT
280. SHEP Collaborative Research Group. Prevention of stroke
by antihypertensive drug treatment in older persons with isolated
systolic hypertension: final results of the Systolic Hypertension
in the Elderly Program (SHEP). JAMA 1991; 265:
3255–3264. RT
281. Dahlof B., Lindholm L.H., Hansson L., Schersten B.,
Ekbom T., Wester P.O. Morbidity and mortality in the Swedish
Trial in Old Patients with Hypertension (STOP-Hypertension).
Lancet 1991; 338: 1281–1285. RT
282. Amery A., Birkenhager W., Brixko P., Bulpitt C., Clement
D., Deruyttere M., De Schaepdryver A., Dollery C., Fagard
R., Forette F. Mortality and morbidity results from the
European Working Party on High Blood Pressure in the Elderly
trial. Lancet 1985; 1: 1349–1354. RT
283. PROGRESS Collaborative Study Group. Randomised
trial of perindopril based blood pressure-lowering regimen
among 6108 individuals with previous stroke or transient ischaemic
attack. Lancet 2001; 358: 1033–1041. RT
284. Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G.,
Birkenhager W.H., Bulpitt C.J., de Leeuw P.W., Dollery C.T.,
Fletcher A.E., Forette F., Leonetti G., Nachev C., O’Brien E.T.,
Rosenfeld J., Rodicio J.L., Tuomilehto J., Zanchetti A., for the
Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and
active treatment for older patients with isolated systolic hypertension.
Lancet 1997; 350: 757–764. RT
285. Gong L., Zhang W., Zhu Y., Zhu J., Kong D., Page V.,
Ghadirian P., LeLorier J., Hamet P. Shanghai trial of nifedipine
in the elderly (STONE). J. Hypertens. 1996; 16: 1237–
–1245. CT
286. Liu L., Wang J.L., Gong L., Liu G., Staessen J.A., for the
Syst-China Collaborative Group. Comparison of active treatment
and placebo in older Chinese patients with isolated systolic
hypertension. J. Hypertens. 1998; 16: 1823–1829. CT
287. Coope J., Warrender T.S. Randomised trial of treatment
of hypertension in elderly patients in primary care. Br. Med.
J. 1986; 293: 1145–1151. RT
288. MRC Working Party. Medical Research Council trial of
treatmeant of hypertension in older adults: principal results.
Br. Med. J. 1992; 304: 405–412. RT
289. PATS Collaborative Group. Post-stroke antihypertensive
treatment study. Chin. Med. J. 1995; 108: 710–717. RT
290. Helgeland A. Treatment of mild hypertension: a five year
controlled drug trial. The Oslo study. Am. J. Med. 1980; 69:
725–732. RT
291. Management Committee. The Australian therapeutic trial
in mild hypertension. Lancet 1980; 1: 1261–1267. RT
292. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Effects of different blood-pressure-lowering regimens on
major cardiovascular events: results of prospectively-designed
overviews of randomised trials. Lancet 2003; 362: 1527–1535. MA
293. Staessen J.A., Wang J.G., Thijs L. Cardiovascular prevention
and blood pressure reduction: a quantitative overview updated
until 1 March 2003. J. Hypertens. 2003; 21: 1055–1076. MA
294. Staessen J.A., Gasowski J., Wang J.G., Thijs L., Den Hond E.,
Boissel J.P., Coope J., Ekbom T., Gueyffier F., Liu L., Kerlikowske
K., Pocock S., Fagard R.H. Risks of untreated and treated
isolated systolic hypertension in the elderly: meta-analysis
of outcome trials. Lancet 2000; 355: 865–872. MA
295. Gueyffier F., Boutitie F., Boissel J.P., Pocock S., Coope J.,
Cutler J., Ekbom T., Fagard R., Friedman L., Perry M., Prineas
R., Schron E. The effect of antihypertensive drug treatment
on cardiovascular outcomes in women and men. Results
from a meta-analysis of individual patient data randomised controlled
trials. Ann. Intern. Med. 1997; 126: 761–767. MA
296. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Effects of different blood pressure-lowering regimens
on major cardiovascular events in individuals with and without
diabetes mellitus. Results of prospectively designed overviews
of randomized trials. Arch. Intern. Med. 2005; 165:
1410–1419. MA
297. Bradley H.A., Wiysonge C.S., Volmink J.A., Mayosi B.M.,
Opie L.H. How strong is the evidence for use of beta-blockers
as first-line therapy for hypertension? Systematic review and
meta-analysis. J. Hypertens. 2006; 24: 2131–2141. MA
298. Neal B., MacMahon S., Chapman N.; Blood Pressure
Lowering Treatment Trialists’ Collaboration. Effects of ACE
inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of
randomised trials. Blood Pressure Lowering Treatment Trialists’
Collaboration. Lancet. 2000; 356: 1955–1964.
299. Brewster L.M., van Montfrans G.A., Kleijnen J. Systematic
review: antihypertensive drug therapy in black patients. Ann.
Intern. Med. 2004; 141: 614–627. MA
300. The Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor,
ramipril, on cardiovascular events in high-risk patients.
N. Engl. J. Med. 2000; 342: 145–153. RT
301. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A.,
FEVER Study Group. The Felodipine Event Reduction
(FEVER) Study: a randomized long-term placebo-controlled
trial in Chinese hypertensive patients. J. Hypertens. 2005;
23: 2157–2172. RT
302. The EURopean trial On reduction of cardiac events with
Perindopril in stable coronary Artery disease Investigators. On
reduction of cardiac events with Perindopril in stable coronary
Artery disease Investigators. Efficacy of perindopril in reduction
of cardiovascular events among patients with stable
coronary artery disease: randomised, double-blind, placebo-
-controlled, multicentre trial (the EUROPA study). Lancet
2003; 362: 782–788. RT
303. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J.,
Wagener G., Danchin N., Just H., Fox K.A., Pocock S.J., Clayton
T.C., Motro M., Parker J.D., Bourassa M.G., Dart A.M.,
Hildebrandt P., Hjalmarson A., Kragten J.A., Molhoek G.P.,
Otterstad J.E., Seabra-Gomes R., Soler-Soler J., Weber S.,
A Coronary disease Trial Investigating Outcome with Nifedipine
gastrointestinal therapeutic system investigators. Effect
of long-acting nifedipine on mortality and cardiovascular morbidity
in patients with stable angina requiring treatment
(ACTION trial): randomised controlled trial. Lancet 2004; 364:
849–857. RT
304. Lubsen J., Wagener G., Kirwan B.A., de Brouwer S., Poole-
Wilson P.A., ACTION (A Coronary disease Trial Investigating
Outcome with Nifedipine GITS) investigators. Effect of
long-acting nifedipine on mortality and cardiovascular morbidity
in patients with symptomatic stable angina and hypertension:
the ACTION trial. J. Hypertens 2005; 23: 641–648. CT
305. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D.,
Ghali M., Garza D., Berman L., Shi H., Buebendorf E., Topol
E.J., CAMELOT Investigators. Effect of antihypertensive
agents on cardiovascular events in patients with coronary disease
and normal blood pressure: the CAMELOT study:
a randomized controlled trial. JAMA 2004; 292: 2217–2225. RT
306. The PEACE trial investigators. Angiotensin-converting-
-enzime inhibition in stable coronary artery disease. New. Engl.
J. Med. 2004; 351: 2058–2068. RT
307. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A.,
Olofsson B., Trenkwalder P., Zanchetti A., SCOPE Study
Group. The Study on Cognition and Prognosis in the Elderly
(SCOPE). Principal results of a randomised double-blind intervention
trial. J. Hypertens 2003; 21: 875–886. RT
308. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch
W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z.,
Shahinfar S., RENAAL Study Investigators. Effects of losartan
on renal and cardiovascular outcomes in patients with type 2
diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861–
–869. RT
309. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A.,
Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., Collaborative
Study Group. Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N. Engl. J. Med. 2001; 345: 851–860. RT
310. Pourdjabbar A., Lapointe N., Rouleau J.-L. Angiotensin
receptor blockers: Powerful evidence with cardiovascular outcomes?
Can. J. Cardiol. 2002; 18 (supl. A): 7A–14A. MA
311. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B.,
Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling
S. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of
the Hypertension Optimal Treatment (HOT) randomised
trial. Lancet 1998; 351: 1755–1762. RT
312. Hypertension Detection and Follow-up Program. The
effect of treatment on mortality in ‘mild’ hypertension: results
of the Hypertension Detection and Follow-up Program.
N. Engl. J. Med 1982; 307: 976– 980. RT
313. Hansson L., Lindholm L.H., Niskanen L., Lanke J.,
Hedner T., Niklason A., Luomanmaki K., Dahlof B., de Faire
U., Morlin C., Karlberg B.E., Wester P.O., Bjorck J.E. Effect
of angiotensin-converting-enzyme inhibition compared with
conventional therapy on cardiovascular morbidity and mortality
in hypertension: the Captopril Prevention Project (CAPPP)
randomised trial. Lancet 1999; 353: 611–616. RT
314. Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke
J., Schersten B., Wester P.O., Hedner T., de Faire U. Randomised
trial of old and new antihypertensive drugs in elderly
patients: cardiovascular mortality and morbidity in the Swedish
Trial in Old Patients with Hypertension-2 study. Lancet
1999; 354: 1751–1756. RT
315. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E.,
Lindholm L.H., Syvertsen J.O., Lanke J., de Faire U., Dahlof B.,
Karlberg B.E. Randomised trial of effects of calcium antagonists
compared with diuretics and beta-blockers on cardiovascular
morbidity and mortality in hypertension: the Nordic
Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365. RT
316. UK Prospective Diabetes Study Group. Efficacy of atenolol
and captopril in reducing risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 39. BMJ.
1998; 317: 713–720. RT
317. Agodoa L.Y., Appel L., Bakris G.L., Beck G., Bourgoignie
J., Briggs J.P., Charleston J., Cheek D., Cleveland W.,
Douglas J.G., Douglas M., Dowie D., FaulknerM., Gabriel A.,
Gassman J., Greene T., Hall Y., Hebert L., Hiremath L., Jamerson
K,. Johnson C.J., Kopple J., Kusek J., Lash J., Lea J.,
Lewis J.B., Lipkowitz M., Massry S., Middleton J., Miller E.R.
3rd, Norris K., O’Connor D., Ojo A., Phillips R.A., Pogue V.,
Rahman M., Randall O.S., Rostand S., Schulman G., Smith W.,
Thornley-Brown D., Tisher C.C., Toto R.D., Wright J.T. Jr,
Xu S., African American Study of Kidney Disease and Hypertension
(AASK) Study Group. Effect of Ramipril vs Amlodipine
on Renal Outcomes in Hypertensive Nephrosclerosis.
A Randomized Controlled Trial. JAMA 2001; 285: 2719–2728. RT
318. Wright J.T. Jr, Bakris G., Greene T., Agodoa L.Y., Appel L.J.,
Charleston J., Cheek D., Douglas-Baltimore J.G., Gassman J.,
Glassock R., Hebert L., Jamerson K., Lewis J., Phillips R.A.,
Toto R.D., Middleton J.P., Rostand S.G., African American
Study of Kidney Disease and Hypertension Study Group. Effect
of blood pressure lowering and antihypertensive drug class
on progression of hypertensive kidney disease: results from the
AASK Trial. JAMA 2002; 288: 2421–2431. RT
319. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of
aggressive blood pressure control in normotensive type 2 diabetic
patients on albuminuria, retinopathy and stroke. Kidney
Int. 2002; 61: 1086–1097. RT
320. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L.,
Gifford N., Schrier R.W. The effect of nisoldipine as compared
with enalapril on cardiovascular outcomes in patients with
non-insulin independent diabetes and hypertension. N. Engl.
J. Med 1998; 338: 645–652. RT
321. Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W.,
Mancia G., Rosenthal T., Ruilope L.M. Morbidity and mortality
in patients randomised to double-blind treatment with a long-acting
calcium-channel blocker or diuretic in the International
Nifedipine GITS study: Intervention as a Goal in
Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–
–372. RT
322. The ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group. Major outcomes in
high-risk hypertensive patients randomized to angiotensin-
-converting enzyme inhibitor or calcium channel blocker vs
diuretic: The Antihypertensive and Lipid-Lowering treatment
to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:
2981–2997. RT
323. Black H.R., Elliott W.J., Grandits G., Grambsch P.,
Lucente T., White W.B., Neaton J.D., Grimm R.H. Jr, Hansson
L., Lacourciere Y., Muller J., Sleight P., Weber M.A., Williams
G., Wittes J., Zanchetti A., Anders R.J., CONVINCE
Research Group. Principal results of the Controlled Onset Verapamil
Investigation of Cardiovascular Endpoints
(CONVINCE) trial. JAMA 2003; 289: 2073–2082. RT
324. Malacco E., Mancia G., Rappelli A., Menotti A., Zuccaro
M.S., Coppini A., SHELL Investigators. Treatment of isolated
systolic hypertension: the SHELL study results. Blood
Press 2003; 12: 160–167. RT
325. NICS Study Group. Randomized double-blind comparison
of a calcium antagonist and a diuretic in elderly hypertensives.
National Intervention Cooperative Study in Elderly Hypertensives
Study Group. Hypertension 1999; 34: 1129–1133. RT
326. Yui Y., Sumiyoshi T., Kodama K., Hirayama A., Nonogi H.,
Kanmatsuse K., Origasa H., Iimura O., Ishii M., Saruta T.,
Arakawa K., Hosoda S., Kawai C., Japan Multicenter Investigation
for Cardiovascular Diseases-B. Study Group. Comparison
of nifedipine retard with angiotensin converting enzyme
inhibitors in Japanese hypertensive patients with coronary
artery disease: the Japan Multicenter Investigation for Cardiovascular
Diseases-B (JMIC-B) randomized trial. Hypertens.
Res. 2004; 27: 181–191. RT
327. Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A.,
Jennings .G.L., Johnston C.I., McNeil J.J., Macdonald G.J.,
Marley J.E., Morgan T.O., West M.J., Second Australian National
Blood Pressure Study Group. A comparison of outcomes
with angiotensin-converting-enzyme inhibitors and diuretics
for hypertension in the elderly. N. Engl. J. Med. 2003;
348: 583–592. RT
328. Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio
M., Thijs L., Staessen J.A., Porcellati C. Angiotensin-
-converting enzyme inhibitors and calcium channel blockers
for coronary heart disease and strokeprevention. Hypertension
2005; 46: 386–392. MA
329. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Blood pressure dependent and independent effects of
agents that inhibit the renin-angiotensin system. J. Hypertens.
2007; 25: 951–958. MA
330. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G.,
Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes
G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.,
ASCOT Investigators. Prevention of cardiovascular events
with an antihypertensive regimen of amlodipine adding perindopril
as required versus atenolol adding bendoflumethiazide
as required, in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):
a multicentre randomized controlled trial. Lancet 2005; 366:
895–906. RT
331. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M.,
Marks R.G., Kowey P., Messerli F.H., Mancia G., Cangiano J.L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H.A., Kolb H.R.,
Bakris G.L., Cohen J.D., Parmley W.W., INVEST Investigators.
A calcium antagonist vs a non-calcium antagonist hypertension
treatment strategy for patients with coronary artery disease.
The International Verapamil-Trandolapril Study
(INVEST): a randomized controlled trial. JAMA 2003; 290:
2805–2816. RT
332. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers
G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K.,
Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S.,
Omvik P., Oparil S., Wedel H., LIFE Study Group. Cardiovascular
morbidity and mortality in the Losartan Intervention
For Endpoint reduction in hypertension study (LIFE): a randomised
trial against atenolol. Lancet 2002; 359: 995–1003. RT
333. Schrader J., Luders S., Kulschewski A., Hammersen F.,
Plate K., Berger J., Zidek W., Dominiak P., Diener H.C.,
MOSES Study Group. Morbidity and Mortality After Stroke.
Eprosartan Compared with Nitrendipine for Secondary Prevention:
principal results of a prospective randomized controlled
study (MOSES). Stroke 2005; 36: 1218–1226. RT
334. Mochizuki S., Dahlof B., Shimizu M., Ikewaki K., Yoshikawa
M., Taniguchi I., Ohta M., Yamada T., Ogawa K., Kanae
K., Kawai M., Seki S., Okazaki F., Taniguchi M., Yoshida
S., Tajima N. for the Jikei Heart Study group. Valsartan in
a Japanese population with hypertension and other cardiovascular
disease (Jikei Heart Study): a randomised, open-label,
blinded endpoint morbidity-mortality study. Lancet 2007; 369:
1431–1439 RT.
335. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman
S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell
L., Plat F., Schork A., Smith B., Zanchetti A., VALUE
trial group. Outcomes in hypertensive patients at high cardiovascular
risk treated with regimens based on valsartan or amlodipine:
the VALUE randomised trial. Lancet 2004; 363:
2022–2031. RT
336. Verma S., Strauss M. Angiotensin receptor blockers and
myocardial infarction. Br. Med. J. 2004; 329: 1248–1249. RV
337. Volpe M., Mancia G., Trimarco B. Angiotensin receptor
blockers and myocardial infarction: the importance of dosage.
J. Hypertens 2006; 24: 1681–1682. RV
338. Verdecchia P., Angeli F., Gattobigio R., Reboldi G.P. Do
angiotensin II receptor blockers increase the risk of myocardial
infarction? Eur. Heart. J. 2005; 26: 2381–2386. MA
339. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F.,
Ramos B., Hilbrich L., Pogue J., Schumacher H., ONTARGET/
TRANSCEND Investigators. Rationale, design, and
baseline characteristics of 2 large, simple, randomized trials
evaluating telmisartan, ramipril, and their combination in
high-risk patients: the Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial/Telmisartan
Randomized Assessment Study in ACE Intolerant Subjects
with Cardiovascular Disease (ONTARGET/TRANSCEND)
trials. Am Heart J 2004; 148: 52–61. RT
340. Dickstein K., Kjekshus J., OPTIMAAL Steering Committee
of the OPTIMAAL Study Group. Effects of losartan
and captopril on mortality and morbidity in high-risk patients
after acute myocardial infarction: the OPTIMAAL randomised
trial. Optimal Trial in Myocardial Infarction with Angiotensin
II Antagonist Losartan. Lancet 2002; 360: 752–760. RT
341. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L.,
Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de
Werf F., White H., Leimberger J.D., Henis M., Edwards S.,
Zelenkofske S., Sellers M.A., Califf R.M., Valsartan in Acute
Myocardial Infarction Trial Investigators. Valsartan, captopril,
or both in myocardial infarction complicated by heart failure,
left ventricular dysfunction, or both. N. Engl. J. Med. 2003;
349: 1893–1896. RT
342. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein
K., Camm A.J., Konstam M.A., Riegger G., Klinger G.H.,
Neaton J., Sharma D., Thiyagarajan B. Effect of losartan compared
with captopril on mortality in patients with symptomatic
heart failure: randomised trial–the Losartan Heart Failure
Survival Study ELITE II. Lancet 2000; 355: 1582–1587. RT
343. Lindholm L.H., Carlberg B., Samuelsson O. Should beta
blockers remain first choice in the treatment of primary hypertension?
A meta-analysis. Lancet 2005; 366: 1545–1553. MA
344. Hypertension: management of hypertension in aduts in
primary care NICE/BHS. June 2006. www.nice.org.uk/
/CG034. GL
345. McInnes G.T., Kjeldsen S.E. Never mind the quality,
feel the width–ALLHAT revisited. Blood Press 2004; 13: 330–
–334. RV
346. Wright J.T. Jr, Dunn J.K., Cutler J.A., Davis B.R., Cushman
W.C., Ford C.E., Haywood L.J., Leenen F.H., Margolis K.L.,
Papademetriou V., Probstfield J.L., Whelton P.K., Habib G.B.,
ALLHAT Collaborative Research Group. Outcomes in hypertensive
black and nonblack patients treated with chlorthalidone,
amlodipine, and lisinopril. JAMA 2005; 293: 1595–1608. CT
347. Cuspidi C., Muiesan M.L., Valagussa L., Salvetti M., Di
Biagio C., Agabiti-Rosei E., Magnani B., Zanchetti A.,
CATCH investigators. Comparative effects of candesartan and
enalapril on left ventricular hypertrophy in patients with essential
hypertension: the Candesartan Assessment in the Treatment
of Cardiac Hypertrophy (CATCH) study J. Hypertens
2002; 20: 2293–2300. RT
348. Jennings G.L., McMullen J.R. Left ventricular hypertrophy.
Beyond the image and defining human cardiac
phenotype in hypertension. J. Hypertens. 2007; 25 (5): 941–
–947. RV
349. Klingbeil A.U., Schneider M. Martus P., Messerli F.H.,
Schmieder R.E. A meta-analysis of the effects of treatment on
left ventricular mass i essential hypertension. Am. J. Med. 2003;
115: 41–46. MA
350. Terpstra W.F., May J.F., Smit A.J., de Graeff P.A., Havinga
T.K., van den Veur E., Schuurman F.H., Meyboom-de
Jong B., Crijns H.J. Long-term effects of amlodipine and lisinopril
on left ventricular mass and diastolic function in elderly,
previously untreated hypertensive patients: the ELVERA
trial. J. Hypertens 2001; 19: 303–309. RT
351. Devereux R.B., Palmieri V., Sharpe N., De Quattro V.,
Bella J.N., de Simone G., Walker J.F., Hahn R.T., Dahlof B.
Effects of once-daily angiotensinconverting enzyme inhibition
and calcium channel blockade-based antihypertensive treatment
regimens on left ventricular hypertrophy and diastolic
filling in hypertension. The Prospective Randomized Enalapril
Study Evaluating Regression of Ventricular Enlargement
(PRESERVE) trial. Circulation 2001; 104: 1248–1254. RT
352. Zanchetti A., Ruilope L.M., Cuspidi C., Macca G., Verschuren
J., Kerselaers W. Comparative effects of the ACE inhibitor
fosinopril and the calcium antagonist amlodipine on
left ventricular hypertrophy and urinary albumin excretion in
hypertensive patients. Results of FOAM, a multicenter European
study. J. Hypertens 2001; 19 (supl. 2): S92 (abstract). RT
353. Agabiti-Rosei E., Trimarco B., Muiesan M.L., Reid J.,
Salvetti A., Tang R., Hennig M., Baurecht H., Parati G., Mancia
G., Zanchetti A., ELSA Echocardiographic Substudy Group.
Cardiac structural and functional changes during long-
-term antihypertensive treatment with lacidipine and atenolol
in the European Lacidipine Study on Atherosclerosis (ELSA).
J. Hypertens. 2005; 23: 1091–1098. CT
354. Thurmann P.A., Kenedi P., Schmidt A., Harder S., Rietbrock
N. Influence of the angiotensin II antagonist valsartan
on left ventricular hypertrophy in patients with essential hypertension.
Circulation 1998; 98: 2037–2042. RT
355. Malmqvist K., Kahan T., Edner M., Held C., Hagg A.,
Lind L., Muller-Brunotte R., Nystrom F., Ohman K.P., Osbakken
M.D., Ostergern J. Regression of left ventricular hypertrophy
in human hypertension with irbesartan. J. Hypertens. 2001;
19: 1167–1176. RT
356. Dahlof B., Zanchetti A., Diez J., Nicholls M.G., Yu C.M.,
Barrios V., Aurup P., Smith R.D., Johansson M., For the
REGAAL Study Investigators. Effects of losartan and atenolol
on left ventricular mass and neurohormonal profile in patients
with essential hypertension and left ventricular hypertrophy.
J. Hypertens. 2002; 20: 1855–1864. RT
357. Devereux R.B., Dahlof B., Gerdts E., Boman K., Nieminen
M.S., Papademetriou V., Rokkedal J., Harris K.E., Edelman
J.M., Wachtell K. Regression of hypertensive left ventricular
hypertrophy by losartan compared with atenolol: the
Losartan Intervention for Endpoint Reduction in Hypertension
(LIFE) trial. Circulation 2004; 110: 1456–1462. RT
358. De Luca N., Mallion J.M., O’Rourke M.F., O’Brien E.,
Rahn K.H., Trimarco B., Romero R., De Leeuw P.W., Hitzenberger
G., Battegay E., Duprez D., Sever P., Safar M.E. Regression
of left ventricular mass in hypertensive patients treated with
perindopril/indapamide as a first-line combination: the REASON
echocardiography study. Am.J. Hypertens 2004; 17: 660–667. RT
359. Dahlof B., Gosse P., Gueret P., Dubourg O., de Simone G.,
Schmieder R., Karpov Y., Garcia-Puig J., Matos L., De Leeuw P.W.,
Degaute J.P., Magometschnigg D., The PICXEL Investigators.
Perindopril/indapamide combination more effective than enalapril
in reducing blood pressure and left ventricular mass: the
PICXEL study. J. Hypertens. 2005; 23: 2063–2070. RT
360. De Luca N., Asmar R.G., London G.M., O’Rourke M.F.,
Safar M.E., REASON Project Investigators. Selective reduction
of cardiac mass and central blood pressure on low-dose
combination perindopril/indapamide in hypertensive subjects.
J. Hypertens. 2004; 22: 1623–1630. RT
361. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R.A.,
Roniker B., Kleiman J., Krause S., Burns D., Williams G.H.
Effects of eplerenone, enalapril, and eplerenone/enalapril in
patients with essential hypertension and left ventricular hypertrophy:
the 4E-left ventricular hypertrophy study. Circulation
2003; 108: 1831–1838. RT
362. Galzerano D., Tammaro P., del Viscovo L., Lama D.,
Galzerano A., Breglio R., Tuccillo B., Paolisso G., Capogrosso
P. Three-dimensional echocardiographic and magnetic
resonance assessment of the effect of telmisartan compared with
carvedilol on left ventricular mass a multicenter, randomized,
longitudinal study. Am. J. Hypertens. 2005; 18: 1563–1569. RT
363. Gosse P., Sheridan D.J., Zannad F., Dubourg O., Gueret P.,
Karpov Y., de Leeuw P.W., Palma-Gamiz J.L., Pessina A.,
Motz W., Degaute J.P., Chastang C. Regression of left ventricular
hypertrophy in hypertensive patients treated with indapamide
SR 1.5mg versus enalapril 20 mg; the LIVE study.
J. Hypertens. 2000; 18: 1465–1475. RT
364. Muiesan M.L., Salvetti M., Rizzoni D., Castellano M.,
Donato F., Agabiti Rosei E. Association of change in left ventricular
mass with prognosis during long-term antihypertensive
treatment. J. Hypertens. 1995; 13: 1091–1095. OS
365. Koren M.J., Ulin R.J., Koren A.T., Laragh J.H., Devereux
R.B. Left ventricular mass change during treatment and
outcome in patients with essential hypertension. Am. J. Hypertens.
2002; 15: 1021–1028. OS
366. Cuspidi C., Ciulla M., Zanchetti A. Hypertensive myocardial
fibrosis. Nephrol Dial Transplant 2006; 21: 20–
–23. RV
367. Ciulla M.M, Paliotti R., Esposito A., Cuspidi C., Muiesan
M.L., Salvetti M., Agabiti-Rosei E., Magrini F., Zanchetti A.
Effects of the angiotension receptor antagonist candesartan and
the ACE inhibitor Enalapril on ultrasound markers of myocardial
fibrosis in hypertensive patients with left ventricular
hypertrophy. J. Hypertens. 2005; 23 (supl. 2): S381 (abstract). RT
368. Christensen M.K., Olsen M.H., Wachtell K., Tuxen C.,
Fossum E., Bang L.E., Wiinberg N., Devereux R.B., Kjeldsen
S.E., Hildebrandt P., Rokkedal J., Ibsen H. Does long-term
losartan- vs atenolol-based antihypertensive treatment influence
collagen markers differently in hypertensive patients?
A LIFE substudy. Blood Press 2006; 15: 198–206. CT
369. Olsen M.H., Wachtell K., Tuxen C., Fossum E., Bang L.E.,
Hall C., Ibsen H., Rokkedal J., Devereux R.B., Hildebrandt P.
N-terminal pro-brain natriuretic peptide predicts cardiovascular
events in patients with hypertension and left ventricular
hypertrophy: a LIFE study. J. Hypertens. 2004; 22: 1597–1604. OS
370. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S.,
Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M.,
Dahlof B., Losartan Intervention for Endpoint reduction in
hypertension Study Investigations. Regression of electrocardiographic
left ventricular hypertrophy by losartan versus atenolol:
The Losartan Intervention For Endpoint reduction in
Hypertension (LIFE) Study. Circulation 2003; 108: 684–690. RT
371. Schneider M.P., Klingbeil A.U., Delles C., Ludwig M.,
Kolloch R.E., Krekler M., Stumpe K.O., Schmieder R.E. Effect
of irbesartan versus atenolol on left ventricular mass and
voltage: results of the CardioVascular Irbesartan Project. Hypertension
2004; 44: 61–66. RT
372. Havranek E.P., Esler A., Estacio R.O., Mehler P.S., Schrier R.W.
Appropriate Blood Pressure Control in Diabetes Trial. Differential
effects of antihypertensive agents on electrocardiographic
voltage: results from the Appropriate Blood Pressure
Control in Diabetes (ABCD) trial. Am. Heart J. 2003; 145:
993–998. RT
373. Muller-Brunotte R., Edner M.,Malmqvist K., Kahan T.
Irbesartan and atenolol improve diastolic function in patients
with hypertensive left ventricular hypertrophy. J. Hypertens.
2005; 23: 633–640. RT
374. Cuspidi C., Meani S., Valerio C., Fusi V., Catini E., Sala C.,
Zanchetti A. Ambulatory blood pressure, target organ damage
and left atrial size in never-treated essential hypertensive individuals.
J. Hypertens. 2005; 23: 1589–1595. OS
375. Gerdts E., Wachtell K., Omvik P., Otterstad J.E., Oikarinen
L., Boman K., Dahlof B., Devereux R.B. Left atrial size
and risk of major cardiovascular events during antihypertensive
treatment: losartan intervention for endpoint reduction
in hypertension trial. Hypertension 2007; 49: 311–316. OS
376. Aksnes T.A., Flaa A., Strand A., Kjeldsen S.E. Prevention
of new-onset atrial fibrillation and its predictors with angiotensin
II-receptor blockers in the treatment of hypertension
and heart failure. J. Hypertens. 2007; 25: 15–23. RV
377. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam
B., Dahlof B., Ibsen H., Julius S., Kjeldsen S.E., Lindholm
L.H., Nieminen M.S., Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent
stroke compared to atenolol: the Losartan Intervention
For End Point Reduction in Hypertension (LIFE) study. J.
Am. Coll. Cardiol. 2005; 45: 712–719. RT
378. Schmieder R., Kjeldsen S.E., Julius S., McInnes G.T.,
Zanchetti A., Hua T. Reduced incidence of new onset atrial
fibrillation with angiotensin II receptor blockade: the VALUE-
-trial. J. Hypertens. 2006; 24: S3 (abstract). RT
379. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S.,
White M., Guerra P.G., Ducharme A. Enalapril decreases the
incidence of atrial fibrillation in patients with left ventricular dysfunction:
insight from the Studies Of Left Ventricular Dysfunction
(SOLVD) trials. Circulation 2003; 107: 2926–2931. RT
380. Ducharme A., Swedberg K., Pfeffer M.A., Cohen-Solal A.,
Granger C.B., Maggioni A.P., Michelson E.L., McMurray J.J.,
Olsson L., Rouleau J.L., Young J.B., Olofsson B., Puu M.,
Yusuf S., CHARM Investigators. Prevention of atrial fibrillation
in patients with symptomatic chronic heart failure by candesartan
in the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) program.
Am. Heart J. 2006; 152: 86–92. RT
381. Maggioni A.P., Latini R., Carson P.E., Singh S.N., Barlera
S., Glazer R., Masson S., Cere E., Tognoni G., Cohn J.N.,
Val-He F.T. Investigators. Valsartan reduces the incidence of
atrial fibrillation in patients with heart failure: results from
the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart
J. 2005; 149: 548–557. RT
382. Okin P.M., Wachtell K., Devereux R.B., Harris K.E., Jern S.,
Kjeldsen S.E., Julius S., Lindholm L.H., Nieminen M.S.,
Edelman J.M., Hille D.A., Dahlof B. Regression of electrocardiographic
left ventricular hypertrophy and decreased incidence
of new-onset atrial fibrillation in patients with hypertension.
JAMA 2006; 296: 1242–1248. OS
383. Madrid A.H., Bueno M.G., Rebollo J.M., Marin I., Pena G.,
Bernal E., Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C.
Use of irbesartan to maintain sinus rhythm in patients with
long-lasting persistent atrial fibrillation: a prospective and randomized
study. Circulation 2002; 106: 331–336. RT
384. Fogari R., Mugellini A., Destro M., Corradi L., Zoppi A.,
Fogari E., Rinaldi A. Losartan and prevention of atrial fibrillation
recurrence in hypertensive patients. J. Cardiovasc. Pharmacol.
2006; 47: 46–50. RT
385. Disertori M., Latini R., Maggioni A.P., Delise P., Di Pasquale
G., Franzosi M.G., Staszewsky L., Tognoni G., on behalf
of the GISSI-AF Investigators; Rationale and design of
the GISSI-Atrial Fibrillation Trial: a randomized, prospective,
multicentre study on the use of valsartan, an angiotensin II
AT1-receptor blocker, in the prevention of atrial fibrillation
recurrence. J. Cardiovasc. Med. 2006; 7: 29–38. RT
386. Wang J.G., Staessen J.A., Li Y., Van Bortel L.M., Nawrot T.,
Fagard R., Messerli F.H., Safar M. Carotid intima-media thickness
and antihypertensive reatment: a meta-analysis of randomized
controlled trials. Stroke 2006; 37: 1933–1940. MA
387. MacMahon S., Sharpe N., Gamble G., Clague A., Mhurchu C.N.,
Clark T., Hart H., Scott J., White H. Randomized, placebo-controlled
trial of the angiotensin-converting enzyme inhibitor, ramipril, in
patients with coronary or other occlusive arterial disease. PART-2
Collaborative Research Group. Prevention of Atherosclerosis with
Ramipril. J. Am. Coll. Cardiol. 2000; 36: 438–443. RT
388. Asselbergs F.W., van Roon A.R., Hillege H.L., de Jong R.E.,
Gans R.O.B., Smit A.J., van Gilst W.H., on behalf of the
PREVEND IT Investigators; PREVEND IT Investigators. Effects
of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 2005; 36: 649–653. RT
389. Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G.
Low-dose metoprolol CR/XL and fluvastatin slow progression
of carotid intimamedia thickness: Main results from the
Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque
Study (BCAPS). Circulation 2001; 103: 1721–1726. RT
390. Zanchetti A., Crepaldi G., Bond M.G., Gallus G., Veglia F.,
Mancia G., Ventura A., Baggio G., Sampietri L., Rubba P.,
Sperti G., Magni A., on behalf of PHYLLIS Investigators.
Different effects of antihypertensive regimens based on fosinopril
or hydrochlorothiazide with or without lipid lowering
by pravastatin on progression of asymptomatic carotid atherosclerosis:
principal results of PHYLLIS — a randomized double-
blind trial. Stroke 2004; 35: 2807–2812. RT
391. Simon A., Gariépy J., Moyse D., Levenson J. Differential
effects of nifedipine and co-amilozide on the progression of early
carotid wall changes. Circulation 2001; 103: 2949–2954. CT
392. Terpstra W.F., May J.F., Smit A.J., Graeff P.A., Meyboom-
de Jong B., Crijns H.J. Effects of amlodipine and lisinopril
on intima-media thickness in previously untreated, elderly
hypertensive patients (the ELVERA trial). J. Hypertens.
2004; 22: 1309–1316. RT
393. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B.,
Mancini G.B.J., Miller M.E., Riley W. Effect of amlodipine
on the progression of atherosclerosis and the occurrence of
clinical events. Circulation 2000; 102: 1503–1510. RT
394. Lonn E.M., Yusuf S., Dzavik V., Doris C.I., Yi Q., Smith S.,
Moore-Cox A., Bosch J., Riley W.A., Teo K.K. Effects of ramipril
and vitamin E on atherosclerosis: The Study to Evaluate
Carotid Ultrasound changes in patients treated with Ramipril
and vitamin E SECURE). Circulation 2001; 103: 919–925. CT
395. Borhani N.O., Mercuri M., Borhani P.A., Buckalew V.M.,
Canossa-Terris M., Carr A.A., Kappagoda T., Rocco M.V.,
Schnaper H.W., Sowers J.R., Bond M.G. Final outcome results
of the Multicenter Isradipine Diuretic Atherosclerosis
Study (MIDAS). A randomized controlled trial. JAMA 1996;
276: 785–791. RT
396. Ciulla M.M., Paliotti R., Ferrero S., Vandoni P., Magrini F.,
Zanchetti A. Assessment of carotid plaque composition in
hypertensive patients by ultrasonic tissue characterization:
a validation study. J. Hypertens. 2002; 20: 1589–1596.
397. Paliotti R., Ciulla M.M., Hennig M., Tang R., Bond M.G.,
Mancia G., Magrini F., Zanchetti A. Carotid wall composition
in hypertensive patients after 4-year treatment with lacidipine
or atenolol: an echoreflectivity study. J. Hypertens. 2005;
23: 1203–1209. CT
398. Asmar R. Effect of antihypertensive agents on arterial stiffness
as evaluated by pulse wave velocity: clinical implications.
Am. J. Cardiovasc. Drugs 2001; 1: 387–397. RV
399. Ichihara A., Hayashi M., Koura Y., Tada Y., Hirota N.,
Saruta T. Long-termneffects of intensive blood-pressure lowering
on arterial wall stiffness inn hypertensive patients. Am.
J. Hypertens. 2003; 16: 959–965. OS
400. Asmar R.G., London G.M., O’Rourke M.E., Safar M.E.,
REASON Project Coordinators and Investigators. Improvement
in blood pressure, arterial stiffness and wave reflections
with a very-low-dose perindopril/ indapamide combination in
hypertensive patient: a comparison with atenolol. Hypertension
2001; 38: 922–926. RT
401. Rajzer M., Klocek M., Kawecka-Jaszcz K. Effect of amlodipine,
quinapril and losartan on pulse wave velocity and plasma
collagen markers in patients with mild-to-moderate arterial
hypertension. Am. J. Hypertens. 2003; 16: 439–444. RT 402.
Munakata M., Nagasaki A., Nunokawa T., Sakuma T.,
Kato H., Yoshinaga K., Toyota T. Effects of valsartan and nifedipine
coat-core on systemic arterial stiffness in hypertensive
patients. Am. J. Hypertens. 2004; 17: 1050–1055. RT
403. Dhakam Z., McEniery C.M., Yasmin, Cockcroft J.R.,
Brown M.J., Wilkinson I.B. Atenolol and eprosartan: differential
effects on central blood pressure and aortic pulse wave
velocity. Am. J. Hypertens. 2006; 19: 214–219. RT
404. Staessen J.A., Richart T., Birkenhager W.H. Less atherosclerosis
and lower blood pressure for a meaningful life perspective
with more brain. Hypertension 2007; 49: 389–400. RV
405. Dufouil C., Chalmers J., Coskun O., Besancon V., Bousser
M.G., Guillon P., MacMahon S., Mazoyer B., Neal B.,
Woodward M., Tzourio-Mazoyer N., Tzourio C.,
PROGRESS MRI Substudy Investigators. Effects of blood
pressure lowering on cerebral white matter hyperintensities in
patients with stroke: the PROGRESS (Perindopril Protection
Against Recurrent Stroke Study) Magnetic Resonance Imaging
Substudy. Circulation 2005; 112: 1644–1650. CT
406. Birns J., Morris R., Donaldson N., Kalra L. The effects of
blood pressure reduction on cognitive function: a review of
effects based on pooled data from clinical trials. J. Hypertens.
2006; 24: 1907–1914. MA
407. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhager
W.H., Babarskiene M.R., Babeanu S., Bossini A., Gil-Extremera
B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomilehto
J., Vanhanen H., Webster J., Yodfat Y., Fagard R. Prevention
of dementia with antihypertensive treatment: new
evidence from the Systolic Hypertension in Europe (Syst-Eur)
study. Lancet 1998; 352: 1347–1351. RT
408. Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A.,
Olofsson B., Trenkwalder P., Zanchetti A., SCOPE Study
Group. Effect of baseline cognitive function and antihypertensive
treatment on cognitive and cardiovascular outcomes:
Study on COgnition and Prognosis in the Elderly (SCOPE).
Am. J. Hypertens. 2005; 18: 1052–1059. RT
409. Goldstein G., Materson B.J., Cushman W.C., Reda D.J.,
Freis E.D., Ramirez E.A., Talmers F.N., White T.J., Nunn S.,
Chapman R.H. Treatment of hypertension in the elderly: II.
Cognitive and behavioral function. Results of a Department
of Veterans Affairs Cooperative Study. Hypertension 1990;
15: 361–369. RT
410. McCorvey E. Jr, Wright J.T. Jr, Culbert J.P., McKenney J.M.,
Proctor J.D., Annett M.P. Effect of hydrochlorothiazide, enalapril,
and propranolol on quality of life and cognitive and motor function
in hypertensive patients. Clin. Pharm. 1993; 12: 300–305. RT
411. Leonetti G., Salvetti A. Effects of cilazapril and nitrendipine
on blood pressure, mood, sleep, and cognitive function
in elderly hypertensive patients: an Italian multicenter study.
J. Cardiovasc. Pharmacol. 1994; 24 (supl. 3): S73–77. RT
412. Starr J.M., Whalley L.J., Deary I.J. The effects of antihypertensive
treatment on cognitive function: results from the
HOPE study. J. Am. Geriatr. Soc. 1996; 44: 411–415. CT
413. Fogari R., Mugellini A., Zoppi A., Marasi G., Pasotti C.,
Poletti L., Rinaldi A., Preti P. Effects of valsartan compared
with enalapril on blood pressure and cognitive function in elderly
patients with essential hypertension. Eur. J. Clin. Pharmacol.
2004; 59: 863–868. RT
414. Prince M.J., Bird A.S., Blizard R.A., Mann A.H. Is the
cognitive function of older patients affected by antihypertensive
treatment? Results from 54 months of the Medical Research
Council’s trial of hypertension in older adults. BMJ 1996;
312: 801–805. CT 415. Casas J.P., Chua W., Loukogeorgakis S., Vallance P.,
Smeeth L., Hingorani A.D., MacAllister R.J. Effect of inhibitors
of the renin-angiotensin system and other antihypertensive
drugs on renal outcomes: systematic review and meta-
-analysis. Lancet 2005; 366: 2026–2033. MA
416. De Zeeuw D., Lewis E.J., Remuzzi G., Brenner B.M.,
Cooper M.E. Renoprotective effects of renin-angiotensin-
-system inhibitors. Lancet 2006; 367: 899–900.
417. Mann J.F., Ritz E., Kunz R. Renoprotective effects of renin-
angiotensinsystem inhibitors. Lancet 2006; 367: 900
418. Zanchetti A., Ruilope L.M. Antihypertensive treatment
in patients with type-2 diabetes mellitus: what guidance from
recent controlled randomized trials? J. Hypertens. 2002; 20:
2099–2110. RV
419. Karalliedde J., Viberti G. Evidence for renoprotection by
blockade of the renin-angiotensin-aldosterone system in hypertension
and diabetes. J. Hum. Hypertens. 2006; 20: 239–
–253. RT
420. Kidney Disease Outcomes Quality Initiative (K/DOQI).
K/DOQI clinical practice guidelines on hypertension and antihypertensive
agents in chronic kidney disease. Am. J. Kidney.
Dis. 2004; 43 (5 supl. 1): S1–290. GL
421. Levey A.S., Greene T., Beck G.J., Caggiula A.W., Kusek J.W.,
Hunsicker L.G., Klahr S. Dietary protein restriction and the
progression of chronic renal disease: what have all of the results
of the MDRD study shown? Modification of Diet in Renal
Disease Study group. J. Am. Soc. Nephrol. 1999; 10: 2426–
–2439. CT
422. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect
of blood pressure control on diabetic microvascular complications
in patients with hypertension and type 2 diabetes.
Diabetes Care 2000; 23 (supl. 2): B54–B64. RT
423. Estacio R.O., Coll J.R., Tran Z.V., Schrier R.W. Effect of
intensive blood pressure control with valsartan on urinary albumin
excretion in normotensive patients with type 2 diabetes.
Am. J. Hypertens. 2006; 19: 1241–1248. RT
424. Ruggenenti P., Perna A., Loriga G., Ganeva M., Ene-
Iordache B., Turturro M., Lesti M., Perticucci E., Chakarski I.N.,
Leonardis D., Garini G., Sessa A., Basile C., Alpa M., Scanziani
R., Sorba G, Zoccali C., Remuzzi G., REIN-2 Study
Group; REIN-2 Study Group. Blood-pressure control for renoprotection
in patients with non-diabetic chronic renal disease
(REIN-2): multicentre, randomised controlled trial. Lancet
2005; 365: 939–946. RT
425. Pohl M.A., Blumenthal S., Cordonnier D.J., De Alvaro F.,
Deferrari G., Eisner G., Esmatjes E., Gilbert R.E., Hunsicker
L.G., de Faria J.B., Mangili R., Moore J. Jr, Reisin E., Ritz E.,
Schernthaner G., Spitalewitz S., Tindall H., Rodby R.A., Lewis
E.J. Independent and additive impact of blood pressure
control and angiotensin II receptor blockade on renal outcomes
in the irbesartan diabetic nephropathy trial: clinical implications
and limitations. J. Am. Soc. Nephrol 2005; 16: 3027–
–3037. CT
426. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G.,
de Jong P.E., de Zeeuw D., Shahinfar S., Toto R., Levey A.S.,
AIPRD Study Group. Progression of chronic kidney disease:
the role of blood pressure control, proteinuria, and angiotensin-
converting enzyme inhibition: a patient-level meta-analysis.
Ann. Intern. Med. 2003; 139: 244–252. MA
427. UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular complications
in Type 2 diabetes. UKPDS38. BMJ 1998; 317: 703–
–713. RT
428. Heart Outcomes Prevention Evaluation (HOPE) Study
investigators. Effects of ramipril on cardiovascular and microvascular
outcomes in people with diabetes mellitus: results of
the HOPE study and MICROHOPE substudy. Lancet 2000;
355: 253–259. RT
429. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews
D.R., Cull C.A., Wright A.D., Turner R.C., Holman R.R.
Association of systolic blood pressure with macrovascular and
microvascular complications of type 2 diabetes (UKPDS 36): prospective
observational study. Br. Med. J. 2000; 321: 412–429. OS
430. Randomised placebo-controlled trial of effect of ramipril
on decline in glomerular filtration rate and risk of terminal
renal failure in proteinuric, non-diabetic nephropathy. The
GISEN Group (Gruppo Italiano di Studi Epidemiologici in
Nefrologia). Lancet 1997; 349: 1857–1863. RT
431. Mann J.F., Gerstein H.C., Yi Q.L., Franke J., Lonn E.M.,
Hoogwerf B.J., Rashkow A., Yusuf S., HOPE Investigators.
Progression of renal insufficiency in type 2 diabetes with and
without microalbuminuria: results of the Heart Outcomes and
Prevention Evaluation (HOPE) randomized study. Am.
J. Kidney. Dis. 2003; 42: 936–942. RT
432. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P.,
Brusegan V., Rubis N., Gherardi G., Arnoldi F., Ganeva M.,
Ene-Iordache B., Gaspari F., Perna A., Bossi A., Trevisan R.,
Dodesini A.R., Remuzzi G., Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) Investigators. Preventing
microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004;
351: 1941–1951. RT
433. Mogensen C.E., Viberti G., Halimi S., Ritz E., Ruilope L.,
Jermendy G., Widimsky J., Sareli P., Taton J, Rull J., Erdogan G.,
De Leeuw P.W., Ribeiro A., Sanchez R., Mechmeche R., Nolan
J., Sirotiakova J., Hamani A,. Scheen A., Hess B., Luger A.,
Thomas S.M., Preterax in Albuminuria Regression (PREMIER)
Study Group. Effect of low-dose perindopril/indapamide
on albuminuria in diabetes: Preterax in albuminuria regression:
PREMIER. Hypertension 2003; 41: 1063–1071. RT
434. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The
effect of angiotensin-converting enzyme inhibition on diabetic
nephropathy. The Collaborative Study Group. N. Engl.
J. Med. 1993; 329: 1456–1462. RT
435. Parving H-H., Lehnert H., Bröchner-Mortensen J., Gomis
R., Andersen S., Arner P. The effect of irbesartan on the
development of diabetic nephropathy in patients with type 2 diabetes.
N. Engl. J. Med. 2001; 345: 870–878. RT
436. Schjoedt K.J., Rossing K., Juhl T.R., Boomsma F., Tarnow
L., Rossing P., Parving H.H. Beneficial impact of spironolactone
on nephritic range albuminuria in diabetic nephropathy.
Kidney Int 2006; 70: 536–542. RT
437. Voyaki S.M., Staessen J.A., Thijs L., Wang J.G., Efstratopoulos
A.D., Birkenhager W.H., de Leeuw P.W., Leonetti G.,
Nachev C., Rodicio J.L., Tuomilehto J., Fagard R., Systolic
Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-
up of renal function in treated and untreated older patients
with isolated systolic hypertension. Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators. J. Hypertens.
2001; 19: 511–519. RT
438. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright
J.T. Jr, Whelton P.K., Barzilay J., Batuman V., Eckfeldt J.H.,
Farber M., Henriquez M., Kopyt N., Louis G.T., Saklayen M.,
Stanford C., Walworth C., Ward H,. Wiegmann T. Renal
outcomes in high-risk hypertensive patients treated with an
angiotensin-converting enzyme inhibitor or a calcium channel
blocker vs a diuretic: a report from the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Arch. Intern. Med. 2005; 165: 936–946. CT
439. Barnett A.H. Preventing renal complications in diabetic
patients: the Diabetics Exposed to Telmisartan And enalaprIL
(DETAIL) study 1. Acta. Diabetol. 2005; 42 (supl. 1): S42–S49. RT
440. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K.,
Lindholm L.H., Mogensen C.E., Dahlof B., Snapinn S.M.,
Wan Y., Lyle P.A. Does albuminuria predict cardiovascular
outcomes on treatment with losartan versus atenolol in patients
with diabetes, hypertension, and left ventricular hypertrophy?
The LIFE study. Diabetes Care 2006; 29: 595–600. CT
441. Viberti G., Wheeldon N.M., MicroAlbuminuria Reduction
With VALsartan (MARVAL) Study Investigators. Microalbuminuria
reduction with valsartan in patients with type 2
diabetes mellitus: a blood pressure-independent effect. Circulation
2002; 106: 672–678. RT
442. Vogt L., Navis G., Koster J., Manolis A.J., Reid J.L., de
Zeeuw D., on behalf of the Angiotensin II Receptor Antagonist
Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS)
Study Group. The angiotensin II receptor antagonist telmisartan
reduces urinary albumin excretion in patients with isolated
systolic hypertension: results of a randomized, double-blind,
placebo-controlled trial. J. Hypertens. 2005; 23: 2055–2061. RT
443. White W.B., Duprez D., St Hillaire R., Krause S., Roniker
B., Kuse-Hamilton J., Weber M.A. Effects of the selective
aldosterone blocker eplerenone versus the calcium antagonist
amlodipine in systolic hypertension. Hypertension 2003; 41:
1021–1026. RT
444. Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla
A., Fioretto P., Crepaldi G. Effect of lercanidipine compared
with ramipril on albumin excretion rate in hypertensive
Type 2 diabetic patients with microalbuminuria: DIAL study.
Diabetes. Nutr. Metab. 2004; 17: 259–266. RT
445. Marre M., Puig J.G., Kokot F., Fernandez M., Jermendy G.,
Opie L., Moyseev V., Scheen A., Ionescu-Tirgoviste C., Saldanha
M.H., Halabe A., Williams B., Mion Junior D., Ruiz M.,
Hermansen K., Tuomilehto J., Finizola B., Gallois Y., Amouyel
P., Ollivier J.P., Asmar R. Equivalence of indapamide SR
and enalapril on microalbuminuria reduction in hypertensive
patients with type 2 diabetes: the NESTOR Study. J. Hypertens.
2004; 22: 1613–1622. RT
446. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T.,
Ideura T. Combination treatment of angiotensin-II receptor
blocker and angiotensin-converting-enzyme inhibitor in nondiabetic
renal disease (COOPERATE): a randomised controlled
trial. Lancet 2003; 361: 117–124. RT
447. Kincaid-Smith P., Fairley K., Packham D. Randomized
controlled crossover study of the effect on proteinuria and blood
pressure of adding an angiotensin II receptor antagonist to
an angiotensin converting enzyme inhibitor in normotensive
patients with chronic renal disease and proteinuria. Nephrol.
Dial. Transplant. 2002; 17: 597–601. RT
448. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper
R., Watts R.W., Cooper M.E. Randomised controlled trial of dual
blockade of renin-angiotensin system in patients with hypertension,
microalbuminuria, and non-insulin dependent diabetes: the
candesartan and lisinopril microalbuminuria (CALM) study.
Br. Med. J. 2000; 321: 1440–1444. RT
449. Andersen N.H., Poulsen P.L., Knudsen S.T., Poulsen S.H.,
Eiskjaer H., Hansen K.W., Helleberg K., Mogensen C.E.
Long-term dual blockade with candesartan and lisinopril in
hypertensive patients with diabetes: the CALM II study. Diabetes.
Care 2005; 28: 273–277. RT
450. MacKinnon M., Shurraw S., Akbari A., Knoll G.A., Jaffey
J., Clark H.D. Combination therapy with an angiotensin
receptor blocker and an ACE inhibitor in proteinuric renal
disease: a systematic review of the efficacy and safety data.
Am. J. Kidney. Dis. 2006; 48: 8–20. MA
451. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., Parving
H.H. Enhanced renoprotective effects of ultrahigh doses
of irbesartan in patients with type 2 diabetes and microalbuminuria.
Kidney Int. 2005; 68: 1190–1198. RT
452. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., Veelken
R., Delles C. Additional antiproteinuric effect of ultrahigh
dose candesartan: a doubleblind, randomized, prospective
study. J. Am. Soc. Nephrol. 2005; 16: 3038–3045. RT
453. Kannel W.B., Wilson P.W., Zhang T.J. The epidemiology
of impaired glucose tolerance and hypertension. Am. Heart
J. 1991; 121: 1268–1273. OS
454. Stamler J., Vaccaro O., Neaton J.D.,Wentworth D. Diabetes,
other risk factors, and 12-yr cardiovascular mortality for
men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care 1993; 16: 434–444. CT
455. Mancia G., Grassi G., Zanchetti A. New-onset diabetes
and antihypertensive drugs. J. Hypertens 2006; 24: 3–10. RV
456. Norris K., Bourgoigne J., Gassman J., Hebert L., Middleton
J., Phillips R.A., Randall O., Rostand S., Sherer S., Toto R.D.,
Wright J.T. Jr, Wang X, Greene T.,. Appel L. J., Lewis J., AASK
Study Group. Cardiovascular outcomes in the African American
Study of Kidney Disease and Hypertension (AASK) Trial.
Am. J. Kidney. Dis. 2006; 48: 739–751. RT
457. Lindholm L.H., Persson M., Alaupovic P, Carlberg B.,
Svensson A., Samuelsson O. Metabolic outcome during 1 year
in newly detected hypertensives: results of the Antihypertensive
Treatment and Lipid Profile in a North of Sweden Efficacy
Evaluation (ALPINE study). J. Hypertens. 2003; 21:
1563–1574. RT
458. Opie L.H., Schall R. Old antihypertensives and new diabetes.
J. Hypertens. 2004; 22: 1453–1458. MA
459. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove
N.M., Pressel S.L., Davis B.R., SHEP Collaborative Research
Group. Long-term effect of diuretic-based therapy on fatal
outcomes in subjects with isolated systolic hypertension with
and without diabetes. Am. J. Cardiol. 2005; 95: 29–35. CT
460. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials
of antihypertensive drugs: a network meta-analysis. Lancet
2007; 369: 201–207. MA
461. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S.,
Peyster E.; Studies of Left Ventricular Dysfunction. Diuretic
use, progressive heart failure, and death in patients in the Studies
Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll.
Cardiol. 2003; 42: 705–708. RT
462. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J.,
Wolffenbuttel B.H., Zinman B., HOPE Study Investigators.
Ramipril and the development of diabetes. JAMA 2001; 286:
1882–1885. RT
463. Pfeffer M.A., Swedberg K., Granger C.B., Held P.,
McMurray J.J., Michelson E.L., Olofsson B., Ostergren J.,
Yusuf S., Pocock S., CHARM Investigators and Committees.
Effects of candesartan on mortality and morbidity in patients
with chronic heart failure: the CHARM-Overall programme.
Lancet 2003; 362: 759–766. RT
464. DREAM Trial Investigators; Bosch J., Yusuf S., Gerstein H.C.,
Pogue J., Sheridan P., Dagenais G., Diaz R., Avezum A., Lanas F.,
Probstfield J., Fodor G., Holman R.R. Effect of ramipril on the
incidence of diabetes. N. Engl. J. Med 2006; 355: 1551–1562. RT 465. Howard B.V., Rodriguez B.L., Bennett P.H., Harris M.I.,
Hamman R., Kuller L.H., Pearson T.A., Wylie-Rosett J. Prevention
Conference VI: Diabetes and Cardiovascular disease: Writing
Group I: epidemiology. Circulation 2002; 105: 132–137. RV
466. Alderman M.H., Cohen H., Madhavan S. Diabetes and
cardiovascular events in hypertensive patients. Hypertension
1999; 33: 1130–1134. OS
467. Dunder K., Lind L., Zethelius B., Berglund L., Lithell H.
Increase in blood glucose concentration during antihypertensive
treatment as a predictor of myocardial infarction: population
based cohort study. Br. Med. J. 2003; 326: 681. OS
468. Eberly L.E., Cohen J.D., Prineas R., Yang L., Intervention
Trial Research group. Impact of incident diabetes and
incident nonfatal cardiovascular disease on 18-year mortality:
the multiple risk factor intervention trial experience. Diabetes
Care 2003; 26: 848–854. CT
469. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio
R., Filippucci L., Norgiolini S., Bracco C., Porcellati C.
Adverse prognostic significance of new diabetes in treated hypertensive
subjects. Hypertension 2004; 43: 963–969. OS
470. Almgren T., Willemsen O., Samuelsson O., Himmelmann
A., Rosengren A., Anderson O.K. Diabetes in treated hypertension
is common and carries a high cardiovascular risk:
results from 20 years follow up. J. Hypertens. 2007; 25 (6): 1311–
–1317. OS
471. Collins R., MacMahon S. Blood pressure, antihypertensive
drug treatment and the risk of stroke and of coronary heart
disease. Br. Med. Bull. 1994; 50: 272–298. MA
472. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Anglo-
-Scandinavian Cardiac Outcomes Trial Investigators. Different
time course for prevention of coronary and stroke events
by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes
Trial-Lipid-Lowering Arm (ASCOT-LLA). Am. J. Cardiol.
2005; 96: 39F–44F. RT
473. Atkins R.C., Briganti E.M., Lewis J.B., Hunsicker L.G.,
Braden G., Champion de Crespigny P.J., DeFerrari G., Drury
P., Locatelli F., Wiegmann T.B., Lewis E.J. Proteinuria reduction
and progression to renal failure in patients with type 2
diabetes mellitus and overt nephropathy. Am. J. Kidney. Dis.
2005; 45: 281–287. OS
474. The ACE Inhibitors in Diabetic Nephropathy Trialist
Group. Should all patients with type 1 diabetes mellitus and
microalbuminuria receive angiotensin-converting enzyme inhibitors?
A meta-analysis of individual patient data. Ann. Int.
Med. 2001; 134: .370–379. MA
475. Parving H.H., Hommel E., Jensen B.R., Hansen H.P.
Long-term beneficial effect of ACE inhibition on diabetic nephropathy
in normotensive type 1 diabetic patients. Kidney.
Int. 2001; 60: 228–234. OS
476. Julius S., Nesbitt S.D., Egan B.M., Weber M.A., Michelson
E.L., Kaciroti N., Black H.R., Grimm R.H. Jr, Messerli
F.H., Oparil S., Schork M.A., Trial of Preventing Hypertension
(TROPHY) Study Investigators. Feasibility of treating
prehypertension with an angiotensin-receptor blocker. N. Engl.
J. Med. 2006; 354: 1685–1697. RT
477. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman
S., Hansson L., Hua T., Laragh J.H., McInnes G.T.,
Mitchell L., Plat F., Schork M.A., Smith B., Zanchetti A. Blood
pressure dependent and independent effects of antihypertensive
treatment on clinical events in the VALUE Trial. Lancet
2004; 363: 2049–2051. CT
478. Pepine C.J., Kowey P.R., Kupfer S., Kolloch R.E., Benetos
A., Mancia G,. Coca A., Cooper-DeHoff R.M., Handberg E., Gaxiola E., Sleight P., Conti C.R., Hewkin A.C., Tavazzi L.,
INVEST Investigators. Predictors of adverse outcome among
patients with hypertension and coronary artery disease. J. Am.
Coll. Cardiol. 2006; 47: 547–551. OS
479. Benetos A., Thomas F., Bean K.E., Guize L. Why cardiovascular
mortality is higher in treated hypertensives versus
subjects of the same age, in the general population. J. Hypertens.
2003; 21: 1635–1640. OS
480. Arima H., Chalmers J., Woodward M., Anderson C., Rodgers
A., Davis S., Macmahon S., Neal B., PROGRESS Collaborative
Group. Lower target blood pressures are safe and effective
for the prevention of recurrent stroke: the
PROGRESS trial. J. Hypertens. 2006; 24: 1201–1208. OS
481. Zanchetti A., Hansson L., Clement D., Elmfeldt D., Julius
S., Rosenthal T., Waeber B., Wedel H., HOT Study Group.
Benefits and risks of more intensive blood pressure lowering
in hypertensive patients of the HOT study with different
risk profiles: does a J-shaped curve exist in smokers? J. Hypertens.
2003; 21: 797–804. CT
482. Freemantle N., Cleland J., Young P., Mason J., Harrison J.
Beta blockade after myocardial infarction: systematic review
and meta regression analysis. Br. Med. Journal 1999; 318: 1730–
–1737. MA
483. Shekelle P.G., Rich M.W., Morton S.C., Atkinson C.S.,
Tu W., Maglione M., Rhodes S., Barrett M., Fonarow G.C.,
Greenberg B., Heidenreich P.A., Knabel T., Konstam M.A.,
Steimle A., Warner Stevenson L. Efficacy of angiotensin-
-converting enzyme inhibitors and beta-blockers in the management
of left ventricular systolic dysfunction according to
race, gender, and diabetic status: a meta-analysis of major clinical
trials. J. Am. Coll. Cardiol. 2003; 41: 1529–1538. MA
484. Sega R., Cesana G., Milesi C., Grassi G., Zanchetti A.,
Mancia G. Ambulatory and home blood pressure normality
in the elderly: data from the PAMELA population. Hypertension
1997; 30: 1–6. OS
485. Mancia G., Parati G. Office compared with ambulatory
blood pressure in assessing response to antihypertensive treatment:
a meta-analysis. J. Hypertens. 2004; 22: 435–445. MA
486. Messerli F.H., Mancia G., Conti C.R., Hewkin A.C.,
Kupfer S., Champion A., Kolloch R., Benetos A., Pepine C.J.
Dogma disputed: can aggressively lowering blood pressure in
hypertensive patients with coronary artery disease be dangerous?
Ann. Intern. Med. 2006; 144: 884–893. OS
487. Boutitie F., Gueyffier F., Pocock S., Fagard R., Boissel J.P.,
INDANA Project Steering Committee. INdividual Data ANalysis
of Antihypertensive intervention. J-shaped relationship
between blood pressure and mortality in hypertensive patients:
new insights from a meta-analysis of individualpatient data.
Ann. Intern. Med. 2002; 136: 438–448. MA
488. Samuelsson O.G., Wilhelmsen L.W., Pennert K.M.,
Wedel H., Berglund G.L. The J-shaped relationship between
coronary heart disease and achieved blood pressure level in
treated hypertension: further analyses of 12 years of follow-up
of treated hypertensives in the Primary Prevention Trial in
Gothenburg, Sweden. J. Hypertens. 1990; 8: 547–555. OS
489. Cruickshank J.M., Pennert K., Sorman A.E., Thorp J.M.,
Zacharias F.M., Zacharias F.J. Low mortality from all causes,
including myocardial infarction, in well-controlled hypertensives
treated with a beta-blocker plus other antihypertensives.
J. Hypertens. 1987; 5: 489–498. OS
490. Staessen J., Bulpitt C., Clement D., De Leeuw P., Fagard R.,
Fletcher A., Forette F., Leonetti G., Nissinen A., O’Malley K.
Relation between mortality and treated blood pressure in elderly
patients with hypertension: report of.the European Working
Party on High Blood Pressure in the Elderly. Br. Med.
J. 1989; 298: 1552–1556. CT
491. Bonet S., Agusti A., Arnau J.M., Vidal X., Diogene E.,
Galve E., Laporte J.R. Beta-adrenergic blocking agents in heart
failure: benefits of vasodilating.and non-vasodilating agents
according to patients’ characteristics: a.metaanalysis of clinical
trials. Arch. Intern. Med. 2000; 160: 621–627. MA
492. Mancia G., Grassi G. Systolic and diastolic blood pressure
control in.antihypertensive drug trials. J. Hypertens. 2002;
20: 1461–1464. RV
493. Mancia G., Brown M., Castaigne A., de Leeuw P., Palmer
C.R., Rosenthal T., Wagener G., Ruilope L.M.,
INSIGHT. Outcomes with nifedipine GITS or Co-amilozide
in hypertensive diabetics and nondiabetics in Intervention
as a Goal in Hypertension (INSIGHT). Hypertension 2003;
41: 431–436. RT
494. Ambrosioni E. Pharmacoeconomic challenges in disease
management of hypertension. J. Hypertens. 2001; 19 (supl.
3): S33–S40. RV
495. Schulzer M., Mancini G.B. ‘Unqualified success’ and
‘unmitigated failure’: number-needed-to-treat-related concepts
for assessing treatment efficacy in the presence of treatment-
induced adverse events. Int. J. Epidemiol. 1996; 25: 704–
–712. RV
496. Zanchetti A., Mancia G. Benefits and cost-effectiveness
of antihypertensive therapy. The actuarial versus the intervention
trial approach. J. Hypertens. 1996; 14: 809–811. RV
497. Zanchetti A., Hansson L., Menard J., Leonetti G., Rahn K.H.,
Warnold I.,Wedel H., Risk assessment and treatment benefit
in intensively treated hypertensive patients of the Hypertension
Optimal Treatment (HOT) study. J. Hypertens. 2001;
19: 819–825. OS
498. Zanchetti A. Costs of implementing recommendations
on hypertension management given in recent guidelines.
J. Hypertens. 2003; 21: 2207–2209. RV
499. Moser M. Are lifestyle interventions in the management
of hypertension effective? How long should you wait before
starting specific medical therapy? An ongoing debate. J. Clin.
Hypertens. 2005; 7: 324–326. RV
500. Dickinson H.O., Mason J.M., Nicolson D.J., Campbell F.,
Beyer F.R., Cook S.W., Williams B., Ford G.A. Lifestyle interventions
to reduce raised blood pressure: a systematic review
of randomised controlled trials. J. Hypertens. 2006; 24: 215–233.
501. Haynes R.B., McDonald H.P., Garg A.X. Helping patients
follow prescribed treatment: clinical applications. JAMA
2002; 288: 2880–2883.
502. Groppelli A., Giorgi D.M., Omboni S., Parati G., Mancia G.
Persistent blood pressure increase induced by heavy smoking.
J. Hypertens. 1992; 10: 495–499.
503. Grassi G., Seravalle G., Calhoun D.A., Bolla G.B., Giannattasio
C., Marabini M., Del Bo A. Mancia G. Mechanisms
responsible for sympathetic activation by cigarette smoking in
humans. Circulation 1994; 90: 248–253.
504. Narkiewicz K., van de Borne P.J., Hausberg M., Cooley R.L.,
Winniford M.D., Davison D.E., Somers V.K. Cigarette smoking
increases sympathetic outflow in humans. Circulation
1998; 98: 528–534.
505. Seltzer C.C. Effect of smoking on blood pressure. Am.
Heart J. 1974; 87: 558–564.
506. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Zampi
I., Battistelli M., Gattobigio R., Sacchi N., Porcellati C.
Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J. Hypertens 1995; 13:
1209–1215. OS
507. Mann S.J., James G.D., Wang R.S., Pickering T.G. Elevation
of ambulatory systolic blood pressure in hypertensive
smokers. A case-control study. JAMA 1991; 265: 2226–2228. OS
508. Bang L.E., Buttenschon L., Kristensen K.S., Svendsen
T.L. Do we undertreat hypertensive smokers? A comparison
between smoking and non-smoking hypertensives. Blood
Press. Monit. 2000; 5: 271–274.
509. Mundal R., Kjeldsen S.E., Sandvik L., Erikssen G., Thaulow
E., Erikssen J. Predictors of 7-year changes in exercise
blood pressure: effects of smoking, physical fitness and pulmonary
function. J. Hypertens. 1997; 15: 245–249. OS
510. Primatesta P., Falaschetti E., Gupta S., Marmot M.G.,
Poulter N.R. Association between smoking and blood pressure:
evidence from the health survey for England. Hypertension
2001; 37: 187–193. OS
511. Omvik P. How smoking affects blood pressure. Blood
Press. 1996; 5: 71–77. RV
512. Doll R., Peto R., Wheatley K., Gray R., Sutherland I.
Mortality in relation to smoking 40 years’ observations on male
British doctors. Br. Med. J. 1994; 309: 901–911. OS
513. Rosenberg L., Kaufman D.W., Helmrich S.P., Shapiro S.
The risk of myocardial infarction after quitting smoking in men
under 55 years of age. N. Engl. J. Med. 1985; 313: 1511–1514. OS
514. Manson J.E., Tosteson H., Ridker P.M., Satterfield S.,
Hebert P., O’Connor G.T., Buring J.E., Hennekens C.H. The
primary prevention of myocardial infarction. N. Engl. J. Med.
1992; 326: 1406–1416.
515. Wilson K., Gibson N., Willan A., Cook D. Effect of smoking
cessation on mortality after myocardial infarction: meta-
-analysis of cohort studies. Arch. Intern. Med. 2000; 160: 939–
–944. MA
516. Tsevat J., Weinstein M.C., Williams L.W., Tosteson A.N.,
Goldman L. Expected gains in life expectancy from various
coronary heart disease risk factor modifications. Circulation
1991; 83: 1194–1201. OS
517. Silagy C., Mant D., Fowler G., Lodge M. Meta-analysis
on efficacy of nicotine replacement therapies in smoking cessation.
Lancet 1994; 343: 139–142. MA
518. Tonstad S., Farsang C., Klaene G., Lewis K., Manolis A.,
Perruchoud A.P., Silagy C., van Spiegel P.I., Astbury C., Hider
A., Sweet R. Bupropion S.R. for smoking cessation in smokers
with cardiovascular disease: a multicentre, randomised
study. Eur. Heart. J. 2003; 24: 946–955. RT
519. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J.,
Anziano R., Reeves K.R. Smoking cessation with varenicline,
a selective alpha4beta2 nicotinic receptor partial agonist: results
from a 7-week, randomized, placebo- and bupropioncontrolled
trial with 1-year follow-up. Arch. Intern. Med. 2006;
166: 1561–1568. RT
520. Law M.R., Morris J.K., Wald N.J. Environmental tobacco
smoke exposure and ischaemic heart disease: an evaluation
of the evidence. Br. Med. J. 1997; 315: 973–980. RV
521. Stranges S., Bonner M.R., Fucci F., Cummings K.M.,
Freudenheim J.L., Dorn J.M., Muti P., Giovino G.A., Hyland
A., Trevisan M. Lifetime cumulative exposure to secondhand
smoke and risk of myocardial infarction in never
smokers: results from the Western New York health
study, 1995-2001. Arch. Intern. Med. 2006; 166: 1961–
–1967. OS
522. Rimm E.B., Williams P., Fosher K., Criqui M., Stampfer
M.J. Moderate alcohol intake and lower risk of coronary heart disease:
meta-analysis of effects on lipids and haemostatic
factors. Br. Med. J. 1999; 319: 1523–1528. MA
523. Fillmore K.M., Kerr W.C., Stockwell T., Chikritzhs T.,
Bostrom A. Moderate alcohol use and reduced mortality risk:
Systematic error in prospective studies. Addiction Research &
Theory 2006; 14: 101–132. RV
524. Puddey I.B., Beilin L.J., Rakie V. Alcohol, hypertension
and the cardiovascular system: a critical appraisal. Addiction.
Biol. 1997; 2: 159–170. RV
525. Wannamethee S.G., Shaper A.G. Patterns of alcohol intake
and risk of stroke in middle-aged British men. Stroke 1996;
27: 1033–1039. OS
526. Puddey I.B., Beilin L.J., Vandongen R. Regular alcohol
use raises blood pressure in treated hypertensive subjects.
A randomised controlled trial. Lancet 1987; 1: 647–651. RT
527. Law M.R. Epidemiologic evidence on salt and blood pressure.
Am. J. Hypertens. 1997; 10 (supl. 5): S42–S45. RV
528. Joint WHO/FAO Expert report on diet, nutrition and the prevention
of chronic disease. Executive Summary. www.who.int. RV
529. Cutler J.A., Follman D., Alexander P.S. Randomized controlled
trials of sodium reduction: an overview. Am. J. Clin.
Nutr. 1997; 65 (supl. 2): S643–S651. MA
530. Graudal N.A., Galloe A.M., Garred P. Effects of sodium
restriction on blood pressure, renin, aldosterone, catecholamines,
cholesterols, and triglyceride: a meta-analysis. JAMA
1998; 279: 1383–1391. MA
531. He F.J., MacGregor G.A. How far should salt intake be
reduced? Hypertension 2003; 42: 1093–1099. RV
532. Robertson J.I.J. Dietary salt and hypertension: a scientific
issue or a matter of faith? J. Eval. Clin. Pract. 2003; 9: 1–22. RV
533. Australian National Health and Medical Research Council.
Dietary Salt Study Management Committee. Effects of
replacing sodium intake insubjects on a low sodium diet: crossover
study. Clin. Exp. Hypertens. 1989; A11: 1011–1024.
534. He F.J., Markandu N.D., MacGregor G.A. Importance
of the renin system for determining blood pressure fall with
acute salt restriction in hypertensive and normotensive whites.
Hypertension 2001; 38 : 321–325. OS
535. Grassi G., Dell’Oro R., Seravalle G., Foglia G., Quarti
Trevano F., Mancia G. Short- and long-term neuroadrenergic
effects of moderate dietary sodium restriction in essential
hypertension. Circulation 2002; 106: 1957–1961.
536. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A.,
Bolla G., Mancia G. Baroreflex impairment by low sodium
diet in mild or moderate essential hypertension. Hypertension
1997; 29: 802–807.
537. Appel L.J., Brands M.W., Daniels S.R., Karanja N., Elmer
P.J., Sacks F.M., American Heart Association. Dietary approaches
to prevent and treat hypertension: a scientific statement from the
American Heart Association. Hypertension 2006; 47: 296–308. GL
538. Otten J., Pitzi Helliwig J., Meyers L.D. The dietary reference
intakes: the essential guide to nutrient requirements.
Washington DC: National Academies Press; 2006. RV
539. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray
G.A., Harsha D., Obarzanek E., Conlin P.R., Miller E.R. 3rd,
Simons-Morton D.G., Karanja N., Lin P.H.; DASH-Sodium
Collaborative Research Group. Effects on blood pressure of
reduced dietary sodium and the Dietary Approaches to Stop
Hypertension (DASH) diet. DASH-Sodium Collaborative
Research Group. N. Engl. J. Med. 2001; 344: 3–10. RT
540. Morris M.C., Sacks F., Rosner B. Does fish oil lower blood
pressure? A meta-analysis of controlled trials. Circulation
1993; 88: 523–533. MA 541. Geleijnse J.M., Giltay E.J., Grobbee D.E.,
Donders A.R., Kok F.J. Blood pressure response to fish oil
suplementation: metaregression analysis of randomized trials.
J. Hypertens 2002; 20: 1493–1499. MA
542. Appel L.J., Miller E.R. 3rd, Seidler A.J., Whelton P.K.
Does suplementation of diet with ’fish oil’ reduce blood pressure?
A meta-analysis of controlled clinical trials. Arch. Intern.
Med. 1993; 153: 1429–1438. MA
543. He J., Whelton P.K. Effect of dietary fiber and protein
intake on blood pressure: a review of epidemiologic evidence.
Clin. Exp. Hypertens. 1999; 21: 785–796. RV
544. He J., Streiffer R.H., Muntner P., Krousel-Wood M.A.,
Whelton P.K. Effect of dietary fiber intake on blood pressure:
a randomized, double-blind, placebo-controlled trial. J. Hypertens.
2004; 22: 73–80. RT
545. Griffith L.E., Guyatt G.H., Cook R.J., Bucher H.C.,
Cook D.J. The influence of dietary and nondietary calcium suplementation
on blood pressure: an updated metaanalysis of randomized
controlled trials. Am. J. Hypertens. 1999; 12: 84–92. MA
546. Jee S.H., Miller E.R. 3rd, Guallar E., Singh V.K., Appel L.J.,
Klag M.J. The effect of magnesium suplementation on blood
pressure: a meta-analysis of randomized clinical trials. Am.
J. Hypertens. 2002; 15: 691–696. MA
547. Visvanathan R., Chen R., Horowitz M., Chapman I. Blood
pressure responses in healthy older people to 50 g carbohydrate
drinks with differing glycaemic effects. Br. J. Nutr. 2004;
92: 335–340. OS
548. Pereira M.A., Swain J., Goldfine A.B., Rifai N., Ludwig D.S.
Effects of a low-glycemic load diet on resting energy expenditure
and heart .disease risk factors during weight loss. JAMA
2004; 292: 2482–2490. OS
549. Margetts B.M., Beilin L.J., Vandongen R, Armstrong B.K.
Vegetarian diet in mild hypertension: a randomised controlled
trial. Br. Med. J. 1986; 293: 1468–1471. RT
550. Bao D.Q., Mori T.A., Burke V., Puddey I.B., Beilin L.J.
Effects of dietary fish and weight reduction on ambulatory blood
pressure in overweight hypertensives. Hypertension 1998;
32: 710–717. OS
551. Daniels S.R., Kimball T.R., Khoury P., Witt S., Morrison J.A.
Correlates of the hemodynamic determinants of blood pressure.
Hypertension 1996; 28: 37–41. OS
552. Stamler J. Epidemiologic findings on body mass and blood
pressure in adults. Ann Epidemiol 1991; 1: 347–362. OS
553. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M.
Influence of weight reduction on blood pressure: a meta-analysis
of randomized controlled trials. Hypertension 2003; 42: 878–
–884. MA
554. Stevens V.J., Corrigan S.A., Obarzanek E., Bernauer E.,
Cook N.R., Hebert P., Mattfeldt-Beman M., Oberman A., Sugars
C., Dalcin A.T. Weight loss intervention in phase 1 of the
Trials of Hypertension Prevention. The TOHP Collaborative
Research Group. Arch. Intern. Med. 1993; 153: 849–858. CT
555. Stevens V.J., Obarzanek E., Cook N.R., Lee I.M., Appel L.J.,
Smith West D., Milas N.C., Mattfeldt-Beman M., Belden L.,
Bragg C., Millstone M., Raczynski J., Brewer A., Singh B.,
Cohen J., Trials for the Hypertension Prevention Research
Group. Long-term weight loss and changes in blood pressure:
results of the Trials of Hypertension Prevention, phase II. Ann.
Intern. Med. 2001; 134: 1–11. RT
556. Huang Z., Willett W.C., Manson J.E., Rosner B., Stampfer
M.J, Speizer F.E., Colditz G.A. Body weight, weight change,
and risk for hypertension in women. Ann. Intern. Med.
1998; 128: 81–88. OS 557. The Trials of Hypertension Prevention Collaborative
Research Group. Effects of weight loss and sodium reduction
intervention on blood pressure and hypertension incidence in
overweight people with high-normal blood pressure. The
Trials of Hypertension Prevention, phase II. The Trials of
Hypertension Prevention Collaborative Research Group. Arch.
Intern. Med. 1997; 157: 657–667. RT
558. Langford H.G., Blaufox M.D., Oberman A., Hawkins
C.M., Curb J.D., Cutter G.R., Wassertheil-Smoller S., Pressel
S., Babcock C., Abernethy J.D. Dietary therapy slows the return
of hypertension after stopping prolonged medication.
JAMA 1985; 253: 657–664. RT
559. Whelton P.K., Appel L.J., Espeland M.A., Applegate W.B.,
Ettinger W.H. Jr, Kostis J.B., Kumanyika S., Lacy C.R., Johnson
K.C., Folmar S., Cutler J.A. Sodium reduction and weight
loss in the treatment of hypertension in older persons:
a randomized controlled trial of nonpharmacologic interventions
in the elderly (TONE). TONE Collaborative Research
Group. JAMA 1998; 279: 839–846. RT
560. Sandvik L., Erikssen J., Thaulow E., Erikssen G., Mundal
R., Rodahl K. Physical fitness as a predictor of mortality
among healthy, middle-aged Norwegian men. N. Engl. J. Med.
1993; 328: 533–537. OS
561. Cornelissen V.A., Fagard R.H. Effects of endurance training
on blood pressure, blood pressure-regulating mechanisms,
and cardiovascular risk factors. Hypertension 2005; 46:
667–675. OS
562. Fagard R.H. Exercise characteristics and the blood pressure
response to dynamic physical training. Med. Sci. Sports.
Exerc. 2001; 33 S484–S492. OS
563. Cornelissen V.A., Fagard R.H. Effect of resistance training
on resting bloodnpressure: a meta-analysis of randomized
controlled trials. J. Hypertens. 2005; 23: 251–259. MA
564. Jennings G.L. Exercise and blood pressure: Walk, run or
swim? J. Hypertens. 1997; 15: 567–569. RV
565. StringerW.W., Wasserman K. Statement on exercise:
American College of Chest Physicians/American Thoracic Society–
exercise for fun or profit? Chest 2005; 127: 1072–1073. GL
566. Fagard R.H., Bjornstad H.H., Borjesson M., Carre F.,
Deligiannis A., Vanhees L., European Society of Cardiology.
ESC Study Group of Sports Cardiology recommendations for
participation in leisure-time physical activities and competitive
sports for patients with hypertension. Eur. J. Cardiovasc.
Prev. Rehabil. 2005; 12: 326–331. GL
567. Heidenreich P.A., McDonald K.M., Hastie T., Fadel B.,
Hagan V., Lee B.K., Hlatky M.A. Meta-analysis of trials comparing
beta-blockers, calcium antagonists, and nitrates for stable
angina. JAMA 1999; 281: 1927–1936. MA
568. Sharma A.M., Pischon T., Hardt S., Kunz I., Luft F.C.
Hypothesis: Beta-adrenergic receptor blockers and weight gain:
a systematic analysis. Hypertension 2001; 37: 250–254. RV
569. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H,
Wachtell K., Dahlof B., Devereux R.B., Beevers G., de Faire U.,
Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-
Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel
H., Aurup P., Edelman J.M., Snapinn S., For the LIFE
study group. Risk of new-onset diabetes in the Losartan Intervention
For Endpoint reduction in hypertension study.
J. Hypertens. 2002; 20: 1879–1886. RT
570. Kjeldsen S.E., Julius S., Mancia G., McInnes G.T., Hua T.,
Weber M.A., Coca A., Ekman S., Girerd X., Jamerson K., Larochelle
P., MacDonald T.M., Schmieder R.E., Schork M.A.,
Stolt P., Viskoper R., Widimsky J., Zanchetti A., VALUE Trial Investigators.
Effects of valsartan compared to amlodipine on
preventing type 2 diabetes in high-risk hypertensive patients:
the VALUE trial. J. Hypertens. 2006; 24: 1405–1412. RT
571. Torp-Pedersen C., Metra M., Charlesworth A., Spark P.,
Lukas M.A., Poole-Wilson P.A., Swedberg K., Cleland J.G.,
Di Lenarda A., Remme W., Scherhaug A. Effects of metoprolol
and carvedilol on preexisting and new onset diabetes in patients
with chronic heart failure Data fromthe Carvedilol or metoprolol
European Trial (COMET). Heart 2007; 93 (8): 968–
–973. RT
572. Kaiser T., Heise T., Nosek L., Eckers U., Sawicki P.T.
Influence of nebivolol and enalapril on metabolic parameters
and arterial stiffness in hypertensive type 2 diabetic patients.
J. Hypertens. 2006; 24: 1397–1403. RT
573. Cushman W.C., Reda D.J., Perry H.M., Williams D.,
Abdellatif M., Materson B.J. Regional and racial differences
in response to antihypertensive medication use in a randomized
controlled trial of men with hypertension in the United
States. Department of Veterans Affairs Cooperative Study
Group on Antihypertensive Agents. Arch. Intern. Med. 2000;
160: 825–831. CT
574. Van Zwieten P.A. Centrally acting antihypertensive drugs.
W: Mancia G., Chalmers J., Julius S., Saruta T., Weber M.
(red.). Manual of Hypertension. Churchill Livingston, London
2002: 401–410. RV
575. Zannad F. Aldosterone antagonist therapy in resistant
hypertension. J. Hypertens. 2007; 25: 747–750. RV
576. The ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group. Major cardiovascular
events in hypertensive patients randomized to doxazosin
vs chlorthalidone: the Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT). JAMA
2000; 283: 1967–1975. RT
577. Nguyen G. Renin/prorenin receptors. Kidney Int. 2006;
69: 1503–1506. RV
578. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H.,
Matrisciano-Dimichino L., Zhang J. Renin inhibition with
aliskiren provides additive antihypertensive efficacy when used
in combination with hydrochlorothiazide. J. Hypertens. 2007;
25: 217–226. RT
579. O’Brien E., Barton J., Nussberger J., Mulcahy D., Jensen C.,
Dicker P., Stanton A. Aliskiren reduces blood pressure and suppresses
plasma rennin activity in combination with a thiazide diuretic,
an angiotensin-converting enzyme inhibitor, or an angiotensin
receptor blocker. Hypertension 2007; 49: 276–284. RT
580. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J.,
Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective
renin inhibitor, provides.dose-dependent antihypertensive efficacy
and placebo-like tolerability in.hypertensive patients.
Circulation 2005; 111: 1012–1018. RT
581. Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend
R., Gratze P.,.Meiners S., Feldman D.L., Webb R.L., Garrelds
I.M., Jan Danser A.H., Luft F.C.,.Muller D.N. Aliskiren,
a human renin inhibitor, ameliorates cardiac and renal damage
in double-transgenic rats. Hypertension 2005; 46: 569–576.
582. Alderman M.H., Madhavan S., Ooi W.L., Cohen H.,
Sealey J.E., Laragh J.H. Association of the renin-sodium profile
with the risk of myocardial infarction in patients with hypertension.
N. Engl. J. Med. 1991; 324: 1098–1104. OS
583. Ruilope L.M., Agabiti-Rosei E., Bakris G.L., Mancia G.,
Poulter N.R., Taddei S., Unger T., Volpe M., Waeber B., Zannad
F. Angiotensin receptor blockers: therapeutic targets and
cardiovascular protection. Blood Press. 2005; 14: 196–209. RV
584. Waeber B., Burnier M., Brunner H.R. Compliance with
antihypertensive therapy. Clin. Exp. Hypertens. 1999; 21:
973–985. RV
585. Parati G., Omboni S., Rizzoni D., Agabiti-Rosei E., Mancia
G. The smoothness index: a new, reproducible and clinically
relevant measure of the homogeneity of the blood pressure
reduction with treatment for hypertension. J. Hypertens.
1998; 16: 1685–1691.
586. Ambrosioni E., Leonetti G., Pessina A.C., Rappelli A.,
Trimarco B., Zanchetti A. Patterns of hypertension management
in Italy: results of a pharmacoepidemiological survey on
antihypertensive therapy. Scientific Committee of the Italian
Pharmacoepidemiological Survey on Antihypertensive Therapy.
J. Hypertens. 2000; 18: 1691–1699. OS
587. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of
low dose combination treatment with blood pressure lowering
drugs: analysis of 354 randomised trials. Br. Med. J. 2003;
326: 1427. MA
588. Materson B.J., Reda D.J., Cushman W.C. Department of
Veterans Affairs single-drug therapy of hypertension study.
Revised figures and new data. Department of Veterans Affairs
Cooperative Study Group on Antihypertensive Agents. Am.
J. Hypertens. 1995; 8: 189–192. RT
589. Morgan T.O., Anderson A.I., MacInnis R.J. ACE inhibitors,
beta-blockers, calcium blockers, and diuretics for the control of
systolic hypertension. Am. J. Hypertens. 2001; 14: 241–247. RV
590. Dickerson J.E., Hingorani A.D., Ashby M.J., Palmer C.R.,
Brown M.J. Optimisation of antihypertensive treatment by
crossover rotation of four major classes. Lancet 1999; 353:
2008–2013. OS
591. Hoes A.W., Grobbee D.E., Lubsen J., Man in ’t Veld A.J.,
van der Does E., Hofman A. Diuretics, beta-blockers, and the
risk for sudden cardiac death in hypertensive patients. Ann.
Intern. Med. 1995; 123: 481–487. OS
592. Helderman J.H., Elahi D., Andersen D.K., Raizes G.S.,
Tobin J.D., Shocken D., Andres R. Prevention of the glucose
intolerance of thiazide diuretics by maintenance of body potassium.
Diabetes. 1983; 32: 106–111. OS
593. Conn J.W. Hypertension, the potassium ion and impaired
carbohydrate tolerance. N. Engl. J. Med. 1965; 273: 1135–1143. RV
594. Ferrari P., Marti H.P., Pfister M., Frey F.J. Additive antiproteinuric
effect of combined ACE inhibition and angiotensin
II receptor blockade. J. Hypertens. 2002; 20: 125–130. RT
595. McMurray J.J., Ostergren J., Swedberg K., Granger C.B.,
Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A.,
CHARM Investigators and Committees. Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting enzyme
inhibitors: the CHARM-Added. trial. Lancet 2003; 362:
767–771. RT
596. Giannattasio C., Achilli F., Failla M., Capra A., Vincenzi A.,
Valagussa F., Mancia G. Radial, carotid and aortic distensibility
in congestive heart failure: effects of high-dose angiotensin-
converting enzyme inhibitor or low-dose association with
angiotensin type 1 receptor blockade. J. Am. Coll. Cardiol.
2002; 39: 1275–1282. OS
597. Bangalore S., Kamalakkannan G., Panjrath G., Messerli F.H.
Fixed-dose combination improves medication compliance: a metaanalysis.
J. Clin. Hypertens. 2006; 8 (supl. A): A72 (abstract). MA
598. Jamerson K.A., Bakris G.L., Wun C.C., Dahlof B., Lefkowitz
M., Manfreda S., Pitt B., Velazquez E.J., Weber M.A.
Rationale and design of the avoiding cardiovascular events
through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized
controlled trial to compare the clinical outcome effects of first-
-line combination therapies in hypertension. Am. J. Hypertens.
2004; 17: 793–801. RT
599. Gueyffier F., Bulpitt C., Boissel J.P., Schron E., Ekbom T.,
Fagard R., Casiglia E., Kerlikowske K., Coope J. Antihypertensive
drugs in very old people: a subgroup analysis of randomised
controlled trials. Lancet 1999; 353: 793–796. MA
600. Bulpitt C.J., Beckett N.S., Cooke J., Dumitrascu D.L.,
Gil-Extremera B., Nachev C., Nunes M., Peters R., Staessen J.A.,
Thijs L., Hypertension in the Very Elderly Trial Working
Group. Results of the pilot study for the Hypertension in the
Very Elderly Trial. J. Hypertens. 2003; 21: 2409–2417. RT
601. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers
efficacious as first-line therapy for hypertension in the
elderly? JAMA 1998; 279: 1903–1907. MA
602. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup
P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen
H., Kristianson K., Lederballe-Pedersen O., Lindholm
L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., Wedel
H., LIFE (Losartan Intervention for Endpoint Reduction)
Study Group. Effects of losartan on cardiovascular morbidity and
mortality in patients with isolated systolic hypertension and left
ventricular hypertrophy: a Losartan Intervention for Endpoint
Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498. CT
603. Papademetriou V., Farsang C., Elmfeldt D., Hofman A.,
Lithell H., Olofsson B., Skoog I., Trenkwalder P., Zanchetti A.,
Study on Cognition and Prognosis in the Elderly study group.
Stroke prevention with the angiotensin II type 1- receptor blocker
candesartan in elderly patients with isolated systolic hypertension:
the Study on Cognition and Prognosis in the Elderly
(SCOPE). J. Am. Coll. Cardiol. 2004; 44: 1175–1180. CT
604. Lakatta E.G. Deficient neuroendocrine regulation of the
cardiovascular system with advancing age in healthy humans.
Circulation 1993; 87: 631–636. RV
605. Fagard R.H., Van den Enden M., Leeman M., Warling X.
Survey on treatment of hypertension and implementation of
WHO-ISH risk stratification in primary care in Belgium.
J. Hypertens. 2002; 20: 1297–1302. OS
606. Somes G.W., Pahor M., Shorr R.I., Cushman W.C., Applegate
W.B. The role of diastolic blood pressure when treating
isolated systolic hypertension. Arch. Intern. Med. 1999;
159: 2004–2009. OS
607. Fagard R.H., Staessen J.A., Thijs L., Celis H., Bulpitt C.J.,
de Leeuw P.W. i wsp. On-treatment diastolic blood pressure
and prognosis in systolic. Hypertension. Arch. Intern. Med.
2007, w druku. OS
608. Mogensen C.E. Long-term antihypertensive treatment inhibiting
progression of diabetic nephropathy. Br. Med. J. 1982;
285: 685–688. OS
609. Mancia G. The association of hypertension and diabetes:
prevalence, cardiovascular risk and protection by blood pressure
reduction. Acta. Diabetol. 2005; 42 (supl. 1): S17–S25. RV
610. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman
G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness
M.I., Charlton-Menys V., Fuller J.H., CARDS investigators.
Primary prevention of cardiovascular disease with atorvastatin
in type 2 diabetes in the Collaborative Atorvastatin
Diabetes Study (CARDS): multicentre randomised placebo-
-controlled trial. Lancet 2004; 364: 685–696. RT
611. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala
B., Davies R.,.Ostergren J., Probstfield J., HOPE Investigators.
Heart outcomes.prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. Br.
Med. J. 2002; 324: 699–701. RT
612. Trenkwalder P., Elmfeldt D., Hofman A., Lithell H.,
Olofsson B., Papademetriou V., Skoog I., Zanchetti A., The
Study on Cognition and Prognosis in the Elderly (SCOPE).
The Study on Cognition and Prognosis in the Elderly
(SCOPE) — major cardiovascular events and stroke in subgroups
of patients. Blood Press 2005; 14: 31–37. CT
613. Bath P., Chalmers J., Powers W., Beilin L., Davis S., Lenfant
C., Mancia G., Neal B., Whitworth J., Zanchetti A., International
Society of Hypertension Writing Group. International
Society of Hypertension (ISH): statement on the management
of blood pressure in acute stroke. J. Hypertens. 2003;
21: 665–672. GL
614, Schrader J., Luders S., Kulschewski A., Berger J., Zidek W.,
Treib J., Einhaupl K., Diener H.C., Dominiak P., Acute Candesartan
Cilexetil Therapy in Stroke Survivors Study Group. The
ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy
in Stroke Survivors. Stroke 2003; 34: 1699–1703. RT
615. COSSACS Trial Group. COSSACS (Continue or Stop
post-Stroke Antihypertensives Collaborative Study): rationale
and design. J. Hypertens. 2005; 23: 455–458. RT
616. Potter J., Robinson T., Ford G., James M., Jenkins D.,
Mistri A., Bulpitt C., Drummond A., Jagger C., Knight J.,
Markus H., Beevers G., Dewey M., Lees K., Moore A., Paul S.,
The CHHIPS Trial Group. CHHIPS. (Controlling Hypertension
and Hypotension Immediately Post-Stroke). Pilot Trial:
rationale and design. J. Hypertens. 2005; 23: 649–655. RT
617. van Dijk E.J., Breteler M.M., Schmidt R,. Berger K., Nilsson
L.G., Oudkerk M., Pajak A., Sans S., de Ridder M., Dufouil
C., Fuhrer R., Giampaoli S., Launer L.J., Hofman A.,
CASCADE Consortium. The association between blood pressure,
hypertension, and cerebral white matter lesions: cardiovascular determinants
of dementia study. Hypertension 2004; 44: 625–630. OS
618. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A.,
Koudstaal P.J., Breteler M.M., Rotterdam Scan Study. Silent
brain infarcts and white matter lesions increase stroke risk in
the general population: the Rotterdam Scan Study. Stroke 2003;
34: 1126–1129. OS
619. Vermeer S.E., Prins N.D., den Heijer T., Hofman A.,
Koudstaal P.J., Breteler M.M. Silent brain infarcts and the risk
of dementia and cognitive decline. N. Engl. J. Med 2003; 348:
1215–1222. OS
620. Sierra C., de La Sierra A., Mercader J., Gomez-Angelats E.,
Urbano-Marquez A., Coca A. Silent cerebral white matter lesions
in middle-aged essential hypertensive patients. J. Hypertens.
2002; 20: 519–524. OS
621. Qiu C., Winblad B., Fratiglioni L. The age-dependent
relation of blood pressure to cognitive function and dementia.
Lancet Neurol. 2005; 4: 487–499. RV
622. Kannel W.B. Risk stratification in hypertension: new insights
from the Framingham Study. Am. J. Hypertens. 2000;
13 (supl. 1): S3–S10. RV
623. Yap Y.G., Duong T., Bland J.M., Malik M., Torp-Pederson
C., Kober L., Connolly S.J., Gallagher M.M., Camm A.J.
Prognostic value of blood pressure measured during hospitalization
after acute myocardial infarction: an insight from survival
trials. J. Hypertens. 2007; 25: 307–313. OS
624. Domanski M.J., Mitchell G.F., Norman J.E., Exner D.V.,
Pitt B., Pfeffer M.A. Independent prognostic information provided
by sphygmomanometrically determined pulse pressure
and mean arterial pressure in patients with left ventricular
dysfunction. J. Am. Coll. Cardiol. 1999; 33: 951–958. OS
625. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein
G.D., Weingarten S.R. Meta-analysis: angiotensin-receptor
blockers in chronic heart failure and high-risk acute myocardial
infarction. Ann. Intern. Med. 2004; 141: 693–704. MA
626. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P.,
McMurray J.J., Michelson E.L., Olofsson B., Ostergren J.,
CHARM Investigators and Committees. Effects of candesartan
in patients with chronic heart failure and preserved left-
-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet 2003; 362: 777–781.
627. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence,
incidence, prognosis, and predisposing conditions for
atrial fibrillation: populationbased estimates. Am. J. Cardiol.
1998; 82: 2N–9N. OS
628. Hankey G.J. Preventable stroke and stroke prevention.
J. Thromb. Haemost. 2005; 3: 1638–1645. RV
629. Lip G.Y., Frison L., Grind M. Effect of hypertension on
anticoagulated patients with atrial fibrillation. Eur. Heart.
J. 2007; 28: 752–759. OS
630. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle
M., Yusuf S., Connolly S.J. Prevention of atrial fibrillation
with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers: a meta-analysis. J. Am. Coll. Cardiol.
2005; 45: 1832–1839. MA
631. Perera G.A. Hypertensive vascular disease: description
and natural history. J. Chronic. Dis. 1955; 1: 33–42.
632. Redon J., Rovira E., Miralles A., Julve R., Pascual J.M.
Factors related to the occurrence of microalbuminuria during
antihypertensive treatment in essential hypertension. Hypertension
2002; 39: 794–798. OS
633. Lawes C.M.M., Vander Hoorn S., Law M.R., Elliott P.,
MacMahon S., Rodgers A. Blood pressure and the global burden
of disease 2000. Part I: Estimates of blood pressure levels.
J. Hypertens. 2006; 24: 413–422. OS
634. Franklin S.S., Gustin W. 4th, Wong N.D., Larson M.G.,
Weber M.A., Kannel W.B., Levy D. Hemodynamic patterns
of age-related changes in blood pressure. The Framingham
Heart Study. Circulation 1997; 96: 308–315. OS
635. Wilson P.W., Castelli W.P., Kannel W.B. Coronary risk
prediction in adults (the Framingham Heart Study). Am. J. Cardiol.
1987; 59: 91G–94G. RV
636. Zanchetti A., Julius S., Kjeldsen S., McInnes G.T., Hua T.,
Weber M., Laragh J.H., Plat F., Battegay E., Calvo-Vargas C.,
Cieslinski A., Degaute J.P., Holwerda N.J., Kobalava J., Pedersen
O.L., Rudyatmoko F.P., Siamopoulos K.C., Storset O.
Outcomes in subgroups of hypertensive patients treated with
regimens based on valsartan and amlodipine: An analysis of
findings from the VALUE trial. J. Hypertens. 2006; 24: 2163–
–2168. CT
637. Dong W., Colhoun H.M., Poulter N.R. Blood pressure
in women using oral contraceptives results from the
Health Survey for England 1994. J. Hypertens. 1997; 15:
1063–1068. OS
638. Chasan-Taber L., Willett W.C., Manson J.A.E., Spiegelman
D., Hunter D.J., Curhan G., Colditz G.A., Stampfer M.J.
Prospective study of oral contraceptives and hypertension among
women in the United States. Circulation 1996; 94: 483–489. OS
639. Lip G.Y., Beevers M., Beevers D.G. Malignant hypertension
in young women is related to previous hypertension in
pregnancy, not oral contraception. Quart. J. Med. 1997; 90:
571–575. OS
640. Woods J.W. Oral contraceptives and hypertension. Hypertension
1998; 11: II11–II15. RV
641. Kawano H., Motoyama T., Kugiyama K., Hirashima O.,
Ohgushi M., Fujii H., Ogawa H., Yasue H. Gender difference in
improvement of endothelium-dependent vasodilation after estrogen
suplementation. J. Am. Coll. Cardiol. 1997; 30: 914–919. OS
642. Skinner S.L., Lumbers E.R., Symonds E.M. Alteration
by oral contraceptives of normal menstrual changes in plasma
renin activity, concentration and substrate. Clin. Sci. 1969; 36:
67–76. OS
643. Giannattasio C., Failla M., Grappiolo A., Stella M.L., Del
Bo A., Colombo M., Mancia G. Fluctuations of radial artery
distensibility throughout the menstrual cycle. Arterioscler.
Thromb. Vasc. Biol. 1999; 19: 1925–1929.
644. Ribstein J., Halimi J.-M., du Cailar G., Mimran A. Renal
characteristics and effect of angiotensin suppression in oral
contraceptive users. Hypertension 1999; 33: 90–95.
645. Inman W.H.W., Vessey M.P. Investigation of deaths from
pulmonary, coronary, and cerebral thrombosis and embolism
in women of childbearing age. BMJ 1968; 2: 193–199. OS
646. Vessey M.P., Doll R. Investigation of the relation between
use of oral contraceptives and thromboembolic disease. BMJ
1968; 2: 199–205. OS
647. Masi A.T., Dudgate M. Cerebrovascular disease associated
with the use of oral contraceptives: a review of the English-language
literature. Ann. Intern. Med. 1970; 72: 111–121. RV
648. Han W.-S., Ray J., Wai E.K., Ginsburg S., Hannah M.E.,
Corey P.N., Ginsberg J.S. Risk of stroke in women exposed to
low-dose oral contraceptives. A critical evaluation of the evidence.
Arch. Intern. Med. 2004; 164: 741–747. MA
649. Curtis K.M., Mohllajee A.P., Martins S.L., Peterson H.B.
Combined oral contraceptive use among women with hypertension:
a systematic review. Contraception 2006; 73: 179–188. MA
650. Gomes M.P., Deitcher S.R. Risk of venous thromboembolic
disease associated with hormonal contraceptives and
hormone replacement therapy. Arch. Intern. Med. 2004; 164:
1965–1976. OS
651. Hussain S.F. Progestogen-only pills and high blood pressure:
is there an association? A literature review. Contraception
2004; 69: 89–97. RV
652. Zanchetti A., Facchetti R., Cesana G.C., Modena G.M.,
Pirrelli A., Sega R. Menopause-related blood pressure increase
and its relationship to age and body mass index: the SIMONA
epidemiological study. J. Hypertens. 2005; 23: 2269–
–2276. OS
653. Shelley J.M., Green A., Smith A.M., Dudley E., Dennerstein
L., Hopper J., Burger H. Relationship of sex hormones
to lipids and blood pressure in mid-aged women. Ann. Epidemiol.
1998; 8: 39–45. OS
654. Grobbee D.E., Van Hemert A.M., Vanderbroucke J.P.,
Hofman A., Valkenburg H.A. Importance of body weight in
determining risk and level of blood pressure in postmenopausal
women. J. Hypertens. 1988; 6 (supl.): S614–S616. OS
655. Staessen J.A., Ginocchio G., Thijs L., Fagard R. Conventional
and ambulatory blood pressure and menopause in a prospective
population study. J. Hum. Hypertens. 1997; 11: 507–514. OS
656. Casiglia E., d’Este D., Ginocchio G., Colangeli G., Onesto
C., Tramontin P., Ambrosio G.B., Pessina A.C. Lack of
influence of menopause on blood pressure and cardiovascular
risk profile: a 16 year longitudinal study concerning a cohort
of 568 women. J. Hypertens. 1996; 14: 729–736. OS
657. Lindqvist O., Bengtsson C. Serum lipids, arterial blood
pressure and body weight in relation to the menopause: results
from a population study of women in Göteborg, Sweden.
Scand. J. Clin. Invest. 1980; 40: 629–636. OS
658. Torng P.L., Su T.C., Sung F.G., Chien K.L., Huang S.C.,
Chon S.N., Lee Y.T. Effects of menopause on intraindividual
changes in serum lipids, blood pressure and body weight: the
Chin-Shan community cardiovascular cohort study. Atherosclerosis
2002; 161: 409–415. OS
659. The Writing Group for the PEPI Trial. Effects of estrogen
or estrogen/progestin regimens on heart disease risk factors
in postmenopausal women. The Postmenopausal Estrogen/
Progestin Interventions (PEPI) Trial. JAMA 1995; 273:
199–208. RT
660. Grodstein F., Manson J.E., Sampfer M.J. Postmenopausal
hormone use and secondary prevention of coronary events
in the nurses’health study, a prospective, observational study.
Ann. Intern. Med. 2001; 135: 1–8. OS
661. Falkenborn M., Persson I., Terent A., Adami H.O., Lithell
H., Bergstrom R. Hormone replacement therapy and the
risk of stroke, follow-up of a population-based cohort in Sweden.
Arch. Intern. Med. 1993; 153: 1201–1209. OS
662. Finucane F.F., Madans J.H., Bush T.L., Wolf P.H., Kleinman
J.C. Decreased risk of stroke among postmenopausal
hormone users, results from a national cohort. Arch. Intern.
Med. 1993; 153: 73–79. OS
663. Scuteri A., Bos A.J.G., Brant L.J., Talbot L., Lakatta E.G.,
Fleg J.L. Hormone replacement therapy and longitudinal
changes in blood pressure in postmenopausal women. Ann.
Intern. Med. 2001; 135: 229–238. OS
664. Hulley S., Grady D., Bush T., Furberg C., Herrington D.,
Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin
for secondary prevention of coronary heart disease in
postmenopausal women. Heart and Estrogen/progestin Replacement
Study (HERS) research group. JAMA 1998; 280:
605–613. RT
665. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z.,
Kopperberg C., Stefanick M.L., Jackson R.D., Beresford S.A.,
Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., Writing
Group of Women’s Health Initiative Investigators. Risks and
benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative
randomized controlled trial. JAMA 2002; 288: 321–333. RT
666. Farquhar C.M., Marjoribanks J., Lethaby A., Lamberts Q.,
Suckling J.A. and the Cochrane HT Study Group. Long term
hormone therapy for perimenopausal and postmenopausal
women. Cochrane database of Systematic Reviews 2005. Issue
3. Art. No. CD004143. DOI 10.1002/1465868.CD004143.pub2. MA
667. Stramba-Badiale M., Fox K.M., Priori S.G., Collins P.,
Daly C., Graham I., Jonsson B., Schenck-Gustafsson K., Tendera
M. Cardiovascular disease in women: a statement from
the policy conference of the European Society of Cardiology.
Eur. Heart. J. 2006; 27: 994–1005. GL
668. Consensus Report: National High Blood Pressure Education
Program Working Group Report on High Blood Pressure
in Pregnancy. Am. J. Obstet. Gynecol. 1990; 163: 1689–
—1712. GL
669. Levine R.J., Ewell M.G., Hauth J.C., Curet L.B., Catalano
P.M., Morris C.D., Choudhary G., Sibai B.M. Should the
definition of preeclampsia include a rise in diastolic blood pressure
of ≥ 15 mm Hg to a level > 90 mm Hg in association with
proteinuria? Am. J. Obstet. Gynecol. 2000; 183: 787–792. GL
670. Staessen J.A., Asmar R., De Buyzere M., Imai Y., Parati G.,
Shimada K., Stergiou G., Redon J., Verdecchia P., Participants of
the 2001 Consensus Conference on Ambulatory Blood Pressure
Monitoring. Task Force II: blood pressure measurement and cardiovascular
outcome. Blood Press. Monit. 2001; 6: 355–370. GL
671. Churchill D., Perry I.J., Beevers D.G. Ambulatory blood pressure
in pregnancy and fetal growth. Lancet 1997; 349: 7–10. OS
672. Penny J.A., Halligan A.W., Shennan A.H., Lambert P.C.,
Jones D.R., de Swiet M., Taylor D.J. Automated, ambulatory,
or conventional blood pressure measurement in pregnancy:
which is the better predictor of severe hypertension? Am. J. Obstet.
Gynecol. 1998; 178: 521–526. OS
673. Perry I.J., Stewart B.A., Brockwell J., Khan M., Davies P.,
Beevers D.G., Luesley D.M. Recording diastolic blood pressure
in pregnancy. Br. Med. J 1990; 301: 1198.
674. Shennan A., Gupta M., Halligan A., Taylor D.J., de Swiet M. Lack
of reproducibility in pregnancy of Korotkoff phase IV as measured
by mercury sphygmomanometry. Lancet 1996; 347: 139–142. OS
675. Higgins J.R., de Swiet M. Blood pressure measurement
and classification in pregnancy. Lancet 2001; 357: 131–135.
676 .Task Force Members, Oakley C., Child A., Lung B., Persbitero
P., Tornos, Klein W., Garcia M.A.A., Blomstrom-Lundqvist
C., de Backer G., Dargie H., Deckers J., Flather M., Hradec
J., Mazzotta G., Oto A., Parkhomenko A., Silber S., Torbicki
A., Trappe H.-J., Dean V., Pourmeyrol-Jumeau D. Expert
consensus document on management of cardiovascular diseases
during pregnancy. Eur. Heart J. 2003; 24: 761–781. GL
677. Moutquin J.-M., Garner P.R., Burrows R.F., Rey E., Helewa
M.E., Lange I.R., Rabkin S.W. Report of the Canadian
Hypertension Society Consensus Conference: 2. Nonpharmacologic
management and prevention of hypertensive disorders
in pregnancy. Can. Med. Assoc. J. 1997; 157: 907–919. GL
678. Atallah A.N., Hofmeyr G.J., Duley L. Calcium suplementation
during pregnancy for preventing hypertensive disorders
and related problems (Cochrane Review). W: The Cochrane
Library, Issue 1. Oxford, Update Software, 2000. MA
679. Olsen S., Secher N.J., Tabor A., Weber T., Walker J.J.,
Gluud C. Randomised clinical trials of fish oil suplementation
in high risk pregnancies. Br. J. Obstet. Gynaecol. 2000;
107: 382–395. RT
680. Knight M., Duley L., Henderson-Smart D.J., King J.F. Antiplatelet
agents and pre-eclampsia (Cochrane Review). W: The
Cochrane Library, Issue 1. Oxford, Update Software, 2000. MA
681. Gilbert J.S., Cox L.A., Mitchell G., Nijland M.J. Nutrient-
-restricted fetus and the cardio-renal connection in hypertensive
offspring. Expert. Rev. Cardiovasc. Ther. 2006; 4: 227–237. RV
682. Sibai B.M., Mabie W.C., Shamsa F., Vilnar M.A., Anderson
G.D. A comparison of no medication versus methyldopa
or labetalol in chronic hypertension during pregnancy. Am.
J. Obstet. Gynecol. 1990; 162: 960–967. RT
683. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine
versus expectant management in mild to moderate hypertension
in pregnancy. Br. J. Obstet. Gynaecol. 1998; 105: 718–722. RT
684. De Swiet M. Maternal blood pressure and birthweight.
Lancet 2000; 355: 81–82. RV
685. von Dadelszen P., Ornstein M.P., Bull S.B., Logan A.G.,
Koren G., Magee L.A. Fall in mean arterial pressure and fetal
growth restriction in pregnancy hypertension: a meta-analysis.
Lancet 2000; 355: 87–92. MA
686. Magee L.A., Ornstein M.P., von Dadelszen P. Management
of hypertension in pregnancy. Br. Med. J. 1999; 318:
1332–1336. GL
687. Coppage K.H., Sibai B.M. Treatment of hypertensive
complications in pregnancy. Curr. Pharm. Design. 2005; 11:
749–757. RV
688. Lydakis C., Lip G.Y., Beevers M., Beevers D.G. Atenolol
and fetal growth in pregnancies complicated by hypertension.
Am. J. Hyperten. 1999; 12: 541–547. OS
689. The Magpie Trial Collaborative Group. Do women with
pre-eclampsia, and their babies, benefit from magnesium sulphate?
The Magpie Trial: a randomised placebo-controlled
trial. Lancet 2002; 359: 1877–1890. RT
690. Paradisi G., Biaggi A., Savone R., Ianniello F., Tomei C.,
Caforio L., Caruso A. Cardiovascular risk factors in healthy
women with previous gestational hypertension. J. Clin. Endocrinol.
Metab. 2006; 91: 1233–1238. OS
691. Wilson B.J., Watson M.S., Prescott G.J., Sunderland S.,
Campbell D.M., Hannaford P., Smith W.C. Hypertensive diseases
of pregnancy and risk of hypertension and stroke in later life:
results from cohort study. Br. Med. J. 2003; 326: 845–851. OS
692. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K.,
Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic
syndrome and total and cardiovascular disease mortality in
middle-aged men. JAMA 2002; 288: 2709–2716. OS
693. Girman C.J., Rhodes T., Mercuri M., Pyorala K., Kjekshus
J., Pedersen T.R., Beere P.A., Gotto A.M., Clearfield M.,
4S Group and the AFCAPS/TexCAPS Research Group. The
metabolic syndrome and risk of major coronary events in the
Scandinavian Simvastatin Survival Study (4S) and the Air
Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS). Am. J. Cardiol. 2004; 93: 136–141. OS
694. Dekker J.M., Girman C., Rhodes T., Nijpels G., Stehouwer
C.D., Bouter L.M., Heine R.J. Metabolic syndrome and
10-year cardiovascular disease risk in the Hoorn Study. Circulation
2005; 112: 666–673. OS
695. Resnick H.E., Jones K., Ruotolo G., Jain A.K., Henderson
J., Lu W., Howard B.V. Insulin resistance, the metabolic
syndrome, and risk of incident cardiovascular disease in non-
-diabetic American Indians: the Strong Heart Study. Diabetes
Care 2003; 26: 861–867. OS
696. Schmidt M.I., Duncan B.B., Bang H., Pankow J.S., Ballantyne
C.M., Golden S.H., Folsom A.R., Chambless L.E.
Identifying individuals at high risk for diabetes: The Atherosclerosis
Risk in Communities study. Diabetes Care 2005; 28:
2013–2018. OS
697. Mulè G., Nardi E., Cottone S., Cusimano P., Volpe V.,
Piazza G., Mongiovi R., Mezzatesta G., Andronico G., Cerasola
G. Influence of metabolic syndrome on hypertension-related
target organ damage. J. Intern. Med. 2005; 257: 503–
–513. OS
698. Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D.,
Parodi A., Falqui V., Tomolillo C., Deferrari G., Pontremoli R.
Metabolic syndrome is associated with early signs of organ
damage in nondiabetic, hypertensive patients. J. Intern. Med.
2005; 257: 454–460. OS
699. Cuspidi C., Meani S., Fusi V., Severgnini B., Valerio C.,
Catini E., Leonetti G., Magrini F., Zanchetti A. Metabolic
syndrome and target organ damage in untreated essential hypertensives.
J. Hypertens. 2004; 22: 1991–1998. OS
700. Schillaci G., Pirro M., Vaudo G., Mannarino M.R., Savarese
G., Pucci G., Franklin S.S., Mannarino E. Metabolic syndrome
is associated with aortic stiffness in untreated essential
hypertension. Hypertension 2005; 45: 1978–1982. OS
701. de Simone G., Palmieri V., Bella J.N., Celentano A., Hong Y.,
Oberman A., Kitzman D.W., Hopkins P.N., Arnett D.K.,
Devereux R.B. Association of left ventricular hypertrophy with
metabolic risk factors: the HyperGEN study. J. Hypertens.
2002; 20: 323–331. OS
702 Schillaci G., Pirro M., Pucci G., Mannarino M.R., Gemelli
F., Siepi D., Vaudo G., Mannarino E. Different impact
of the metabolic syndrome on left ventricular structure and in hypertensive men and women. Hypertension 2006;
47: 881–886. OS
703. Cuspidi C., Meani S., Fusi V., Valerio C., Catini E., Sala C.,
Sampieri L., Magrini F., Zanchetti A. Prevalence and correlates
of left atrial enlargement in essential hypertension: role of
ventricular geometry and the metabolic syndrome: the Evaluation
of Target Organ Damage in Hypertension study. J. Hypertens.
2005; 23: 875–882. OS
704. Kawamoto R., Tomita H., Oka Y., Kodama A., Kamitani A.
Metabolic syndrome amplifies the LDL-cholesterol associated
increases in carotid atherosclerosis. Intern. Med. 2005; 44:
1232–1238. OS
705. Cuspidi C., Meani S., Valerio C., Fusi V., Catini E., Sala C.,
Zanchetti A. Ambulatory blood pressure, target organ damage
and left atrial size in never-treated essential hypertensive individuals.
J. Hypertens. 2005; 23: 1589–1595. OS
706. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical
update. J. Clin. Invest. 2003; 111: 1805–1812. RV
707. Nesto R. C-reactive protein, its role in inflammation, type 2
diabetes and cardiovascular disease, and the effects of insulin-
-sensitizing treatment with thiazolidinediones. Diabet. Med.
2004; 21: 810–817. RV
708. Mancia G., Bousquet P., Elghozi J.L., Esler M., Grassi G.,
Julius S., Reid J. Van, Zwieten P.A. The sympathetic nervous system
and the metabolic syndrome. J. Hypertens. 2007; 25 (5): 909–
–920 RV
709. Clinical guidelines on the identification, evaluation, and
treatment of overweight and obesity in adults-the evidence
report. National Institutes of Health. Obes. Res. 1998; 2 (supl. 6):
51S–209S. GL
710. Krauss R.M., Eckel R.H., Howard B., Appel L.J., Daniels S.R.,
Deckelbaum R.J., Erdman J.W. Jr, Kris-Etherton P., Goldberg
I.J., Kotchen T.A., Lichtenstein A.H., Mitch W.E., Mullis
R., Robinson K., Wylie-Rosett J., St Jeor S., Suttie J., Tribble
D.L., Bazzarre T.L. AHA Dietary Guidelines: revision
2000: A statement for healthcare professionals from the Nutrition
Committee of the American Heart Association. Circulation
2000; 102: 2284–2299. GL
711. Thompson P.D., Buchner D., Pina I.L., Balady G.J.,
Williams M.A., Marcus B.H., Berra K., Blair S.N., Costa F.,
Franklin B., Fletcher G.F., Gordon N.F., Pate R.R., Rodriguez
B.L., Yancey A.K., Wenger N.K., American Heart Association
Council on Clinical Cardiology Subcommittee on Exercise,
Rehabilitation, and Prevention; American Heart Association
Council on Nutrition, Physical Activity, and Metabolism Subcommittee
on Physical Activity. Exercise and physical activity
in the prevention and treatment of atherosclerotic cardiovascular
disease: a statement from the American Heart Association
Council on Clinical Cardiology (Subcommittee on Nutrition,
Physical Activity and Metabolism (Subcommittee on
Physical Activity). Circulation 2003; 107: 3109–3116. GL
712. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman
R.F., Lachin J.M., Walker E.A., Nathan D.M., Diabetes
Prevention Program Research Group. Reduction in the incidence
of type 2 diabetes with lifestyle intervention or metformin.
N. Engl. J. Med. 2002; 346: 393–403. RT
713. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T.,
Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S.,
Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa
M., Finnish Diabetes Prevention Study Group. Prevention of
type 2 diabetes mellitus by changes in lifestyle among subjects
with impaired glucose tolerance. N. Engl. J. Med. 2001; 344:
1343–1350. RT 714. Orchard T.J., Temprosa M., Goldberg R., Haffner S.,
Ratner R., Marcovina S., Fowler S., Diabetes Prevention Program
Research Group. The effect of metformin and intensive
lifestyle intervention on the metabolic syndrome: the Diabetes
Prevention Program randomized trial. Ann. Intern. Med.
2005; 142: 611–619. RT
715. Pischon T., Sharma A.M. Use of beta-blockers in obesity
hypertension: potential role of weight gain. Obes. Rev. 2001;
2: 275–280. RV
716. Jacob S., Rett K., Henriksen E.J. Antihypertensive therapy
and insulin sensitivity: do we have to redefine the role of beta-
-blocking agents? Am. J. Hypertens. 1998; 11: 1258–1265. RV
717. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda
A., Hanrath P., Komajda M., Lubsen J., Lutiger B.,
Metra M., Remme W.J., Torp-Pedersen C., Scherhag A., Skene
A., Carvedilol Or Metoprolol European Trial Investigators.
Comparison of carvedilol and metoprolol on clinical outcomes
in patients with chronic heart failure in the Carvedilol
Or Metoprolol European Trial (COMET): randomised controlled
trial. Lancet 2003; 362: 7–13. RT
718. Abuissa H., Jones P.G., Marso S.P., O’Keefe J.H. Jr. Angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers for prevention of type 2 diabetes: a meta-analysis
of randomized clinical trials. J. Am. Coll. Cardiol. 2005; 46:
821–826. MA
719. Rocchini A.P. Obesity hypertension, salt sensitivity and insulin
resistance. Nutr .Metab. Cardiovasc. Dis. 2000; 10: 287–294. RV
720. Bakris G., Molitch M., Hewkin A., Kipnes M., Sarafidis P.,
Fakouhi K., Bacher P., Sowers J., STAR Investigators. Differences
in glucose tolerance between fixed-dose antihypertensive
drug combinations in people with metabolic syndrome.
Diabetes Care 2006; 29: 2592–2597.
721. Zillich A.J., Garg J., Basu S., Bakris G.L., Carter B.L. Thiazide
diuretics, potassium, and the development of diabetes:
a quantitative review. Hypertension 2006; 48: 219–224. MA
722. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de
Lisdonk E.H., De Grauw W.J. Alpha-glucosidase inhibitors for
people with impaired glucose tolerance or impaired fasting blood
glucose. Cochrane Database Syst. Rev. 2006; 4: CD005061. RV
723. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of
angiotensin-converting enzyme inhibitors and angiotensin II
receptor antagonists: beyond the renin-angiotensin system.
J. Hypertens. 2004; 22: 2253–2261. RV
724. Schupp M., Janke J., Clasen R., Unger T., Kintscher U.
Angiotensin type 1 receptor blockers induce peroxisome proliferator-
activated receptorgamma activity. Circulation 2004;
109: 2054–2057.
725. DREAM (Diabetes REduction Assessment with ramipril
and rosiglitazone Medication) Trial Investigators; Gerstein
H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N.,
Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J.,
Zinman B., Holman R.R. Effect of rosiglitazone on the frequency
of diabetes in patients with impaired glucose tolerance or
impaired fasting glucose: a randomised controlled trial. Lancet
2006; 368: 1096–1105. RT
726. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E.,
Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H.,
Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen
L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi
L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T.,
Scheen A., Scherbaum W., Schernthaner G., Schmitz O.,
Skrha J., Smith U., Taton J., PROactive investigators. Secondary
prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised controlled
trial. Lancet 2005; 366: 1279–1289. RT
727. Sarafidis P.A., Nilsson P.M. The effects of thiazolidinediones
on blood pressure levels — a systematic review. Blood
Press. 2006; 15: 135–150. RV
728. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner
S., RIO-Europe Study Group. Effects of the cannabinoid-1
receptor blocker rimonabant on weight reduction and cardiovascular
risk factors in overweight patients: 1-year experience from
the RIO-Europe study. Lancet 2005; 365: 1389–1397. RT
729. Despres J.P., Golay A., Sjostrom L., Rimonabant in Obesity-
Lipids Study Group. Effects of rimonabant on metabolic
risk factors in overweight patients with dyslipidemia. N. Engl.
J. Med. 2005; 353: 2121–2134. RT
730. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J.,
Rosenstock J., RIO-North America Study Group. Effect of rimonabant,
a cannabinoid-1 receptor blocker, on weight and
cardiometabolic risk factors in overweight or obese patients:
RIO-North America: a randomized controlled trial. JAMA
2006; 295: 761–775. RT
731. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van
Gaal L.F., RIO-Diabetes Study Group. Efficacy and tolerability
of rimonabant in overweight or obese patients with type 2
diabetes. Lancet 2006; 368: 1160–1172. RT
732. ClinicalTrials.gov.CRESCENDO: comprehensive rimonabant
evaluation study of cardiovascular endopoints and
outcomes. December 2005: http//clinicaltrials.gov/. RT
733. Deedwania P., Barter P., Carmena R., Fruchart J.C.,
Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner
H., Shepherd J., Waters D.D. Reduction of low-density
lipoprotein cholesterol in patients with coronary heart disease
and metabolic syndrome: analysis of the Treating to New
Targets study. Lancet 2006; 368: 919–928. RT
734. Wing R.R., Phelan S. Long-term weight loss maintenance.
Am. J. Clin. Nutr. 2005; 82 (1 supl.): 222S–225S. RV
735. Cuspidi C., Macca G., Sampieri L., Michev I. Salerno M.,
Fusi V., Severgnini B., Meani S., Magrini F., Zanchetti A. High
prevalence of cardiac and extracardiac target organ damage in
refractory hypertension. J. Hypertens. 2001; 19: 2063–2070. OS
736. Logan A.G., Perlikowski S.M., Mente A., Tisler A., Tkacova
R., Niroumand M., Leung R.S., Bradley T.D. High prevalence
of unrecognized sleep apnoea in drug-resistant hypertension.
J. Hypertens. 2001; 19: 2271–2277. OS
737. Parati G., Ongaro G., Bonsignore M.R., Glavina F., Di
Rienzo M., Mancia G. Sleep apnoea and hypertension. Curr.
Opin. Nephrol. Hypertens. 2002; 11: 201–214. RV
738. Narkiewicz K., Wolf J., Lopez-Jimenez F., Somers V.K.
Obstructive sleep apnea and hypertension. Curr. Cardiol. Rep.
2005; 7: 435–440. RV
739. Baguet J.P., Narkiewicz K., Mallion J.M. Update on hypertension
management: obstructive sleep apnea and hypertension.
J. Hypertens. 2006; 24: 205–208. RV
740. Calhoun D.A. Low-dose aldosterone blockade as a new
treatment paradigm for controlling resistant hypertension.
J. Clin. Hypertens. 2007; 9 (supl. 1): 19–24. RV
741. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner
M.A., Zhao Q., Pratt J.H. Improvement in blood pressure
with inhibition of the epithelial sodium channel in blacks
with hypertension. Hypertension 2005; 46: 481–487. RT
742. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone
in management of resistant hypertension: a surveillance
study. J. Hypertens. 2007; 25: 891–894. OS
743. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl
N.P. Low-renin status in therapy-resistant hypertension:
a clue to efficient treatment. J. Hypertens. 2004; 22: 2217–2226. OS
744. de Leeuw P.W., Kroon A.A., Scheffers I., Tordoir J.,
Schmidli J., Mohaupt M., Allemann Y., Jordan J., Engeli S.,
Liebeskind U., Luft F.C., Eckert S., Hansky B., Kieval R., Cody R.,
Rossing M., Irwin E., Peters T. Baroreflex hypertension therapy
with a cronically implanted system: preliminary efficacy
and safety results from the rheos debut-ht study in patients
with resistant hypertension. J. Hypertens. 2006; 24 (supl. 4):
S300 (abstract).
745. Isles C.G. Malignant hypertension and hypertensive encephalophaty.
W: Swales J.D. (red.). Textbook of Hypertension.
Balckwell Scientific Publications, London 1994: 1233–
–1248. RV
746. Davis B.A., Crook J.E., Vestal R.E., Oates J.A. Prevalence of
renovascular hypertension in patients with grade III or IV hypertensive
retinopathy. N. Engl. J. Med. 1979; 301: 1273–1276. OS
747. Lip G.Y., Beevers M., Beevers G. The failure of malignant
hypertension to decline: a survey of 24 years’ experience
in a multiracial population in England. J Hypertens 1994; 12:
1297–1305. OS
748. Giese J. Acute hypertensive vascular disease, 2: Studies
on vascular reaction patterns and permeability changes by
means of vital microscopy and colloidal tracer technique. Acta
Pathol. Microbiol. Scand. 1964; 62: 497–515. OS
749. Kincaid-Smith P., McMichael J., Murphy E.A. The clinical
cause and pathology of hypertension with papilloedema.
Quart. J. Med. 1958; 27: 117–154. OS
750. Isles C.G., Liu K.G., Boulton-Jones M., Cameron H.,
Lever A.F., Murray G., Robertson J.W.K. Factors influencing
mortality in malignant hypertension. J. Hypertens. 1985; 3
(supl. 3): 405–407. OS
751. Lip G.Y., Beevers M., Beevers D.G. Complications and
survival of 315 patients with malignant-phase hypertension.
J. Hypertens. 1995; 13: 915–924. OS
752. Gotto A.M. Jr. Review of primary and secondary prevention
trials with lovastatin, pravastatin, and simvastatin. Am.
J. Cardiol. 2005; 96: 34F–38F. RV
753. Clearfield M. Statins and the primary prevention of cardiovascular
events. Curr. Atheroscler. Rep. 2006; 8: 390–396. RV
754. Thavendiranathan P., Bagai A., Brookhart M.A., Choudhry
N.K. Primary prevention of cardiovascular diseases with
statin therapy: a meta-analysis of randomized controlled trials.
Arch. Intern. Med. 2006; 166: 2307–2313. MA
755. Gorelick P.B., Schneck M, Berglund L.F., Feinberg W.,
Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiol.
1997; 16: 107–115. RV
756. Heart Protection Study Group. MRC/BHF Heart Protection
Study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial.
Lancet 2002; 360: 7–22. RT
757. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley
B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W.,
Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J.,
Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C.,
Westendorp R.G., PROSPER study group. PROspective Study
of Pravastatin in the Elderly at Risk. Pravastatin in elderly
individuals at risk of vascular disease (PROSPER): a randomised
controlled trial. Lancet 2002; 360: 1623–1630. RT
758. Amarenco P., Bogousslavsky J., Callahan A. 3rd, Goldstein
L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic
L., Szarek M., Welch K.M., Zivin J.A., Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
High-dose atorvastatin after stroke or transient
ischemic attack. N. Engl. J. Med. 2006; 355: 549–559. RT
759. The ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group. Major outcomes in
moderately hypercholesterolemic, hypertensive patients randomized
to pravastatin vs. usual care. The Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT-LLT). JAMA 2002; 288: 2998–3007. RT
760. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G.,
Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes
G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.,
ASCOT investigators. The prevention of coronary events and
stroke with atorvastatin in hypertensive subjects with average
or below average cholesterol levels. The Anglo-Scandinavian
Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:
LLA). Lancet 2003; 361: 1149–1158. RT
761. Borghi C., Dormi A., Veronesi M., Immordino V., Ambrosioni
E. Use of lipid-lowering drugs and blood pressure
control in patients with arterial hypertension. J. Clin. Hypertens.
2002; 4: 277–285. RV
762. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini
J.F., Bergman A.J., Alton K.B. Ezetimibe: a review of its
metabolism, pharmacokinetics and drug interactions. Clin.
Pharmacokinet. 2005; 44: 467–494. RV
763. Antithrombotic Trialists’ Collaboration. Collaborative
meta-analysis of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and stroke in high
risk patients. BMJ 2002; 324: 71–86. MA
764. Zanchetti A., Hansson L., Dahlöf B., Julius S., Menard J.,
Warnold I., Wedel H. Benefit and harm of. low-dose aspirin
in well-treated hypertensives at different baseline cardiovascular
risk. J. Hypertens. 2002; 20: 2301–2307. CT
765. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C.,
Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J.
Aspirin and clopidogrel compared with clopidogrel alone after
recent ischaemic stroke or transient ischaemic attack in highrisk
patients (MATCH): randomised, double-blind, placebocontrolled
trial. Lancet 2004; 364: 331–337. RT
766. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M.,
Manson J.E., Hennekens C.H., Buring J.E. A randomized trial
of low-dose aspirin in the primary prevention of cardiovascular
disease in women. N. Engl. J. Med. 2005; 352: 1293–1304. RT
767. Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin
for the primary prevention of cardiovascular events: a summary
of the evidence for the U.S. Preventive Services Task
Force. Ann. Intern. Med. 2002; 136: 161–172. MA
768. Wald N.J., Law M.R. A strategy to reduce cardiovascular
disease by more than 80%. BMJ 2003; 326: 1419. RV
769. Sanmuganathan P.S., Ghahramani P., Jackson P.R.,
Wallis E.J., Ramsay L.E. Aspirin for primary prevention of
coronary heart disease: safety and absolute benefit related to
coronary risk derived from meta-analysis of randomised trials.
Heart 2001; 85: 265–271. MA
770. Zanchetti A., Hansson L., Leonetti G., Rahn K.H., Ruilope
L., Warnold I., Wedel H. Low-dose aspirin does not interfere
with the blood pressurelowering effects of antihypertensive
therapy. J. Hypertens. 2002; 20: 1015–1022. RT
771. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M.
Mortality from coronary heart disease in subjects with type
2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction. N. Engl. J. Med. 1998; 339:
229–234. OS
772. Stamler J., Vaccaro O., Neaton J.D.,Wentworth D. Diabetes,
other risk factors, and 12-yr cardiovascular mortality for
men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care 1993; 16: 434–444. OS
773. Knowler W.C., Sartor G., Melander A., Schersten B. Glucose
tolerance and mortality, including a substudy of tolbutamide
treatment. Diabetologia 1997; 40: 680–686. OS
774. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati
F.L. Hypertension and antihypertensive therapy as risk
factors for type 2 diabetes mellitus. Atherosclerosis Risk in
Communities Study. N. Engl. J. Med. 2000; 342: 905–912. OS
775. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with
type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853. RT
776. Chiasson J. L. , Josse R. G. , Gomis R. , Hanefeld M. , Karasik A.,
Laakso M. Acarbose treatment and the risk of cardiovascular disease
and hypertension in patients with impaired glucose tolerance:
the STOPNIDDM trial. JAMA 2003; 290: 486–494. RT
777. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H.,
Pedersen O. Multifactorial intervention and cardiovascular
disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;
348: 383–393. RT
778. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;
329: 977–986. RT
779. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M.,
Lachin J.M., Orchard T.J., Raskin P., Zinman B., Diabetes
Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study Research
Group. Intensive diabetes treatment and cardiovascular
disease in patients with type 1 diabetes. N. Engl. J. Med.
2005; 353: 2643–2653. CT
780. Balkau B., Shipley M., Jarrett R.J., Pyörälä K., Pyorala
M., Forhan A., Eschwege E. High blood glucose concentration
is a risk factor for mortality in middleaged nondiabetic
men. 20-year follow-up in the Whitehall Study, the Paris Prospective
Study, and the Helsinki Policemen Study. Diabetes
Care 1998; 21: 360–367. OS
781. European Diabetes Policy Group 1999. A desktop guide to
type 2 diabetes mellitus. Diabet. Med. 1999; 16: 716–730. GL
782. ADVANCE trial study group Rationale and design of
the ADVANCE study: a randomised trial of blood pressure
lowering and intensive glucose control in high-risk individuals
with type 2 diabetes mellitus. Action in Diabetes and
Vascular Disease: PreterAx and DiamicroN Modified-Release
Controlled Evaluation. J. Hypertens. 2001; 19 (supl.):
S21–S28. RT
783. Campos C., Segura J., Rodicio J.L. Investigations in secondary
hypertension: renal disease. W: Zanchetti A., Hansson
L., Rodicio J.L. (red.). Hypertension. McGraw Hill International,
London 2001: 119–126. RV
784. Keane W.F., Eknoyan G. Proteinuria, albuminuria, risk
assessment, detection, elimination (PARADE): a position paper
of the National Kidney Foundation. Am. J. Kidney Dis.
1999; 33: 1004–1010. GL
785. Köler H., Wandel E., Brunck B. Acanthocyturia — a characteristic
marker for glomerular bleeding. Kidney Int. 1991;
40: 115–120. OS
786. Elliott W.J., Secondary hypertension: renovascular hypertension.
W: Black H., Elliott W.G. (red.). Hypertension: a Companion to
Braunwald’s Heart Disease. Saunders Elsevier
2007: 93–105. RV
787. Safian R.D., Textor S.C. Renal-artery stenosis. N. Engl.
J. Med. 2001; 344: 431–442. RV
788. Krumme W., Blum U., Schwertfeger E., Flügel P., Hölstin F.,
Schollmeyer P., Rump L.C. Diagnosis of renovascular disease
by intra- and extrarenal Doppler scanning. Kidney Int. 1996;
50: 1288–1292. OS
789. Vasbinder B.G.C., Nelemans P.J., Kessels A.G.H., Kroon
A.A., De Leeuw P.W., van Engelshoven J.M.A. Diagnostic
tests for renal artery stenosis in patients suspected of having
renovascular hypertension: a meta-analysis. Ann. Intern. Med.
2001; 135: 401–411. MA
790. Bruce G.H. Intervention for renal artery stenosis: endovascular
and surgical roles. J. Hypertens. 2005; 23 (supl. 3):
S23–S29. RV
791. Aurell M., Jensen G. Treatment of renovascular hypertension.
Nephron 1997; 75: 373–383. RV
792. Plouin P.F., Chatellier G., Darne B., Raynaud A. Blood
pressure outcome of angioplasty in atherosclerotic renal artery
stenosis: a randomized trial. Essai Multicentrique Medicaments
vs Angioplastie (EMMA) Study Group. Hypertension
1998; 31: 823–829. RT
793. Webster J., Marshall F., Abdalla M., Dominiczak A.,
Edwards R., Isles C.G., Loose H., Main J., Padfield P., Russell I.T.,
Walker B., Watson M., Wilkinson R. Randomised comparison
of percutaneous angioplasty vs. continued medical therapy
for hypertensive patients with atheromatous renal artery
stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative
Group. J. Hum. Hypertens. 1998; 12: 329–335. OS
794. van Jaarsveld B.C., Krijnen P., Pieterman H., Derkx F.H.,
Deinum J., Postma C.T., Dees A., Woittiez A.J., Bartelink A.K.,
Man in ’t Veld A.J., Schalekamp M.A. The effect of balloon
angioplasty on hypertension in atherosclerotic renalartery stenosis.
Dutch Renal Artery Stenosis Intervention Cooperative
Study Group. N. Engl. J. Med. 2000; 342: 1007–1014. OS
795. Nordmann A.J., Woo K,. Parkes R., Logan A.G. Balloon
angioplasty or medical therapy for hypertensive patients with
atherosclerotic renal artery stenosis? A meta-analysis of randomized
controlled trials. Am. J. Med. 2003; 114: 44–50. MA
796. Reisch N., Peczkowska M., Januszewicz A., Neumann H.P.
Pheochromocytoma: presentation, diagnosis and treatment.
J. Hypertens. 2006; 24: 2331–2339. RV
797. Sawka A.M., Jaeschke R., Singh R.J., Young W.F. Jr.
A comparison of biochemical tests for pheochromocytoma: measurement
of fractionated plasma metanephrines compared with
the combination of 24-hour urinary metanephrines and catecholamines.
J. Clin. Endocrinol. Metab. 2003; 88: 553–558. OS
798. Bravo E.L. Evolving concepts in the pathophysiology,
diagnosis and treatment of pheochromocytoma. Endocrine
Rev. 1994; 15: 356–368. RV
799. Goldstein D.S., Eisenhofer G., Flynn J.A., Wand G., Pacak
K. Diagnosis and localization of pheochromocytoma.
Hypertension 2004; 43: 907–910. RV
800. Sjoberg R.J., Simcic K.J., Kidd G.S. The clonidine suppression
test for pheochromocytoma. A review of its utility and
pitfalls. Arch. Intern. Med. 1992; 152: 1193–1197. RV
801. Ilias I., Pacak K. Current approaches and recommended
algorithm for the diagnostic localization of pheochromocytoma.
J. Clin. Endocrinol. Metab. 2004; 89: 479–491. RV
802. Gimm O., Koch C.A., Januszewicz A.,Opocher G., Neumann
H.P. The genetic basis of pheochromocytoma. Front.
Horm. Res. 2004; 31: 45–60. RV
803. Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B.,
Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M.,
Mallamaci F., Mannelli M., Mattarello M.J., Moretti A., Palumbo
G., Parenti G., Porteri E., Semplicini A., Rizzoni D.,
Rossi E., Boscaro M., Pessina A.C., Mantero F., PAPY Study
Investigators. A prospective study of the prevalence of primary
aldosteronism in 1125 hypertensive patients. J. Am. Coll. Cardiol.
2006; 48: 2293–2300. OS
804. Stowasser M., Gordon R.D., Gunasekera T.G., Cowley D.C.,
Ward G., Archibald C., Smithers B.M. High rate of detection
of primary aldosteronism, including surgically treatable forms,
after ‘non-selective’ screening of hypertensive patients. J. Hypertens.
2003; 21: 2149–2157. OS
805. Bravo E.L., Tarazi R.C., Dustan H.P., Fouad F.M., Textor
S.C., Gifford R.W., Vidt D.G. The changing clinical spectrum
of primary aldosteronism. Am. J. Med. 1983; 74: 641–
–651. RV
806. Ganguly A. Primary aldosteronism. N. Engl. J. Med. 1998;
339: 1828–1834. RV
807. Kaplan N.M. The current epidemic of primary aldosteronism:
causes and consequences. J. Hypertens. 2004; 22: 863–
–869. RV
808. Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A.,
Rutherford J.C. High incidence of primary aldosteronism in
199 patients referred with hypertension. Clin. Exp. Pharmacol.
Physiol. 1994; 21: 315–318. OS
809. Lins P.E., Adamson U. Plasma aldosterone-plasma renin
activity ratio. A simple test to identify patients with primary
aldosteronism. Acta Endocrinol. 1986; 113: 564–569. OS
810. Pimenta E., Calhoun D.A. Primary aldosteronism: diagnosis
and treatment. J. Clin. Hypertens. 2006; 8: 887–893. RV
811. Phillips J.L., Walther M.M., Pezzullo J.C., Rayford W.,
Choyke P.L., Berman A.A., Linehan W.M., Doppman J.L.,
Gill J.R. Jr. Predictive value of preoperative tests in discriminating
bilateral adrenal hyperplasia from an aldosterone-producing
adrenal adenoma. J. Clin. Endocrinol. Metab. 2000;
85: 4526–4533. OS
812. Bravo E.L. Secondary hypertension: mineralocorticoid
excess states. W: Black H.R., Elliott W.J. (red.). Hypertension:
A Companion to Braunwald’s Heart diseases. Saunders-Elsevier,
Amsterdam 2007: 106–118. RV
813. Krum H., Gilbert R.E. Novel therapies blocking the renin-
angiotensin-aldosterone system in the management of hypertension and related disorders. J. Hypertens. 2007; 25: 25–
–35. RV
814. Newell-Price J., Bertagna X., Grossman A.B., Nieman L.K.
Cushing’s syndrome. Lancet 2006; 367: 1605–1617. RV
815. Findling J.W., Raff H. Cushing’s Syndrome: important
issues in diagnosis and management. J. Clin. Endocrinol.
Metab. 2006; 91: 3746–3753. RV
816. Strollo P.J. Jr, Rogers R.M. Obstructive sleep apnea.
N. Engl. J. Med. 1996; 334: 99–104. RV
817. Lavie P., Herer P., Hoffstein V. Obstructive sleep apnoea
syndrome as a risk factor for hypertension: population study.
Br. Med. J. 2000; 320: 479–482. OS
818. Grote L., Ploch T., Heitmann J., Knaack L., Penzel T.,
Peter J.H. Sleep-related breathing disorder is an independent
risk factor for systemic hypertension. Am. J. Respir. Crit. Care
Med. 1999; 160: 1875–1882. OS
819. Parati G., Bilo G., Lombardi C., Mancia G. Secondary
hypertension: sleep apnea. W: Black H.R., Elliott W.J. (red.).
Hypertension: A companion to Braunwald’s Heart diseases.
Saunders-Elsevier, Amsterdam 2007: 134–143. RV
820. Australian National Health and Medical Research Council
Dietary Salt Study Management Committee. Fall in blood
pressure with modest reduction in dietary salt intake in mild
hypertension. Lancet 1989; i: 399–402. RT
821. Port K., Palm K., Viigimaa M. Daily usage and efficiency
of remote home monitoring in hypertensive patients over a one-
-year period. J. Telemed. Telecare 2005; 11 (supl. 1): 34–36. OS
822. Kearney P.M., Whelton M., Reynolds K., Whelton P.K.,
He J. Worldwide prevalence of hypertension: a systematic review.
J. Hypertens. 2004; 22: 11–19. RV
823. Burt V.L., Cutler J.A., Higgins M., Horan M.J., Labarthe D.,
Whelton P., Brown C., Roccella E.J. Trends in the prevalence,
awareness, treatment, and control of hypertension in the
adult US population. Data from the Health Examination Surveys,
1960 to 1991. Hypertension 1995; 26: 60–69. OS
824. Amar J., Chamontin B., Genes N., Cantet C., Salvador M.,
Cambou J.P. Why is hypertension so frequently uncontrolled
in secondary prevention? J. Hypertens. 2003; 21: 1199–1205. OS
825. Mancia G., Ambrosioni E., Agabiti-Rosei E., Leonetti G.,
Trimarco B., Volpe M. Blood pressure control and risk of stroke
in untreated and treated hypertensive patients screened from
clinical practice: results of the ForLife study. J. Hypertens.
2005; 23: 1575–1581. OS
Data publikacji: 31.10.2008
COPYRIGHT BY VIA MEDICA,
WSZELKIE PRAWA ZASTRZEŻONE.
Via Medica, ul. Świętokrzyska 73, 80-180 Gdańsk,
tel.: (0 58) 3209494, faks: (0 58) 3209460,
viamedica@viamedica.pl
